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Abstract
Existing thermoplastic polyurethanes (TPUs), used in the manufacturing of
cardiovascular devices, still have unproven long-term biostability and may be prone to
excessive plastic deformation when subjected to cyclic loading. These negative aspects
can be attributed to, among other factors, the weak nature of virtual crosslinking through
microphase separation. The modification and covalent crosslinking of existing medical grade
polyurethanes with unsaturated acyl chlorides are thus proposed to improve these
properties.
A model compound study was used to find a suitable acyl chloride (4-pentenoyl
chloride), confirm the intended carbamate nitrogen as successful reaction site and to
optimize the chemistry of the reaction. Two medical grade polyurethanes, Pellethane® 2363-
80AE (Pellethane) and PurSil 35-80A (PurSil), were subsequently successfully modified
with 4-pentenoyl chloride. The degree of modification could be accurately controlled (R2 =
0.99) to between 4.5% to 20.0% and between 11.5% to 18.5% for the respective
polyurethanes.
The degree of modification and method of crosslinking were then optimized to obtain
the required mechanical properties (i.e. minimum hysteresis). The hysteresis and creep of
the modified and crosslinked Pellethane were reduced by 42.5% and 44.0%, respectively,
while the hysteresis of the modified and crosslinked PurSil was reduced by 12.9%.
The chemical stability of Pellethane (control) modified Pellethane (15% modification)
and crosslinked Pellethane (Pell15.0) was evaluated in an in vitro degradation study. The
hysteresis of the crosslinked polymer was at least 27.5% better when compared to
Pellethane, and showed a significant resistance to surface degradation (as studied with
scanning electron microscopy). Although the soft phases in both polyurethanes are
vulnerable toward degradation, it was not as pronounced in Pell15.0, mainly due to the
restriction of chain movement resulting from the crosslinking.
Small-diameter tubular constructs, with similar fiber and wall thicknesses, were
electrospun from Pellethane and the 15% modified Pellethane. A standard electrospinning
technique was used in the case of the former while in the case of the latter a novel
“reactive” electrospinning technique was used for the in situ crosslinking of the novel
material, while simultaneously forming the tubular constructs.
It is suggested that the manufacturing of Pell15.0 be scaled up to produce adequate
amounts of material to enable the extrusion and in vivo evaluation of e.g. pacemaker leads.
A circulatory animal model, e.g. a senescent baboon model, could be used to evaluate and
further optimize the electrospun tubular constructs.
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Opsomming
Beskikbare termoplastiese poliuretane, wat gebruik word in die vervaardiging van
kardiovaskulêre toestelle het nog nie ‘n lang termyn rekord van biostabiliteit nie en is ook nog
geneig tot geweldige plastiese deformasie, wanneer dit blootgestel word aan sikliese
lading. Hierdie negatiewe aspekte is te wyte aan onder andere, die swak virtuele
kruisbinding wat bewerkstellig word deur mikrofase skeiding. Die modifikasie en kovalente
kruisbinding van beskikbare mediese graad poliuretane deur die gebruik van asiel chloriede
word dus voorgestel om die eienskappe daavan te verbeter.
In ‘n model komponent studie is ‘n toepaslike asiel chloried (4-pentenoiel chloried)
gevind, bewys is gelewer van die suksesvolle reaksie met die karbamaat stikstof en die
betrokke chemie is geoptimeer. Twee mediese graad poliuretane Pellethane® 2363-80AE
(Pellethane) en PurSil 35-80A (PurSil) is daarop volgens gemodifiseer met die 4-pentenoiel
chloried. Die graad van modifikasie kon akkuraat beheer word tussen 4.5% tot 20.0% vir
Pellethane en tussen 11.5% tot 18.5% vir PurSil.
Die graad van modifikasie en kruisbinding is toe geoptimeer om die verlangde
meganiese eienskappe (histerese) te verkry. Dit was moontlik om die histerese en kruip van
die gemodifiseerde en gekruisbinde Pellethane met sowat 42.5% en 44.0%, onderskeidelik
te verbeter, terwyl die histerese van die gemodifiseerde en gekruisbinde PurSil met sowat
12.9% verbeter is.
‘n In vitro degradasie studie is gebruik om die chemiese stabiliteit van Pellethane
(kontrole) en die gemodifiseerde (15% gemodifiseerd) en gekruisbinde Pellethane (Pell15.0)
te vergelyk. Die histerese van die gekruisbinde polimeer was ten minste 27.5% beter in
vergeleke met die Pellethane en het ook beduidende weerstand gebied teen oppervlak
degradasie, soos bestudeer met skandering elektron mikroskopie. Alhoewel die sagte
segmente in beide poliuretane vatbaar is vir degradasie, was dit nie so merkbaar in Pell15.0
nie, weens die beperkte beweging van die kettings a.g.v die kruisbinding.
Buisvormige konstruksies met klein diameter en met dieselfde draad en wanddikte is
elektries geweef van Pellethane, deur van standaard tegnieke gebruik te maak. ‘n Nuwe
“reaktiewe” weef proses is vervolgens gebruik om die 15% gemodifiseerde Pellethane in
situ te kruisbind, terwyl die buisvormige konstruksie gevorm is.
Dit word voorgestel dat die produksie van Pell15.0 opgeskaleer moet word om
genoegsame produk te kan lewer om die ekstrusie van die materiaal moontlik te maak om
sodoende die in vivo evaluering van bv. pasaangeër drade te kan ondersoek. ‘n
Sirkulerende diere model bv. ‘n bobbejaan model, kan gebruik word in die veredere
optimering van die geweefde pypagtige konstruksies.
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1-D One-dimensional
2-D Two-dimensional
3-D Three-dimensional
4-PCL 4-Pentenoyl chloride
AB Generic polyurethane with hard and soft segments
ACA Acetic acid
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AcSH Thiolacetic acid
AFM Atomic force microscopy
AIBN 2,2’-Azobisisobutyronitrile
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ArDI Generic aromatic diisocyante
ASTM American standard test method
B Base
BA Buthylacrylate
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BPO Benzoyl peroxide
BtOH 1-Butanol
BuDO Butane diol
Caplry Capillary
Cat Catalogue
CB Cathepsin B
CDCl3 Deuterated chloroform
CE Cholesterol esterase
CHDI 1,4-cyclohexane diisocyanate
Co. Company
CO Colagnenase
Conc Concentration
CT Computed tomography
d Doublet
DA Generic diamine
DAC Diaminocyclohexane
DAMCH 1,4-Diamino cyclohexane
DBTDL Dibutyltin dilaurate
DCM Dichloromethane
DC Direct current
DCP Dicumyl peroxide
DEG Diethylene diol
Dist Distance
DMA Dynamic mechanical analysis
DMAc N,N-dimethyl acetamide
DMAP Dimethylaminopyridine
DMF N,N-dimethylformamide
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DMSO Dimethyl sulfoxide
DNA Deoxyribose nucleic acid
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DSC Differential scanning calorimetry
EA Ethyl acetate
EC Endothelial cells
ECM Extracellular matrices
EDA Ethylene diamine
EDAX Electron dispersive analysis by X-ray
EDGM Ethylene glycol dimethacrylate
EDO Ethane diol
EHMA 2-Ethylhexyl methacrylate
El Electrophile
xEq Equation
ESCA Electron spectroscopy for chemical analysis
ESEM Environmental scanning electron microscopy
E-spun Electrospun
EtOH Ethanol
FA Formic acid
Fiber. Fiber thickness
FL Florida
Flow. Flow rate
FT-IR Fourier-transform infrared
GPC Gel permeation calorimetry
HBP Hyperbranched polyamides
HDO Hexane diol
HEMA Hydroxy ethyl methacrylate
HEPM Human embroyonic palatal mesenchymal
HFIP 1,1,1,3,3,3-Hexafluoro-2-propanol
HLF Human ligament fibroblast
HMDI 4,4-Methylenebis(cyclohexylisocyanate)
HMOD Hydroxymethyl octadecanol
hMSCs Human mesenchymal stem cells
HPLC High-pressure liquid chromatography
HRMS High-resolution mass spectroscopy
HTPBD Hydroxy-terminated polybutadiene
HxCl Hexanoyl chloride
HVK Hoftyzer and Van Krevelen
I Initiator
ID Inside diameter
Inc Incorporated
IPDI 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate
KK Kallikrein
kV Kilovolt
M Monomer
MALDI Matrix-assisted laser desorption/ionization
Mass 1 Mass of dry polymer
Mass 2 Submerged mass of dry polymer
Mass 3 Mass of swollen polymer gel
Mass 4 Submerged mass of swollen polymer gel
MbA N,N’-methylenebisacrylamide
MC Model compound
MDA 4,4-Methylenebis(phenylaniline)
MDI 4,4-Methylenebis(phenylisocyanate)
MeOH Methanol
MIO Metal ion induced oxidation
MN Minnesota
MPC 2-methacryloylethyl phosphorylcholine
n Number
NaH Sodium hydride
n-BuLi n-Butyllithium
NDI 1,5-Naphthalene diisocyanate
nHAP Hydroxyapatite
NJ New Jersey
NMR Nuclear magnetic resonance spectroscopy
NRS Non-recovered strain
Nuc Nucleophile
p Coefficient of statistical significance
PAA Poly(acrylic acid)
PANi Polyaniline
PBD Hydrogenated polybutadiene
PBS Phosphate buffer solution
PCDO Polycarbonate diol
PCL Polycaprolactone
PCLEEP Poly(caprolactone-co-ethyl ethylene phosphate)
PCLG Poly(caprolactone) glycol
PCN Polycarbonate
xi
PDMS Poly(dimethyl siloxane)
PEA Polyethylene adipate glycol
PED Generic polyether diol
PEG Poly(ethylene glycol)
PELA Poly(ethylene-b-lactide)
Pellm Modified Pellethane® 2363-80AE
Pellx Modified and crosslinked Pellethane® 2363-80AE
PEO Poly(ethylene oxide)
PesD Generic polyester diol
PEUU Poly(ester urethane) urea
PGA Poly(glycolic acid)
PHMC Poly(hexamethylene carbonate) glycol
PHECD Poly(1,6-hydroxyl 1,2-ethyl carbonate) diol
PHMO Poly(hexamethylene oxide)
phr Parts per hundred resin
PIB Hydroxy-terminated polyisobutylene
pKa Acid dissociation constant
PKK Prekallikrein
PLA Polylactide
PLCL Poly(L-lactide-co-caprolactone)
PLGA Poly(D,L-lactide-co-glycolide)
PMMA Poly(methyl methacrylate)
PMN Neutrophils
PO Polyol
POADA Poly(oxyalkylene) diamine
POPG Poly(propylene oxide) glycol
PPG Poly(propylene glycol)
PTG Polymer Technology Group
PTLC Preparative thin layer chromatography
PTMEG Poly(tetramethylene oxide) glycol
PTMO Poly(tetra methylene oxide)
PU Polyurethane
Purm Modified PurSil 35-80A
Purx Modified and crosslinked PurSil 35-80A
PUU Poly(urethane urea)
PVA Poly(vinyl alcohol)
PVC Poly(vinyl chloride)
PVDF Poly(vinylidiene fluoride)
q Quartet
r Linear regression coefficient
R Alkyl or aryl
R2 Regression coefficient
Ref Reference
RT Room temperature
s Singlet
SAXS Small-angle X-ray scattering
SEM Scanning electron microscopy
SPU Segmented polyurethane
SMC Smooth muscle cells
std dev Standard deviation
ST-gelatin Styrenated gelatin
t Triplet
TBAI Tetrabutylammonium iodide
TDI Toluene diisocyanate (2,4-2,6)
TGA Thermal gravimetric analysis
THF Tetrahydrofuran
TLC Thin layer chromatography
TMPTA Trimethylolpropane triacrylate
TMPTMA Trimethylol propane trimethacrylate
TMS Tetramethylsilane
TODI Methylene bis(toluene isocyanate)
TPU Thermoplastic polyurethane
USA United States of America
UV Ultraviolet
xii
Volt Voltage
WBC White blood cells
X Leaving group
XO Xanthine oxidase
XPS X-ray photoemission spectroscopy
Symbols Description Units
Δ Difference [ - ]
ΔGM Gibbs free energy of mixing [ J/mol ]
ΔHM Enthalpy of mixing per unit volume [ J/cm3 ]
ΔhM Enthalpy of mixing [ J/mol ]
ΔHvap Molar heat of evaporation [ J/mol ]
ΔSM Enthropy of mixing [ J/mol ]
ΔT Lyderson correction for non-ideality [ - ]
ΔU Internal energy per mole [ J/mol ]
α Molar aggregation number [ - ]
δ1 Solvent solubility parameter [ MPa1/2 ]
δ2 Polymer solubility parameter [ MPa1/2 ]
δC Carbon shift [ ppm ]
δdi,j
Contribution of dispersion of components i and j to the
solubility parameter
[ MPa1/2 ]
δhi,j
Contribution of hydrogen bonding of components i and j
to the solubility parameter
[ MPa1/2 ]
δH Proton shift [ ppm ]
δi,j Solvent solubility parameter of components i and j [ MPa1/2 ]
δpi,j
Contribution of polar forces of components i and j to the
solubility parameter
[ MPa1/2 ]
εb Elongation at break [ % ]
φ i,j Volume fractions of components i and j [ - ]
γ w Water contact angle [ - ]
ρ Density [ g/cm3 ]
ρ1 Density of the solvent in the swollen gel [ g/cm3 ]
ρ2 Density of the swollen gel [ g/cm3 ]
σb Stress at break [ MPa ]
ν2 Volume fraction of the polymer in the swollen gel [ - ]
[DCP] Dicumyl peroxide concentration [ % ]
[DMPA] ω,ω-Dimethoxy-ω-phenylacetophenone concentration [ % ]
B Base value [ - ]
e Cohesive energy density in the amorphous state [ MPa ]
E100 Modulus at 100% elongation [ MPa ]
Eγ Young’s modulus [ MPa ]
Ecoh Cohesive energy [ J/mol ]
Ed Dispersion force [ J/mol ]
Eh Hydrogen bonding [ J/mol ]
Ep Polar forces [ J/mol ]
F Molar attraction coefficient [ J1/2/mol1/2 ]
Fd Contribution of dispersion to the molar attractioncoefficient
[ J1/2/mol1/2 ]
Fh Contribution of hydrogen bonding to the molar attractioncoefficient
[ J1/2/mol1/2 ]
Fp Contribution of polar forces to the molar attractioncoefficient
[ J1/2/mol1/2 ]
G’ Storage modulus [ Pa ]
Mc Molecular mass between crosslinks [ g/mol ]
Mdry Dry scaffold mass [ g ]
Mn Number average molar mass [ g/mol ]
Mr Molecular mass of the linear polymer [ g/mol ]
Msub Submerged scaffold mass [ g ]
Mw Mass average molecular mass [ g/mol ]
Mwet Wet scaffold mass [ g ]
ñ Number of repeat units per polymer chain segment [ - ]
p Statistical significance coefficient [ - ]
Q Swelling index [ - ]
xiii
R2 Regression coefficient [ - ]
R Universal gas constant [ J/mol.K ]
r Linear correlation coefficient [ - ]
t0 Time at point 0 [ min ]
t90 Time at point 90 [ min ]
T Temperature [ K ]
T1 First polyurethane transition temperature [ 0C ]
T2 Second polyurethane transition temperature [ 0C ]
V Specific volume [ cm3/mol ]
v1 Specific volume of the solvent [ cm3/mol ]
V1 Volume of solvent in swollen polymer gel [ cm3 ]
V2 Volume of dry polymer [ cm3 ]
V3 Volume of swollen polymer gel [ cm3 ]
Va Apparent scaffold cube volume [ cm3 ]
Vg Scaffold volume [ cm3 ]
W1 Mass of solvent in swollen gel [ g ]
W2 Mass of swollen gel [ g ]
w% Mass percentage [ % ]
w/w Mass per unit mass [ - ]
X1 Polymer-solvent interaction parameter [ - ]
Chapter 1
Introduction
1.1 General introduction
The human body is inherently a very aggressive and hostile environment towards
foreign objects, e.g. implantable cardiovascular devices [1]. The wide range of
cardiovascular applications demands materials with versatile properties. It should be
possible to process the material, using different manufacturing techniques (e.g. solvent
casting or electrospinning), to economically and consistently manufacture uniform and high
quality devices. While exhibiting excellent elastomeric properties, good suturability and
general handling characteristics, the material should not be prone to excessive dilation (i.e.
poor hysteresis). Chemical stability is one of the key demands and the material should not
be susceptible to oxidation and hydrolysis, nor be prone to environmental stress cracking.
There are numerous thermoplastic polyurethanes exhibiting a unique combination of
biocompatibility, toughness, biostability and surface functionality, which has led to their
widespread use in implantable devices such as vascular grafts, pacemaker leads, blood
bags, catheters, bladders and artificial hearts. The elastomeric properties of certain
polyurethanes also make them good potential candidates for applications where interaction
with, and mimicking of, soft tissue are required [2-4].
The properties of segmented polyurethanes (comprising hard and soft segments)
depend not only on their chemical nature and constitutive elements, but also on the manner
in which these hard and soft segments are arranged in the bulk of the polymer.
The chemical stability of polyurethanes is closely linked to the chemical nature of the
macroglycol that constitutes the soft segment. Early polyurethane implants failed [5, 6] due
to degradation of the hydrolytically unstable polyester macroglycols used in their synthesis.
Replacement of the polyester-based soft segments with those based on polyethers
provided the required in vivo hydrolytic stability, while retaining most of the desired
mechanical properties. Subsequent studies have shown, however, that although
hydrolytically stable, certain polyether urethanes are susceptible to oxidative degradation in
the presence of metal ions and other strong oxidants.
Porous tissue engineered scaffolds (e.g. vascular grafts) have a large surface area
to volume ratio. It is therefore important that any polyurethane used in such an application
should have exceptionally good mechanical properties in order to cope with the resulting
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weaker structure. As a result of the large surface area the prosthesis will also be more
susceptible to in vivo degradation [2, 7]. Chemical stability is therefore a key issue.
Polyurethanes currently used in cardiovascular prosthesis mainly suffer from two
drawbacks: 1) they still have unproven long-term biostability [4, 6, 8-19] and 2) they are
prone to excessive plastic deformation [20-27], especially when used as porous implants
[28]. These negative aspects can be attributed to (among other factors) the weak nature of
virtual crosslinking of thermoplastic polyurethanes, through microphase separation.
In order to improve on the above the following aspects had to be considered.
1.2 Considerations
The chemical/bio-stability and the elastic response (the plastic deformation) of existing
or new thermoplastic polyurethanes, especially those intended for a medical application,
could be increased by chemically modifying the thermoplastic polyurethane with functional
groups (pendent groups) capable of undergoing crosslinking reactions. The crosslinking
reactions could be induced during (e.g. by extrusion processing) or after (e.g. by solvent
casting techniques) the manufacturing of the required device so that the positive aspects
of the thermoplastic materials (ease of processing and recycling) are combined with the
positive aspects of thermoset materials (high elastic response and increased chemical
stability resulting from the high molecular mass).
Controlling the degree of chemical modification, and therefore the crosslinking is
critical when polyurethanes are considered to mimic soft tissue, such as in peripheral and
coronary porous vascular graft applications, where the mechanical properties, like elastic
response and compliance, and the long-term chemical stability, are among the key issues in
the healing response [29-34].
Polyurethanes that are used for medical applications are often large (Mn ≥ 30 000
g/mole) and very complex molecules. Hence monitoring the extent of modification, involving
small molecules (Mr = 80 - 120 g/mole), using standard analytical techniques like nuclear
magnetic resonance spectroscopy (NMR) is not a trivial task. The synthesis and use of a
smaller, less complex molecule i.e. a model compound, which resembles the same hard
segment of the intended medical grade polyurethane, e.g. Pellethane® 2363-80AE, would
enable a more accurate investigation of the chemistry involved, using standard analytical
techniques such as nuclear magnetic resonance spectroscopy (NMR), high resolution
mass spectroscopy (HRMS) and matrix-assisted laser desorption/ionization (MALDI).
The chemistry and reaction conditions optimized in such a model urethane study could
then be transferred and scaled up, in an effort to modify the polyurethanes successfully.
Initial work could be focused on a well-known and existing medical grade polyurethane e.g.
Pellethane® 2363-80AE (academic standard), whereafter other polyurethanes (e.g. PurSil®
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35 80A) could be considered. Controlling the degree of chemical modification and hence the
crosslinking accurately and reproducibly would be a key issue, as the different resulting
crosslinked polyurethanes could find application in a wide range of medical products that
may require different mechanical properties.
The chemical stability of the novel modified and crosslinked materials could be tested
together with the untreated materials (controls) in an in vitro degradation study. An
accelerated degradation study could be conducted at elevated temperature (higher than
physiological temperature, e.g. 65 0C) using very aggressive chemicals like hydrogen
peroxide and silver nitrate to simulate the oxidative conditions in the body, and especially in
the presence of metal ions (e.g. found in pacemaker leads). Such conditions are frequently
used to accelerate degradation conditions (see Table E1, Appendix E).
Pending the successful modification and crosslinking, Pellethane® 2363-80AE and the
novel modified polyurethane material could then be used to manufacture small-diameter (1.6
mm ID) tubular constructs using an electrospinning technique, for example. An ultraviolet
light source and initiator could be used to crosslink the modified polyurethane while
electrospinning the tubular construct.
1.3 Objectives
The overall goal of this study was to develop crosslinkable, thermoplastic
polyurethanes for cardiovascular application. In order to achieve this the following
objectives were proposed:
1. Conduct a literature survey of the chemical and mechanical properties of
polyurethanes available for the use as biomaterials in the development of
cardiovascular prostheses.
2. Study the hard segment structure of typical existing medical grade polyurethanes
(preferably an academic polyurethane standard) and the nucleophilic character of
the carbamate nitrogen, then investigate the use of acyl chlorides as potential
modification reagents.
3. Synthesize a model urethane compound, based on the hard segment structure of
the academic polyurethane standard, in order to determine the proposed reaction
between the carbamate nitrogen and an acyl chloride, find a suitable acylating
agent, and then optimize the chemistry of the reaction (to later be transferred to
existing medical grade polyurethanes).
4. Modify Pellethane® 2363-80AE (an existing academic standard medical grade
polyurethane) and a second polyurethane (PurSil® 35 80A), for post-process
crosslinking.
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5. Optimize the degree of modification and method of crosslinking of the two modified
polyurethanes to obtain the required mechanical properties (i.e. minimum
hysteresis).
6. Evaluate the chemical stability of Pellethane® 2363-80AE (control) and compare it
with that of the novel modified and crosslinked polyurethane material (Pellx) in an in
vitro degradation study.
7. Manufacture tubular constructs from Pellethane® 2363-80AE (control) and from the
novel modified polyurethane using a standard electrospinning technique in the case
of the former and, in the latter, a novel “reactive” electrospinning technique for the
in situ crosslinking of the novel material, while simultaneously forming the tubular
constructs.
This dissertation is multi-disciplinary; it covers aspects of several subject areas,
including: polymer science, synthetic and analytical organic chemistry and process
engineering.
1.4 Layout of dissertation
This dissertation consists of eight chapters, five of which are experimental. The
layout is illustrated in the flow diagram presented in Figure 1.1. Chapter 2 provides a brief
background to the synthesis, degradation, mechanical properties and general medical
application of polyurethanes as biomaterial.
The reactivity of the carbamate nitrogen of polyurethanes towards nucleophilic
addition reactions was studied and the use of acyl chlorides as modification reagents
investigated. The complexities involved in the acylation of the proposed carbamate nitrogen
of medical grade polyurethanes necessitated the synthesis and use of a model compound.
This is described in Chapter 3. The synthesized model compound was then used in studies
to find suitable unsaturated acyl chlorides, identify the successful acylated reaction site
and to optimize the reaction conditions.
In Chapter 4 the chemistry optimized in the model compound study (Chapter 3) was
first transferred to Pellethane® 2363-80AE (an academic standard) and then to a second
medical grade polyurethane, PurSil® 35 80A. The control of the modification reactions was
also studied.
The novel modified polyurethanes were then used to study different methods of
crosslinking, including heat, ultraviolet light and gamma irradiation, using different initiators
and crosslinking enhancing monomers. This is described in Chapter 5. The measured
swelling indices and mechanical properties (tensile testing) were used to find the optimum
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degree of modification and crosslinking (i.e. lowest hysteresis) for the novel modified
polyurethanes.
Figure 1.1 Flow diagram of thesis layout
Pellethane® 2363-80AE (control) and the modified and crosslinked polyurethane (Pellx)
were then subjected to an in vitro degradation study. Changes in mechanical properties (as
determined by tensile and dynamic mechanical analysis) and chemical properties (as
determined by scanning electron microscopy, Fourier transform infrared spectroscopy etc.)
were investigated. This is described in Chapter 6.
The electrospinning of small-diameter tubular constructs (1.6 mm ID), manufactured
from Pellethane® 2363-80AE, was studied and then a novel “reactive” electrospinning
technique was developed for the in situ crosslinking of the novel modified polyurethane
developed in Chapter 4. This is described in Chapter 7.
In Chapter 8 the main conclusions are presented and some recommendations for
future research are given.
Results of this study contribute to the fields of both the development and optimization
of the mechanical properties and the in vitro chemical stability of crosslinkable thermoplastic
polyurethanes and the fabrication of tubular constructs.
CHAPTER 2
Polyurethanes as biomaterial: Background
and theoretical considerations
CHAPTER 1
Conceptualization
CHAPTER 3
Model urethane compound study
CHAPTER 4
Polyurethane modification
CHAPTER 5
Crosslinking of novel modified polyurethanes
CHAPTER 6
In vitro chemical stability assay
CHAPTER 7
Electrospinning of tubular scaffolds
CHAPTER 8
Conclusions and future work
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Chapter 2
Polyurethanes as biomaterial: Background and
theoretical considerations
Abstract
The great variety in their chemical and physical properties makes thermoplastic
polyurethanes very attractive candidates as biomaterials, especially for the
mimicking of soft tissue. They are therefore generally accepted as materials of
choice in many cardiovascular applications. Although not useful when first
introduced in 1937 by Prof. Otto Beyer, polyurethanes have since had a long
history filled with a number of historical milestones. They have also emerged as
very attractive materials for use in the medical industry because of the numbers of
available raw materials and reaction conditions. Thermoplastic polyurethanes also
have very good processability properties. They do however have an unproven
long-term biostability and suffer from plastic deformation due to the weak nature of
virtual crosslinking. This chapter will provide a general background to medical
grade polyurethanes.
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2.1 Introduction
Due to the almost endless number of formulations that may be used to prepare
polyurethanes, they offer the greatest variety of chemical and physical properties of any
family of polymers. Their physical properties range from hard, rigid thermosetting materials
to those of softer thermoplastic elastomers, while their chemical properties may be tailored
to control durability and chemical stability. Polyurethanes have been extensively studied
over the past four decades and this has led to the development of a number of medical
devices, such as complaint vascular grafts and low profile pacemaker leads (see Table
2.1) [1-3], which would otherwise not have been possible.
Table 2.1: Biomedical applications of polyurethanes [4]
Blood bags, closures, fittings
Blood oxygenation tubing
Breast prostheses
Cardiac assist pump bladders, tubing, housing, coatings
Catheters
Dental cavity liners
Endotracheal tubes
Heart pacemaker connectors, coatings, lead insulators,
fixation devices
Hemodialysis tubing, membranes, connectors
Heart valve leaflets
Mechanical heart valve coatings
Orthopedic splints, bone adhesives
Percutaneous shunts
Reconstructive surgery materials
Skin dressing and tapes
Surgical drapes
Suture material
Synthetic bile ducts
Vascular grafts and patches
The number of candidate materials available for long-term implant applications,
especially those elastomeric materials required for the mimicking of soft tissue, is limited due
to design, biocompatibility and availability constraints [4]. The only alternative elastomeric
material to polyurethanes (PU) that has enjoyed some degree of success in the body is
silicone rubber. Fluoroelastomers, such as Fluorel® (3M Co., Minneapolis, MN), which could
have been a likely candidate, unfortunately require additives such as fillers and initiators
which could leach out into the body over time [4].
According to Pinchuk [4] there are mainly two families of elastomers with tensile
strengths in the range of that of polyurethanes (28 – 62 MPa): the amorphous nylons and
the glycolated polyester terephthalates. It is well known that polyamides (nylons) are
biodegradable and that the glycolated polyesters suffer from a predisposition that ester
groups are susceptible to both hydrolysis and esterase enzyme activity in the body. This
leaves only polyurethanes for high tensile strength applications.
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2.2 History
Professor Otto Bayer introduced the first polyurethanes in 1937 (Leverkusen,
Germany) when he was trying to synthesize novel fibers not covered in the polyamide
(Nylon) patents held by Carothers at E.I. du Pont de Nemours & Co (1935). His first attempts
involved the reactions between diamines and aliphatic diisocyanates [5, 6]. The resulting
polyurea materials could not compete with the existing Nylons, mainly due to their
hydrophilic nature, and were dismissed as impractical by his superiors at I.G.
Farbenindustrie. Further research led to the use of high molecular mass glycols and
aromatic diisocyanates, and yielded the first polyurethane elastomers. A brief summary of
the milestones in polyurethane development is presented in Table 2.2.
Table 2.2: Historical milestones in polyurethane development
1937
1938
1941
1942
1943
1947
1952
1954
1955
1957
1958
1960
1971
1972
1977
1979
1984
1989
1992
1993
2001
First polyurethane patent application (I.G. Farbenindustrie)
First US patent application (Rinke et al.)
Reaction of glycols and diisocyanates
Introduction of Igamid U & UL and Perlon U in Germany   
Vulcollan – introduction of linear polyesters to PU manufacture
First rigid foams (Bayer)
First flexible polyurethanes
Lycra® patent (Langerak)
Patent for Estane® (B.F. Goodrich)
Polyether urethane foams commercially available
Thermoplastic polyurethanes (TPU’s) discovered
US Lycra® patent awarded to Steuber (DuPont)
Avcothane® patent awarded to E. Nyilas (Avco)
Biomer® ((Lycra T-126)
Pellethane® materials introduced (Upjohn)
Second generation aliphatic polyurethanes (PU) disclosed
Patent on thermoplastic elastomers awarded (M Szycher)
Biostable PU (M48) patent awarded (Coury et al.)
Bionate® patent awarded (L. Pinchick)
Chronoflex ® patent awarded (M. Szyzher)
Elast-Eon patent awarded (Meijs et al.)
[5]
[5]
[6]
[5]
[5]
[6]
[6]
[5]
[5]
[6]
[6]
[5]
[5]
[5]
[5]
[5]
[2]
[7]
[8]
[9]
[10]
It is not exactly known when polyurethanes were first introduced to the market for
medical applications [4]. According to Pinchuk [4] the introduction of these materials might
have come from three independent paths. The first might have been as early as the 1950s
when Pangman [11] patented composite polyurethane breast prosthesis, unfortunately
consisting of hydrolytically unstable polyester foams, the only commercially available
polyurethane foams at the time. He continued with his research and it led to the
development of the Natural-Y breast prosthesis patented in 1971 [12].
The second path might have been in the mid-1960s, when Cordis Corporation (Miami,
FL) began marketing the polyurethane diagnostic catheter. The third came in 1967 with the
publication by Boretos and Pierce [13], which may have stimulated the introduction of
aromatic polyether urethanes, such as BiomerTM (Ethicon, Somerville, NJ) and aromatic
polyether urethane pacemaker lead insulators and pacemaker connector modules by
Medtronic (Minneapolis, MN) in 1977 [14].
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Pacemakers require sensing and stimulation in both the ventricle and atrium and
therefore multiple insulated wires have to be maneuvered to the inside of the heart. Silicone
rubber as lead insulation material was found to be too bulky and it was difficult to slide one
lead over another. Polyurethanes offered a solution to both the dimensional constraint and
lubricity problem [4], and they had tensile strengths five times that of silicone rubber.
2.3 Polyurethane synthesis
2.3.1 Reaction conditions
In order to discuss the material properties of polyurethanes and the effect of polymer
structure on such properties, a brief introduction to segmented polyurethane synthesis is
required. Polyurethanes are commercially synthesized via either a “one-step” or a “multi-
step” process. A “two-step” process is generally preferred in the manufacturing of
medical-grade polyurethanes as greater control over the chemistry is possible, influencing
the structure, physical properties, reactivity, and processability of the finished product.
In the first step of the two-step process a prepolymer (Mn up to 15000 – 20000) is
synthesized from the reaction of a macromolecular diol with excess diisocyanate (Figure
2.1). In the second step, the prepolymer (and the remaining unreacted diisocyanate from
the first step) is then further reacted with a diol or diamine chain extender to produce the
desired segmented multiblock copolymer of type (AB)n, where A denotes the soft segment
and B represents the hard segment.
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Figure 2.1: Synthesis of segmented polyurethanes and polyurethaneureas
During the synthesis the reactive diisocyanate may be involved in a number of side
reactions, including [6]:
a) Allophanate reactions (reaction with a urethane group)
b) Biuret formation (reaction with a urea group)
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c) Acylurea (intermolecular interaction with an amide)
d) Isocyanurate formation (trimerization of isocyanate groups)
e) Uretidione formation (dimerization of isocyanate groups)
f) Carbodiimide formation (reaction with another diisocyanate).
Processing considerations that also have an influence on the reaction product include:
reaction temperature, stirring speed, reactor geometry, addition rates of raw materials and
catalyst, choice of catalyst, and reaction medium. For example, chain extension is generally
favored at temperatures below 50 0C, while higher temperatures (50 – 150 0C) will promote
crosslinking and branching reactions. Reaction temperatures above 150 0C lead to
dissociation of biuret and allophanate linkages and degradation of aromatic polyurethanes,
while temperatures above 220 0C will result in the degradation of aliphatic polyurethanes.
Catalysts commonly used in polyurethane synthesis include sodium hydroxide, sodium
acetate and triamines, and transition metals (tin compounds) [6].
2.3.2 Raw materials
An almost endless number and combination of different chain extenders,
diisocyanates and polymeric diols are used in the manufacturing of medical grade
polyurethanes. The generic structure and some examples of commonly used raw materials
used to prepare medical grade polyurethanes are summarized in Table A.1, and a non-
exhaustive list of medical grade polyurethanes, including some of their physical properties,
is given in Table A.2, in Appendix A.
2.4 Biostability of polyurethanes
Polyurethanes undergo a variety of degradation reactions. Polyurethane surfaces are
“mobile”: in an effort to minimize free energy the hard and soft segments can rearrange in
response to the biological environment [5]. If the polyurethane is hydrophobic, the
degradation is usually limited to the surface, while hydrophilic polyurethanes will absorb
water, leading to bulk degradation [5].
It is now generally accepted that the degradation of polyurethanes exposed to blood
and extracellular fluids includes the following processes: (1) adsorption of the medium (e.g.
lipids and proteins) on the polymer surface, (2) diffusion and absorption of the medium into
the bulk of the polymer, (3) chemical reactions with the unstable chemical bonds in the
polymer, and (4) desorption and transport of the degradation products out of the polymer
matrix. Not necessarily all of the above processes occur in every case. Chemical
degradation is often associated with the scission of covalent bonds, but may also involve
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ionic bond transformations or even covalent crosslinking [1] and will thus lead to a
compromise in the chemical and/or physical performance.
In applications of tissue-engineered scaffolds (e.g. vascular grafts) where structural
integrity is required, the physical changes (swelling, crystallization, melting/crystallization
loss, plasticization, fatigue fracture, creep and stress cracking) that might occur could be
detrimental.
Biodegradation will be defined here as the changes in the mechanical and/or chemical
properties of a biomaterial that are initiated or accelerated by the activity of the host
environment. In the following sections the major factors (hydrolysis, oxidation and
mineralization) involved in the biostability/biodegradation of polyurethanes are discussed.
2.4.1 Hydrolysis
Hydrolysis is the scission of susceptible molecular functional groups (e.g. ester bonds
typically found in some polyurethanes) by reaction with the aqueous environment of the
body. Hydrolysis may also be facilitated by polar groups in side chains of the polymer
backbone [15, 16] and be catalyzed by acids, bases, salts or enzymes [17].
The urethane and urethane-urea bonds, found in poly(ether urethanes) and
poly(ether urethane-ureas), although capable of hydrolyzing under accelerated conditions
(e.g. months in boiling water), appear to be more stable and are not considered susceptible
to hydrolysis under normal implant conditions [18]. These conditions could however occur
during manufacturing processes, such as extrusion and injection molding [6]. Other bonds
considered to be very stable to hydrolysis are tabulated in Table 2.3.
Table 2.3: Groups considered to be very stable to hydrolysis [17]
Structure Group
CH2 CH
R
R = H, Alkyl, Aryl
Hydrocarbon
Halocarbon
SiO
CH3
CH3
Dimethylsiloxane
S
O
O
Sulfone
CX2 CX'2
X = F, Cl, H
X' = F, Cl
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Factors that could suppress hydrolysis kinetics include hydrophobic moieties (e.g.
hydrocarbon or fluorocarbon), crosslinking, high crystallinity due to chain order, thermal
annealing or orientation, low stress and compact shape [17]. Porous hydrolyzable
structures, however, undergo especially rapid property loss because of their high surface
area to volume ratio.
Lamba et al. [6] illustrated the hydrolysis reactions of bonds typically involved in
polyurethane degradation, as shown in Figure 2.2. As hydrolysis reactions are facilitated
by water, hydrophilic polyurethanes are therefore more susceptible to hydrolytic
degradation than hydrophobic polyurethanes. Extensive hydrolysis will result in the
presence of deep, usually random cracks on the surface of the material, resulting from
significant reduction in molecular mass [6, 17].
R OC R1
O
H2O
R OH + R1 COOH
Hydrolysis of an ester bond
O R1R
H2O R OH + R1 OH
Hydrolysis of an ether bond
R NH C
O
O R1
H2O R NH2 + R1 OH + CO2
Hydrolysis of an urethane bond
R NH C
O
NH
H2O R NH2 + R1 NH2 + CO2R1
Hydrolysis of an urea bond
Figure 2.2: Hydrolysis reactions of polyurethanes [6]
2.4.2 Oxidation
Poly(ether urethanes) are susceptible to oxidative degradation processes. This
usually requires a continuous source of oxidants (e.g. oxygen) and a means of generating
free radicals [1]. Two powerful sources of free radicals are heat and ultraviolet light. There
are several mechanisms of oxidation, including autoxidation and metal ion induced oxidation
(MIO) (§2.4.2.2), oxidation by peroxides, free radicals, enzymes and cells (§2.4.5).
It had been suggested [4, 6] that oxidation occurs in the polyether soft segment at the
α-methylene position. Degradation can also occur in the soft segment by abstraction of a
hydrogen atom from the methylene carbon by free radicals. Anions and cations could
catalyze the oxidation reaction in a similar manner to that in which they catalyze hydrolysis
[4].
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2.4.2.1 Autoxidation
Most polyurethanes undergo autoxidation, but it is considered to occur at a negligibly
slow rate. Overheating (e.g. as occurring during processing or sterilization) could catalyze
the reaction, resulting in the cleavage of the urethane bond between the isocyanate and
the diol (Figure 2.3), ultimately leading to the formation of shallow (≤ 10 µm) “mud-cracks”.
R NH C
O
OR1
Δ
R N C O + R1 OH
R NH C
O
O CH2 CH2R1
Δ R NH2 CO2+ H2C CH2 R1+
R NH C
O
OR1
Δ
R NH R1 CO2+
2 R N C O
Δ
R N C N R CO2+
Figure 2.3: Thermal degradation of polyurethanes [6]
Autoxidation (considered as thermal oxidation) is believed to take place by a free-
radical process at temperatures above 150 0C [6]. A detailed description of the reactions
involved is given by Stokes et al. [19]. Initiation, propagation and termination result in chain
cleavage, which could be self-propagating once initiated.
2.4.2.2 Metal ion induced oxidation
The process of metal ion induced oxidation, thus far only reported in the pacemaker
literature, requires a very specific set of conditions. Metal ion induced oxidation takes place
on the enclosed inner surface of the pacing lead insulation near corroded metallic
components and their entrapped corrosion products. Metal ions are often found at the sites
of degradation: cobalt and molybdenum have been implicated as particularly vigorous
promoters of metal ion induced oxidation [3]. Smooth crack walls and a microscopically
random crack orientation are indicative of brittle fracture [17].
Several mechanisms have been proposed for metal ion induced oxidation, involving
cell encapsulation with high concentrations of hydrogen peroxide or superoxides from cells
[6]. Stokes et al. [20] have suggested that metal ion induced oxidation can possibly occur by
anaerobic processes as well as autoxidation.
In the anaerobic mechanism, polymer oxidation is initiated by the abstraction of
hydrogen by oxidized transition metal ions [20], but it is possible that other mechanisms
could also be involved, given the complex biological environment [6].  
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2.4.3 Mineralization (calcification)
Mineralization is the attachment and incorporation of inorganic crystalline materials to
implanted structures [1]. Micro defects (induced or enhanced by intensive flexing),
neointemal surfaces or fabrication imperfections catch debris, which can nucleate the
formation and growth of crystals rich in forms of calcium phosphate [1].
It predominantly occurs in devices subjected to dynamic flexing in soft tissue or in the
bloodstream where mechanical activity is most pronounced. Polyurethanes subjected to
gentle motion in vivo are less likely to show overt calcification [18]. Mineralization in
polyurethane insulated pacemaker leads has not yet been observed, even after 3.5 years
implantation [1, 18]. Mineralization of the fibrotic sheath surrounding the leads have been
observed, but it had no effect on the leads [6].
2.4.4 Sterilization
The use of high-energy radiation is generally considered an attractive form of
sterilization, because of the resistance that polyurethanes exhibit [6]. Extremely high doses
could however have a detrimental effect and result in progressive degradation [21].
Shintani and Nakamura [22] found that γ radiation could lead to the release of MDA
(methylene bis (p-phenyl aniline)) in MDI (methylene bis (p-phenyl isocyanate)) based
polyurethanes, with correlation between the radiation levels and the release of MDA.
Steam sterilization has also been indicated as a contributing factor in polyurethane
degradation, resulting in the formation of MDA in MDI-based polyurethanes, and suppliers
have therefore cautioned the use of steam for sterilization purposes [6, 23]. Ethylene oxide
treatment is usually preferred, as it causes essentially no change in the properties of the
polyurethanes [24].
2.4.5 Biological catalysis of degradation
The biological degradation of polyurethanes occurs as a result of direct cellular and
enzymatic interaction or by the production of oxidative or hydrolytic components. The
mechanisms of enzyme and cell associated degradation can be the basic mechanisms of
oxidation and hydrolysis, as described above [6]. Calcification (§2.4.3) and environmental
stress cracking (§2.4.6) have been found in association with cells and enzymes [6].
2.4.5.1 Enzymes
Enzymes, whether secreted from cells or from the blood, are now known to be
involved in both the hydrolysis and oxidative degradation of many different polymers,
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including polyurethanes [6, 25-28]. Enzymes, including esterase, trypsin, chymotrypsin,
collagenase, cathepsin B, xanthine oxidase and lysosomal liver enzymes, just to name a
few, have been implicated.
A well-known and extensively studied polyurethane, Pellethane® 2363-80A (Dow
Chemicals), is highly sensitive to especially chymotrypsin, papain and trypsin, resulting in
the cleavage of the ether bond [29-31]. The exact mechanism and enzyme involved is
however highly dependent on the specific polyurethane [6].
2.4.5.2 Cells
Many different cells release active compounds that affect the degradation of
polyurethanes. In an extensive study conducted by Labow et al. [32] both macrophages
and neutrophils have been directly implicated in polyurethane degradation. Phagocytes,
macrophages and neutrophils will try to engulf the foreign material in an attempt to digest or
“kill” it. It has been speculated [5, 6, 20, 31, 33] that this could occur through an oxygen-
dependent or oxygen-independent mechanism.
In the oxygen-dependent mechanism, cells release superoxide anions, hydrogen
peroxide, hydroxyl radicals and a host of halogenating substances, which will result in
oxidative degradation. The oxygen-independent mechanism appears to involve hydrolytic
enzymes.
2.4.6 Environmental stress cracking
Environmental stress cracking requires an “active chemical agent” and tensile stress.
The biological environment is a particularly aggressive one and thus provides a number of
possible active chemical agents [5, 6, 18, 31, 34]. Stress could be introduced during the
manufacturing (e.g. extrusion or injection molding) of the specific device or due to phase
separation in response to the biological environment [5].
The attachment of cells onto the surface of a polymeric material may provide an
interfacial area where the cell/polymer interactions are possibly accentuated, thereby
initiating surface microcracks propagated by residual (internal) stress. Applied external
stress results in the elongation and enlargement of the cracks for cells to enter, thus
facilitating degradation, and which can propagate deeper into the bulk [31]. Environmental
stress cracking is characterized by deep ragged fractures within the polyurethane,
perpendicular to the direction of the applied stress (Figure 2.4). In more advanced cases
the polyurethane has three-dimensional cracks, referred to as mud-cracks [6].
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Figure 2.4: Scanning electron microscope image showing environmental stress
cracking in Pellethane® 2363 80A [4]
2.5 Mechanical properties of medical grade polyurethanes
Some of the most important mechanical properties of selected medical grade
polyurethanes, as summarized in Table A.2 (Appendix A), will briefly be discussed in this
section.
The Pellethane 2363 medical grade polyurethane family (Dow Chemicals, USA) has
been widely used since its introduction as biomaterial in 1977 [1, 3, 5, 18, 19, 24, 34, 35]. It
is an aromatic poly(ether urethane) with a hard segment consisting of 4,4-
methylenebis(phenylisocyanate) (MDI) and 1,4-butanediol (BDO), while its soft segment
consists of poly(tetramethylene oxide) glycol (PTMEG) (Mn = 1000 g/mole) [18, 36-39].
It is available in a shore hardness range of (80A, 80AE, 90A, 90AE) and (55D, 55DE,
65D, 75D). The former, which is the softer, has a stress and strain at break ranging from
28.9 to 41.3 MPa and from 500 to 650%, respectively. In contrast, the harder Pellethane (D
shore hardness) has a significantly higher stress at break (40.0 - 47.5 MPa), but a much
lower strain at break (380 - 450%). The difference in tensile properties between the
Pellethane A and D series is further evident in the large difference in their Young’s moduli
(13.2 MPa and 87 MPa, respectively).
Techothane TT (Thermedics, USA) is another example of a aromatic poly(ether
urethane) and, like Pellethane, have hard and soft segments consisting of MDI and PTMEG,
respectively, although the exact chain extender used is not known [40, 41]. Techothane TT
is also available in a shore hardness of A and D, but has a much higher stress at break
(41.3 - 68.9 MPa) and significantly lower strain at break (150 - 450%), when compared to
Pellethane.
Tecoflex EG (Thermedics, USA) is an aliphatic poly(ether urethane) with a soft
segment and chain extender consisting of PTMEG and BDO, respectively, but is based on
the fully hydrogenated version of MDI namely HMDI (4,4-methylenebis (cyclohexyl
isocyanate)) [18, 37, 40]. Tecoflex EG is available in a shore hardness of (80A, 85A, 93A
and 100A) and (60D, 65D, 68D and 72D), respectively. Tecoflex generally has a much
higher stress at break (40.0 - 57.2 MPa), but a significantly lower strain at break (310 -
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660%) when compared to the Pellethane 2363 series. The stress at 100% elongation (E100)
of Tecoflex EG however compares very well with Pellethane 2363 for both the A and D
shore hardness series.
Biospan (Polymer Technology Group, USA) is an aromatic poly(ether urethane urea)
based on MDI and PTMEG, but is chain extended with a diamine [37, 42]. Biospan is only
available in a shore hardness of 70A and has a stress at break of 41.3 MPa, which is
comparable with Pellethane and Techothane. The strain at break of Biospan (850%) is
among the highest of all polyurethanes studied, while its Young’s modulus (5.9 MPa) is
among the lowest.
Bionate (Polymer Technology Group, USA), an aromatic polycarbonate polyurethane,
has a hard segment and chain extender, comprising MDI and BDO, respectively. Poly(1,6-
hydroxyl 1,2-ethyl carbonate) diol is used as the soft segment [37, 41, 42]. It is available in
a softer grade (80A and 90A) and a harder grade (55D and 75D). The stress (48.1 - 68.9
MPa) and strain (260 - 570%) at break of the Bionate series is comparable to the aromatic
polyether urethane, Techothane, but has a much higher stress and lower strain at break
when compared to Pellethane. The stress (37.9 - 55.2 MPa) and strain (255 - 490%) at
break of Chronoflex C (Cardiotech Inc., USA) (80A, 55D, 75D), also an aromatic
polycarbonate polyurethane, is more comparable to Pellethane [43].
In general, the aliphatic polycarbonate polyurethanes Chronoflex AL (Cardiotech Inc.,
USA) and Carbothane (Thermedics, USA) have lower stress and strain at break when
compared to the aromatic polycarbonate polyurethanes Bionate and Chronoflex C [37, 40,
41, 43].
Silicones have long been known to be biostable and biocompatible in most implants
[42]. Conventional silicone elastomers can have very high ultimate elongations, but
unfortunately have low tensile strengths [36, 42]. Elast-Eon 3 (Aortecbio, USA), PurSil and
CarboSil (Polymer Technology Group, USA) are thermoplastic copolymers containing
polysiloxanes in the soft segment. These polyurethanes are prepared by a multi-step bulk
synthesis where poly(dimethyl siloxane) (PDMS) is incorporated into the polymer soft
segment with PTMEG (PurSil), an aliphatic hydroxyl-terminated polycarbonate (CarboSil), or
poly(hexamethylene oxide) (PHMO) (Elast-Eon 3).
The hard segment of PurSil is either based on MDI (PurSil AR) or an aliphatic aromatic
diisocyanate (AIDI) (PurSil AL). The stress and strain at break of PurSil AR and AL are
comparable, and in the range of 24.8 MPa to 36.5 MPa and 620% to 900%, respectively.
The Young’s modulus of PurSil AL (1.9 MPa) is significantly lower than for PurSil AR (5.6 -
7.2 MPa). Although the stress at break of CarboSil (29.6 - 42.6 MPa) is of the same order of
magnitude as that of PurSil, CarboSil has a significant lower strain at break and much higher
Young’s modulus than PurSil.
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In the following section the influence of the raw materials on the biostability and
mechanical properties of the polyurethanes will be discussed.
2.6 Influence of polyurethane chemistry on biostability and
mechanical properties
Polyurethanes used in the manufacturing of medical devices are generally elastomers
consisting of hard and soft chain segments. These segments are to some degree
thermodynamically incompatible, resulting in a heterophase microstructure [24]. The
physical and chemical properties of segmented polyurethanes depend therefore not only on
the chemical nature of the raw materials and relative ratios used, but also on the structure
of the resulting microphases and the interaction between these phases. The hard
segments form glassy or semi-crystalline domains dispersed in the amorphous soft
segment matrix. Virtual crosslinking is achieved through hydrogen bonding of the
respective hard segments (glassy hardness, and where applicable, crystallinity), resulting
in a material exhibiting high modulus and elastic behavior normally associated with
covalently crosslinked polymers.
2.6.1 Diisocyanate
One of the main considerations in the choice of the hard segment is the use of an
aromatic versus an aliphatic isocyanate. This has been a topic of much discussion over the
past few years. The most frequently used aromatic isocyanate in the medical industry to
date has been methylene bis(p-phenyl isocyanate) (MDI) while methylene bis(p-cyclohexyl
isocyanate) (HMDI) has been the most frequently used aliphatic isocyanate [4].
Organic chemistry dictates that aromatic isocyanates should be more stable than
aliphatic ones. Aromatic isocyanates are stabilized by resonance, an effect involving the
sharing of π-electrons by adjacent atoms. The bond strengths of the resonance stabilized
aromatic isocyanates are significantly higher than in the equivalent aliphatic molecule, thus
requiring more energy to break or degrade [4, 6]. Aromatic diisocyanates (e.g. MDI) also
have a rigid planar structure that provides stiffness, strength and hard-segment character
to polyurethanes, while the fully hydrogenated version of MDI, namely HMDI (4,4-
methylenebis (cyclohexyl isocyanate)), provides for weaker hard-segment aggregation and
yields weaker polyurethanes with poorer dynamic performance, such as shorter flex life,
larger stress hysteresis, lower impact and abrasion resistance [24].
Aromatic isocyanates have greater intermolecular bond strengths than aliphatic
isocyanates, because of their semicrystalline nature. Crystallization of the hard segment is
favored with increasing symmetry of the isocyanate, resulting in an increase in phase
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separation, modulus, hardness and abrasion resistance [6]. Cycloaliphatic isocyanates, e.g.
HMDI, cannot crystallize due to the configurational isomers present. HMDI can change from
a boat form to a chair form, which disturbs its crystallinity [4] and will generally result in
polyurethanes with poorer high-temperature properties and lower solvent resistance.
Polyurethanes based on aliphatic diisocyanates do however have certain
advantages. They have been shown by Frisch et al. [44] to be more stable to alkaline
hydrolysis and to have greater thermal stability [45]. They also do not yellow when
exposed to light for prolonged periods of time, whereas aromatic polyurethanes may
yellow. This is however only a cosmetic difference, and has no bearing on the
performance of the respective polyurethanes [4].
2.6.2 Polymeric diol
The flexibility (especially at low temperatures) and the elongation at break of
polyurethanes are to a large degree dependent on the polymeric diol used as the soft
segment. The glass transition temperature will decrease with an increase in molecular
mass of the diol and a higher degree of microphase separation is achieved, which also
increases the ease of the backbone rotation in the soft segment, which ultimately results in
a more extensible material [6].
The chemical stability of polyurethanes is closely linked to the chemical nature of the
polymeric diol that constitutes the soft segment. Although polyurethanes synthesized from
polyester-containing soft segments possess good mechanical properties, they are very
sensitive to hydrolytic cleavage of the ester linkage. As an alternative, polyether soft
segments provide the required in vivo hydrolytic stability, while maintaining most of the
desired mechanical properties [1]. They have however been shown to be susceptible to
oxidative degradation in the presence of metal ions and other strong oxidants [3, 18].
Poly(tetramethylene oxide) glycol (PTMEG) containing polyurethanes have comparable
mechanical properties to the polyester counterparts and further possess relatively good
hydrolytic stability [45].
This finding had prompted further research into possible soft segment replacement,
resulting today in the incorporation of polymeric carbonates [37, 40, 41, 43, 46-50],
siloxanes [36, 42, 51-53], hydrocarbons [52] and fluorinated ethers [54-56].
2.6.3 Chain extender
Polyurethanes are also strongly influenced by the chemical nature and ratio of the
chain extender incorporated. An increase in the ratio of the chain extender will result in a
harder, stiffer and stronger material with higher tear strength, but with lower abrasion
resistance and elongation [24]. Generally, the use of aliphatic extenders leads to polymers
Jacobus Petrus Theron Chapter 2: Background
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prostheses 22
that are softer than those obtained with aromatic extenders [6]. The molecular mass of the
extenders also has a strong influence on the crystallinity of the hard segment, which in turn
will affect the physical properties of the resulting polyurethane [6].
The most commonly used chain extenders are: 1,4-butanediol used in Pellethane®,
Tecoflex® and CorethaneTM polyurethanes, while amine terminated chain extenders such
as ethylene diamine (EDA) and 1,4-diamino cyclohexane (DAMCH) are used in
polyurethanes such as Lycra®, BiomerTM and CoremerTM. The resulting urea linkage
renders the polyurethane difficult to extrude or mold, therefore limiting application in dip-
coating or fiber production [4].
2.7 Proposed polyurethane requirements for the manufacture of
cardiovascular devices
It is therefore proposed that, depending on the particular application, the polyurethane
used should have the following required properties:
(A) Processability:
• It should be possible to use different manufacturing techniques (e.g. solvent
casting, extrusion, electrospinning etc) to economically and consistently
manufacture uniform and high quality devices.
• The use of conventional methods of sterilization should not have a negative
impact on material integrity and other properties.
(B) Mechanical properties
• The intended material should be elastomeric.
• It should display good suturability and general handling characteristics.
• The material should not be prone to excessive dilation (unrecovered energy
loss) when subjected to continuous cyclic stresses as in a vascular graft
application.
(C) Chemical stability (biostability)
• The material should not be susceptible to oxidation and hydrolysis, nor be
prone to environmental stress cracking and calcification.
• It should further not be toxic, inflammatory or thrombogenic, either in itself or
upon the release of possible degradation products.
The required material should therefore preferably contain:
• Aromatic hard segments for good microphase separation
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• Hydrocarbon- or siloxane-based soft segments for oxidative and stress
cracking resistance
• Permanent covalent crosslinks as opposed to weak hydrogen bonds.
Two polyurethanes were selected as starting materials in this study: Pellethane®
2363-80AE (Dow Chemicals, USA) and PurSil® 35 80A (Polymer Technology Group Inc,
USA). The hard segments of both these polyurethanes consist of MDI. The soft segment of
the former is poly(tetramethylene oxide) glycol (PTMEG), and chain extended with 1,4-
butanediol, while the latter has a soft segment consisting of 35% polydimethylsiloxane.
2.8 Conclusions
Thermoplastic polyurethanes are very attractive candidates as biomaterials due to
their great flexibility in chemical and physical properties (e.g. processability) and are
therefore widely used for the manufacture of a great variety of medical devices.
The body is a very aggressive environment and polyurethanes have not yet been
shown to have the long-term biostability required for use as a long-term medical implants.
Polyurethanes further suffer from large energy losses (hysteresis) when subjected
to continuous cyclic loading, due to the transient (weak) nature of virtual crosslinking by
physical associations.
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Chapter 3
Model urethane compound study
Abstract
Difficulties in following the chemistry of the modification reactions of large, complex
polyurethanes involving small molecules, prompted the synthesis of a model
urethane compound as a smaller, less complex structure, but representative of the
hard segment of Pellethane® 2363-80AE (academic polyurethane standard). The
resulting molecule was then reacted with different acyl chlorides (including
hexanoyl, acryloyl and 4-pentenoyl chloride). Reactions with hexanoyl chloride
confirmed the proposed reaction site to be the carbamate nitrogen. Reaction
conditions were optimized and good conversions were achieved when the
nucleophilicity of the carbamate nitrogen was increased using either sodium
hydride (53.3%) or butyllithium (79.1%). Reactions with 4-pentenoyl chloride
simulated the introduction of latent crosslinking groups. The highest conversion
was again achieved using nucleophilic enhancement with sodium hydride (51.5%)
and butyllithium (63.1%). The model compound could be used to simulate and
optimize the reaction between the carbamate nitrogen and selected acyl chlorides
for future application to polyurethane modification via crosslinking.  
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3.1 Introduction
The accurate control of the modification of polyurethanes with latent crosslinking
groups, and thus control over the structural crosslinking, is a critical consideration for
materials intended for medical or biological applications.
Polyurethanes are large and complex molecules. The number average molecular mass
(Mn) of Pellethane® 2363-80AE, a well-known medical grade polyurethane (PU), is
approximately 45 000 g/mole. Many commercial thermoplastic polyurethanes (TPU) comprise
a hard segment consisting of 4,4-methylenebis(phenylisocyanate) (MDI) and 1,4-butanediol
(BDO) [1]. Pellethane® 2363-80AE has a soft segment consisting of poly(tetramethylene
oxide) glycol (PTMEG) (Mn = 1000 g/mole) [2].
The size and complexity of such polyurethane molecules therefore make it almost
impossible to study modification reactions involving small molecules by standard analytical
techniques (including nuclear magnetic resonance spectroscopy (NMR)), due to e.g.
dynamic range problems (i.e. limited concentration ranges, especially with proton NMR).
The utilization of a smaller, less complicated molecule, a so-called model compound,
could hence enable more accurate investigation of the chemistry involved in modification
reactions, by enabling the monitoring of reactions using standard organic chemistry
techniques, such as thin layer chromatography. Quantitative analyses of the product using
nuclear magnetic resonance spectroscopy (NMR), high-resolution mass spectrometry
(HRMS) and matrix-assisted laser desorption/ionization (MALDI) is then also possible.
Thus, in order to avoid the complexities of macromolecules and the difficulties
associated with their characterization, a model urethane compound with similar structure to
the repeating hard segment of Pellethane® 2363-80AE (see Figure 3.1) was synthesized
via the reaction between MDI and 1-butanol (BtOH) and the product then isolated, purified
and characterized.
Figure 3.1: Chemical structure of Pellethane® 2363-80AE showing hard segment
structure in square brackets
The synthesized model compound was then used to study and evaluate the acylation
reaction to be used on the polymer by reaction with different candidate acyl chlorides. As
the reaction may be achieved by either increasing the strength of the nucleophile
(carbamate nitrogen), or by improving the electrophilicity of the modification agent (acyl
chloride), both routes were investigated. The complicating factor, however, lay in the fact
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that the concept requires the modification reagent to also contain a second group that is
unaffected by the modification reaction, but is capable of crosslinking the modified material
at a later stage (in this case, an acrylate or a vinyl was desireable). It was therefore hoped
that results of the model compound study would identify an effective acylating agent and
appropriate acylation conditions, which would yield a product that would still be effective in
crosslinking.
These two aspects were separated such that optimized acylation conditions were
initially identified using an acyl chloride with a long saturated aliphatic tail (e.g. hexanoyl
chloride). Reactions were subsequently carried out with other acyl chlorides containing
unsaturated groups capable of remaining stable during the N-acylation reaction in order to
address the crosslinking aspect.
3.2 Historical
3.2.1 Synthesis and modification of the model urethane compound
As the hard segments of most commercial TPUs are based on MDI and BDO, it is no
surprise that model compounds containing MDI and BDO have been investigated by a
number of authors [1, 3-8]. Most have focused on either the kinetics involved in the reaction
between various diisocyanates and alcohols, including MDI and BDO [8], or the physical
properties of these materials [3-5, 8], while one study [1] has investigated reactions
between model compounds and several common functional groups.
Although the references mentioned above do not include the acylation reactions
intended in the current study, it is considered useful to describe the most applicable
reactions in some further detail.   
Caraculacu and Agherghinei [8] described a new method of following the kinetics of
uncatalyzed reactions between diisocyanates and alcohols (including MDI and BtOH). Their
method allowed for the determination of the concentration of all species occurring during
the reaction by means of high-performance liquid chromatography. It was found that the
relationship between the unchanged fraction and the fraction that reacts, theoretically
inferred for ideal systems (null catalytic effect), is validated over the whole reaction for real
systems. The rate constant for the reaction between MDI and BtOH was found to be equal
to 1.36 in comparison to 3.07 when a mixture of methanol and 1-butanol was used instead.
Yang et al. [3] found that terminal hydroxyl groups facilitated the thermal degradation
of carbamate groups. Lu et al. [1] therefore chose model urethanes with hydrocarbon end
groups in the high temperature reaction studies. They first prepared a model compound by
capping MDI with BtOH. The reactions between the model compound and various mono-
functional compounds, as well as two model poly(ethylene glycols), were studied at
elevated temperatures (170 – 200 0C). Carbamate conversion was measured, by NMR, in
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this kinetic study. The ranking of reactivity of the functional groups with the model
compound was found to be: primary amine > secondary amine >>> hydroxyl ~ acid ~
anhydride >>> epoxide.
Model compounds (similar to the one used in the current study) were successfully
synthesized and characterized. The rate constant for the uncatalyzed reaction between
MDI and BtOH was found to be low, while model compounds with terminal hydroxyl groups
would not only surely lead to polymerization, but also facilitate thermal degradation.
Modification reactions involving the carbamate moiety of the model compound were carried
out under vigorous reaction conditions (high temperatures), not necessarily suitable for the
intended future modification of polyurethanes.     
 Functionalization of the carbamate moiety, an important structural element of biological
active compounds, has played a crucial role in synthetic organic chemistry [9]. It offers
great potential e.g. in the generation of large combinatorial libraries for rapid screening and
drug design [9]. Reactions with other small organic compounds containing carbamate
moieties not necessarily similar to the specific one under investigation in this dissertation
are considered useful and a brief overview will be given.
3.2.2 Functionalization of carbamate-containing organic compounds
Salvatore et al. [9] reported on the use of cesium carbonate (Cs2CO3) and
tetrabutylammonium iodide (TBAI), which serve as base and catalyst, respectively, in the
chemoselective alkylation of various aliphatic and aromatic carbamates. In one such an
example (Scheme 3.1) an aromatic carbamate was alkylated and a yield of up to 98% was
achieved using benzyl chloride (BnCl) as alkylating agent (at room temperature) in N,N-
dimethylformamide as solvent. In a further example, however, the reaction with cyclooctyl
carbamate (aliphatic carbamate) was not successful and the developed method proved to
be very sensitive to the chemical structure of the carbamate.
Scheme 3.1: N-Alkylation of an aromatic carbamate using benzyl chloride [9]
Similarly, also in the context of N-acylation of a nitrogen molecule attached to a
carbonyl group, Kondo et al. [10] attempted to synthesize N-acylanilides (Scheme 3.2),
using acyl chloride or anhydride in pyridine, as a potentially good leaving group for the
chemoselective acylation of amino groups, but did not succeed.
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Scheme 3.2: Attempted synthesis of N-acylanilides [10]
Surprisingly, no successful examples could be found in the open literature on the
acylation of small carbamate containing organic molecules. It can only be concluded that the
proposed N-acylation of the carbamate moiety, as described in this dissertation, is not a
trivial problem and that it may require the use of harsh reaction conditions, involving e.g. the
use of a strong base like sodium hydride or n-butyllithium, to enhance the nucleophilicity of
the carbamate nitrogen.
3.3 Theoretical considerations related to the modification of the
carbamate nitrogen
3.3.1 Basicity and nucleophilicity of the carbamate nitrogen
Nucleophilicity is the ability of a donar atom (nitrogen) to form a bond by electron
donation (δ-). The lone pair of electrons on the nitrogen atom thus generally renders amines
basic and nucleophilic. The pKa values of the conjugated acids of simple amines increase
(i.e. increase in basicity) with increasing alkyl substitution; this is due to the electron
release from the alkyl groups, up to the di-alkylamine level [11]. The pKa values of some
conjugated acids in water at 25 0C are given in Table 3.1.
Table 3.1: pKa values for some conjugated acids in water at 25 0C [11]
Amine pKa
NH3 9.25
C2H5NH2 10.80
(C2H5)2NH 16.09
(C2H5)3N 10.85
C6H4NH2 4.58
C6H4N(C2H5)2 6.56
Aromatic amines are generally less basic, and nucleophilic, than their alkyl
counterparts because of back donation of the nitrogen lone pair into the aromatic p system,
therefore rendering it less available for direct reaction (+R effect).
Carbamates, on the other hand, are even less basic, and nucleophilic, than aromatic
amines [11]. Not only is the lone electron pair (on the nitrogen) compromised by back
donation into the aromatic p system (as described above), but also because of
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delocalization into the carbonyl group, rendering the nitrogen atom even less available for
direct reaction (Figure 3.2).
Figure 3.2: Resonance structure of the carbamate nitrogen
3.3.2 Acyl chlorides as possible modification reagent
Many important functional groups used in organic chemistry contain a carbonyl group
(CO): aldehydes, ketones, carboxylic acids, esters, amides, etc.
The carbon of a C=O bond is sp2 hybridized and, further, lies in the same plane as the
atoms attached to it, with bond angles around 1200. The carbon – oxygen bond length is
typically ≈120 pm in aldehydes and ketones compared to ≈140 pm in alcohols and ethers.
Oxygen is more electronegative than carbon and the C=O bond is polarized accordingly
(Figure 3.3).
Figure 3.3: Polarization of the carbonyl bond
As a result, substrates of the type R(CO)X (where X is referred to as the leaving
group and R forms part of the substrate) are very reactive towards nucleophilic
substitution. They are, for example, much more reactive than the corresponding RCH2X type
substrates. The three main reasons for the enhanced reactivity of R(CO)X can be given as
follows. (1) The carbonyl carbon has a sizeable partial positive charge that makes it very
attractive to nucleophiles. (2) In a tetrahedral mechanism (mechanism involved in substrates
of the type R(CO)X) π electrons shift, which requires much less energy than in the SN2
reactions (RCH2X) where a σ bond must break in the rate-determining step. (3) A trigonal
carbon offers less steric hindrance to a nucleophile than a tetrahedral carbon [11]. An
illustration of the generalized mechanism for the addition step is given in Figure 3.4.
R R'
O
Nuc
O
R R'
Nuc
Figure 3.4: Generalized mechanism for the nucleophilic addition step
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The leaving group (X) has a direct influence in the success and rate of the
nucleophilic substitution reaction and affects the reactivity of the substrate. It alters the
electron density at the carbonyl carbon, which affects the rate of the reaction. The greater
the electron withdrawing character of X, the greater the partial positive charge on the
carbon atom and the more rapid the attack by the nucleophile. The following sequence in
reactivity is hence obtained: R(CO)Cl (acid chloride) > R(CO)O(CO)R’ > R(CO)OAr >
R(CO)OR’ > R(CO)NH2 > R(CO)NR’2 > R(CO)O- [11].
Hydrogen atoms alpha to the carbonyl are acidic and may be abstracted by a strong
base or an anion, resulting in the formation of an enolate ion, as illustrated in Figure 3.5.
R''C R
O
H
B
R''C R
O
R''C R
O
Figure 3.5: Resonance structure showing formation of the enolate atom
The proton is acidic because the carbonyl group can stabilize the negative charge.
The pKa of an alpha proton in a ketone is ≈20 and a strong base such as n-butyllithium can
remove it. The pKa of an alpha proton in a 1,3-dicarbonyl compound is ≈10 and a base such
as an ethoxide ion can remove it [11].
3.3.3 Reaction approach
3.3.3.1 Increasing the electrophilicity of the acyl chloride
Although acyl chlorides are generally good electrophiles (as discussed in §3.3.2) their
electrophilic character can further be enhanced by increasing its leaving group potential.
Acylpyridinium salts e.g. enhance the acylating potential of acyl chlorides, because pyridine
is a better leaving group and it is neutral compared to e.g. anionic chloride.
Scheme 3.3: Resonance structures of the dimethylaminopyridine-acylpyridinium
salt, illustrating electrophilic enhancement
NN + Cl C
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O
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Jacobus Petrus Theron Chapter 3: Model compound study
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prosthesis 33
Delocalizing the cationic charge of the acylpyridinium species can further enhance
this character, as is illustrated in Scheme 3.3. A good example of such a species is
dimethylaminopyridine-acylpyridinium salt. Other species could also include imidazole.
3.3.3.2 Increasing the nucleophilicity of the carbamate nitrogen
The nucleophilic character of the nitrogen of carbamates can be enhanced by
inonizing the carbamate. A strong base can be used to deprotonate the amide, rendering a
strong base and also enhancing the nucleophilicity of the amide (Scheme 3.4).
Strong bases that have the potential to deprotonate the amide include n-butyllithium
and sodium hydride.
Scheme 3.4: Resonance structures of the carbamate, illustrating nucleophilic
enhancement
3.4 Experimental
3.4.1 Materials
The following materials were used for the preparation of the model urethane
compound. Methylenebis(p-phenylisocyanate) (Aldrich, Cat: 25,643-9) and 1-butanol
(Riedel-de Haën, Cat: 34931) were used as the only two reagents. Tetrahydrofuran (THF)
(Merck, Cat: AB009731) was used as solvent and dibutyltin dilaurate (DBTDL) (Aldrich, Cat:
29,123-4) as catalyst. n-Hexane was obtained from Merck (Cat: 152496G). Molecular
sieves (Riedel-de Haën Cat: 31812) were used as drying agent for the tetrahydrofuran,
which was freshly distilled.
The following materials were used for the acylation, extraction and purification of the
model urethane compound. A number of acyl chlorides were investigated, including:
acryloyl chloride (Aldrich, Cat: A2,410-9), hexanoyl chloride (Aldrich, Cat: 29,465-9) and
4–pentenoyl chloride (Aldrich, Cat: 46,847-9). N,N-dimethylformamide (DMF) (Aldrich, Cat:
27,054-7) and dichloromethane (DCM) (Aldrich, Cat: 27,099-7) were used as solvents. n-
Butyllithium (Aldrich, Cat: 18,617-1), 60% (w%) sodium hydride (Fluka, Cat: 71620) (strong
bases) and dimethylaminopyridine (DMAP) (Aldrich, Cat: 10,770-0) (acyl transfer agent).
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Diisopropylethylamine (Hünig's base) (Aldrich, Cat: 49,621-9) and pyridine (Aldrich, Cat:
27,040-7) were used as acid acceptors.
Thin-layer chromatography plates (TLC) with aluminum support (Merck, Cat:
1.05554.0001) were used for monitoring purposes, and preparative thin-layer
chromatography plates (PTLC) with glass support (Merck, Cat: 5717) for the separation of
reaction products. A mixture of ethyl acetate (Merck (SA), Cat: 2235020) and petroleum
ether (Merck (SA), Cat: 4947040) were used as mobile phases.
3.4.2 Synthesis of the model urethane compound
The experimental formulation for the preparation of 50 g (theoretical yield) of the model
compound (chemical structure which is given later in Scheme 3.5) is summarized in Table
3.3. A fifty percent excess of 1-butanol was used.
A 1000-ml round-bottomed flask was fitted with a thermometer, inert gas (He) inlet,
gas outlet, magnetic follower, a cooled condenser and a heating mantle.
Table 3.3: Formulation of model compound synthesis
Reactants Mass (g)
1-Butanol (BtOH) 27.96
Tetrahydrofuran (THF) 280.00
4,4-Methylenebis(phenylisocyanate) 31.46
Dibutyltin dilaurate (DBTDL) 0.10
The reaction vessel was charged with the 1-butanol, and water was removed by
azeotropic distillation (93 0C). The condenser was then removed and the helium flow rate
set at 3 l/min. After cooling to 40 0C and addition of 120 g of THF, DBTDL (0.10 g) (catalyst)
was added and the reaction mixture re-heated to 50 0C.
Pre-dissolved MDI (31.46 g in 160 g THF) was subsequently added to the vessel over
5 - 10 min, from a dropping funnel. After 5 h of reaction at 50 0C the heating source was
removed. The reaction mixture was allowed to cool to room temperature (RT, ≈20 0C) and
thereafter reacted for an additional 17 h. The reaction was performed throughout under
constant stirring and inert (He) atmosphere.
Excess solvent was removed by bubbling with helium gas, and the concentrated
product recovered by precipitation in a 10-fold excess of cold n-hexane (-10 0C). After
drying (under vacuum, RT, 24 h) the product was purified by redissolving in THF and
precipitating with n-hexane, before calculation of the yield.  
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3.4.3 Acylation of model urethane compound
Reactions involving an array of different reagents and solvents were first performed
on small scale (0.5 mmol) involving two reaction approaches (see §3.4.3.1A and §3.4.3.1B)
and the reactions were qualitatively analyzed using thin-layer chromatography (TLC).
Selected reactions were scaled up (§3.4.3.2) and products separated by preparative thin-
layer chromatography. The products were then quantitatively analyzed by nuclear magnetic
resonance spectroscopy, high-resolution mass spectroscopy and matrix-assisted laser
desorption/ionization.
3.4.3.1 Small-scale reactions
A: Increasing the nucleophilicity of the carbamate nitrogen
A 25-ml round-bottomed reaction vessel was supplied with a septum and inert gas
supply. Reactions were carried out under anhydrous conditions using freshly distilled
solvents under an inert atmosphere (helium gas). Either sodium hydride or n-butyllithium
was selected as base.
Sodium hydride (1.25 mmol) and THF (2 ml) were added to the reactor and cooled to
below 0 0C, using a mixture of ice and ethanol. The model compound, pre-dissolved in 1 ml
of THF, was then slowly added to the reactor over 5 min and the resulting mixture was left
for 30 min to allow the formation of the anion.
When n-butyllithium was used as base, the pre-dissolved model compound was first
added to the reactor, whereafter the contents were cooled down (below 0 0C), followed
by the addition of the n-butyllithium (dropwise over 5 min) (see Table 3.4 for list of
reactants and formulation used).
Table 3.4: Formulation for acylation reactions of the model compound (compound 1)
to increase nucleophilicity
Components Reactants Quantity Mass
1. Strong base 1.1 Sodium hydride (NaH) 1.25 mmol 0.05 g
1.2 n-Butyllithium (n-BuLi) 1.25 mmol 0.53 g
2. Solvent 2.1 Tetrahydrofuran (THF) 3.0 ml 2.64 g
3. Starting material 3.1 Model compound (MC) 0.5 mmol 0.20 g
4. Acyl chloride 4.1 Acryloyl chloride (AcCl) 2.0 mmol 0.18 g
4.2 Hexanoyl chloride (HxCl) 2.0 mmol 0.27 g
4.3 4-Pentenoyl chloride (4-PCl) 2.0 mmol 0.24 g
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Four molar equivalents (two-fold excess) of acyl chloride were added dropwise over
a period of 15 - 20 min using a syringe and the resulting mixture was left for 30 min at 0 0C,
whereafter the ice-bath was removed and the reaction mixture allowed to warm to room
temperature (≈20 0C). Reactions were monitored using TLC, and stopped after 60 min.
B: Increasing the electrophilicity of the acyl chloride
A 25-ml round-bottomed reaction vessel was supplied with a septum and inert gas
supply. Reactions were carried out under anhydrous conditions using freshly distilled
solvents under an inert atmosphere (helium gas).
Table 3.5: Formulation for acylation reactions of the model compound (compound 1)
to increase electrophilicity
Components Reactants Quantity Mass
1. Acid acceptor 1.1 Hunig’s base 2.0 mmol 0.26 g
1.2 Pyridine 2.0 mmol 0.16 g
2. Acyl transfer agent 2.1 Dimethylaminopyridine (DMAP) 0.2 mmol 0.03 g
3. Solvent 3.1 Tetrahydrofuran (THF) 3.0 ml 2.64 g
3.2 Dichloromethane (DCM) 3.0 ml 3.96 g
4. Starting material 4.1 Model compound (MC) 0.5 mmol 0.20 g
5. Acyl chloride 5.1 Acryloyl chloride (AcCl) 2.0 mmol 0.18 g
5.2 Hexanoyl chloride (HxCl) 2.0 mmol 0.27 g
5.3 4-Pentenoyl chloride (4-PCl) 2.0 mmol 0.24 g
The reactor was charged with the acyl transfer agent, acid acceptor (base for HCl)
and 2 ml of solvent. The model compound (which was pre-dissolved in 1 ml of solvent)
was then added to the reactor over 5 min, and the resulting mixture was cooled down to
below 0 0C using a bath containing a mixture of ice and ethanol.
Four molar equivalents (two times excess) of acyl chloride were then added drop-
wise over a period of 15 - 20 min using a syringe. The resulting mixture was left for 30 min
at 0 0C, whereafter the ice-bath was removed and the reaction mixture allowed to warm to
room temperature (≈20 0C). See Table 3.5 for a list of the reactants and the formulation
used. Reactions were monitored using TLC, and stopped after 24 h.
3.4.3.2 Scale-up and purification of product
The selected reactions were then scaled up (by a factor of 5) in order to produce
sufficient crude product for separation into the respective fractions using gravity columns
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and preparative TLC, and for subsequent characterization. The synthesis method as
described in §3.3.3.1 was used for the initial reactions, followed by the following additional
steps.
The reaction product was diluted with 150 ml of diethyl ether and transferred to a
250-ml separating funnel. The excess base was neutralized using 50 ml of saturated
ammonium chloride and washed four times with water (4 x 50 ml) to remove most of the
unreacted reagents (including the salt formed during the reaction with the free metal ion of
the strong base). After an additional wash with a saturated sodium chloride solution, the
product-rich phase was transferred to a beaker, dried with anhydrous magnesium
sulphate, filtered, and the solvent removed in vacuo on a rotary evaporator.
The dried product was dissolved in a sparing volume of diethyl ether and carefully
transferred to a gravity column pre-packed with silica-gel. A product to silica-gel ratio of
approximately 1:50 was used with a 15% ethyl acetate/petroleum ether mixture as mobile
phase to elute the product. The fractions were evaporated on a Büchi rotary-evaporator.
3.4.4 Analyses
3.4.4.1 Thin-layer chromatography
Approximately 0.3 - 0.5 ml of sample was withdrawn from the reactor during
reactions and quenched in saturated ammonium chloride, after which the product was
extracted into ethyl acetate. TLC was used to monitor the progress of the reaction. The TLC
plates were spotted and allowed to develop in a 15% ethyl acetate/petroleum ether mixture,
whereafter the plates were visualized with 254-nm ultraviolet light (UV).
3.4.4.2 Preparative thin-layer chromatography
No more than 100 mg of product was dissolved in a sparing volume of diethyl ether. A
syringe and needle was used and the product was applied to the preparative-TLC plate as
a very thin line, approximately 20 mm from the bottom of the plate.
A 5% mixture of ethyl acetate/petroleum ether was used as mobile phase. After the
plate was allowed to run in the mobile phase, it was removed and carefully dried. This was
repeated five times or until good separation was achieved.
The regions on the plate where the different fractions were observed by UV were
carefully marked and scraped off the plate, whereafter they were extracted, with ethyl
acetate, and vacuum dried.
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3.4.4.3 Nuclear magnetic resonance spectroscopy
Approximately 40 - 60 mg of product was dissolved in deuterated chloroform. 1H and
13C NMR spectra of the sample were obtained from a Varian Unity 400 spectrometer at 400
and 100 MHz frequency respectively. Chemical shifts are reported as δ (ppm) - values
relative to tetramethylsilane (TMS) as internal reference.
3.4.4.4 High-resolution mass spectroscopy
High-resolution mass spectroscopy was performed at the University of the
Witwatersrand, South Africa, on a Micromass VG 70SEQ MS. A direct insertion probe with
sample introduction was used with a positive polarity. Four scans/decade were used and
the mass range was 3000 amu/8 kV.
3.4.4.5 Matrix-assisted laser desorption/ionization
Approximately 1 – 2 mg of product was diluted 1:100 with tetrahydrofuran. A
saturated solution of 2,5-dihydroxybenzoic acid in deuterated water was used as matrix.
One microliter of the matrix was applied to a MALDI P100 gold sample plate and 1 µl of
sample added by mixing it with a micropipette. The spot was then allowed to completely dry
under a gentle stream of air in order to crystallize the matrix and trap the sample in the
crystals. After crystal formation was confirmed by light microscopy, the plate was then
inserted into a Perspective Biosystems Voyager DE-PRO Biospectrometry Workstation
(which possesses delayed extraction technology) for analysis.
The sample was analyzed using the positive ion method, with an accelerating voltage
of 20 kV, grid voltage of 94%, guide wire voltage of 0.05%, delayed extraction at 250 ns,
and laser intensity of 2600. Spectra were captured using Perspective Grams/32(R) v.4.14.
3.5 Results and discussion
3.5.1 Synthesis of the model urethane compound
The reaction scheme for the synthesis of the urethane model compound (compound
1) is presented below (Scheme 3.5).
Scheme 3.5: Synthesis of model urethane compound (compound 1)
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A final yield of 93% (mass %) was calculated. The signals of the recorded 1H and 13C
NMR spectra (Figure 3.6 and Figure 3.7) were assigned on the basis of chemical shifts and
multiplicities.
The characteristic signal at 6.62 ppm in the 1H NMR spectrum (Figure 3.6) was
assigned to the N-H hydrogen of the carbamate group while the resonance at 3.87 ppm
was attributed to the methylene protons between the two aryl rings (Ar2CH2). These
signals are important and sensitive signatures for monitoring structured changes within the
model urethane compound on acylation [1].
The methylene protons (H -4, 22) α to oxygen were observed at 4.15 ppm (expected
at 4.1 - 4.2 ppm) [12] and the absence of a signal at 3.6 ppm indicated full conversion of 1-
butanol.
1H NMR (400MHz, CDCl3) δH 0.94 (6H, t, J = 7.3Hz, H -1, 25), 1.41 (4H, m, J = 7.5Hz, H -2, 24), 1.64 (4H, q, J = 7.3Hz, H -
3, 23), 3.87 (2H, s, H -13), 4.15 (4H, t, J = 6.6Hz, H -4, 22), 6.62 (2H, s, H -6, 20), 7.09 (4H, d, J = 7.8Hz, H -9, 11, 15, 19), 7.28
(2H, d, J = 7.8Hz, H -8, 12, 16, 18)
Figure 3.6: 1H NMR spectrum of compound 1 showing structure and assignment of
signals
The signals of the 13C spectrum were assigned and found to be consistent with the
proposed product (compound 1). The distinctive signals of deuterated chloroform (CDCl3)
solvent were observed at 77.3 ppm (Figure 3.7), the terminal methyl (C -1, 25) at 13.9 ppm,
the carbonyl carbons (C -5, 21) at 154.0 ppm, while the characteristic methylene carbon
signal (for the carbon attached to the oxygen of the ester) (C -4, 22) was observed at 65.3
ppm [13].
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13C NMR (100MHz, CDCl3) δC 13.9 (C -1, 25), 19.3 (C -2, 24), 31.2 (C -3, 23), 40.7 (C -13), 65.3 (C -4, 22), 119.1 (C –7, 17), 129.6
(C –8, 9, 11, 12, 15, 16, 18, 19), 136.3 (C -10, 14), 154.0 (C -5, 21)
Figure 3.7: 13C NMR spectrum of compound 1 showing assignment of signals
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Figure 3.8: High-resolution mass spectrometry of compound 1
The returned mass obtained from the HRMS (Figure 3.8) (mass for compound 1.
HRMS: 398.22) was compared with the theoretically calculated mass (calculated for
C23H30O4N2 = 398.22) and found to compare well. The calculated error (6.6 ppm) was well
below the instrument’s allowable error (10 ppm).
Thus, in conclusion, the model urethane compound was considered successfully
synthesized, purified and characterized. The returned mass (HRMS) and NMR spectra
were found to be consistent with the structure of compound 1 and the latter was also
found to be consistent with reported spectra [1, 3-5].
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3.5.2 Acylation of model compound
3.5.2.1 Acylation using hexanoyl chloride
The reaction scheme for the reaction between the synthesized model urethane
compound (compound 1) and hexanoyl chloride is presented in Scheme 3.6, showing the
possible formation of the mono- and di-acylated products. Acylation was anticipated to
proceed at the nitrogen rather than the oxygen, in view of literature precedent.
Scheme 3.6: Acylation of compound 1 with hexanoyl chloride
The first approach investigated was to try and increase the electrophilicity of the
hexanoyl chloride using different acyl transfer agents (e.g. DMAP) and acid acceptors (e.g.
Hünig’s base). Extensive trials were performed and the best results (monitored by TLC)
obtained when Hünig's base was used with catalytic amounts (10%) of DMAP in DCM or
THF. Thin-layer chromatography revealed two spots, the starting material (compound 1)
and a second, faintly observed, less polar spot. This was believed to be the mono-acylated
urethane compound (compound 2) (confirmed later, see below).
Reactions were then carried out for different reaction times and temperatures in an
attempt to increase the conversion. Minor influences, as monitored with TLC, were
observed and the best results were obtained when the reaction temperature was
moderately increased (from room temperature to 55 0C), following the addition of hexanoyl
chloride, and maintained for 24 h.
In the alternative approach, attention was focused on enhancing the nucleophilicity of
the donor by using the carbamate anion. This was achieved by either using sodium hydride
or n-butyllithium (25% molar excess). TLC revealed the formation of three fractions, the
starting material (compound 1) (faintly observed) and two distinctive less polar fractions,
believed to be the mono- and di-acylated products. This observation led to the scale-up of
the reaction.
It was found to be possible to separate and isolate the product fractions by using
preparative TLC plates following column chromatography (which only gave a band of
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compounds). The two new, less polar fractions, assigned as compound 2 and compound
3, in order of decreasing polarity (each as single spots on TLC), were submitted for 1H and
13C NMR analyses and HRMS. The returned spectra were found to be identical, irrespective
whether the reactions were carried out with NaH or n-BuLi. The 1H and 13C NMR spectra,
as well as the HRMS of the isolated fractions (2 & 3), for the reactions carried out with n-
BuLi are presented below (see Figures 3.9 - 3.14).
1H NMR (400MHz, CDCl3) δH 0.78 - 0.99 (9H, m, H -1, 25, 31), 1.10 - 1.74 (14H, m, H -2, 3, 23, 24, 28, 29, 30), 2.30-2.39 (m,
unknown), 2.92 (2H, t, J = 7.4Hz, H -27), 3.95 (2H, s, H -13), 4.10 (2H, t, J = 6.6Hz, H -22), 4.16 (2H, t, J = 6.6Hz, H -4), 6.60 (1H,
s, H -20), 6.98 (2H, d, J 8.4Hz, H -15, 19), 7.11 (2H, d, J 8.3Hz, H -9, 11), 7.18 (2H, d, J = 8.3Hz, H -8, 12), 7.29 (2H, d, J = 8.4Hz,
H -16, 18)
Figure 3.9: 1H NMR spectrum of compound 2 showing structure and assignment of
signals
The following observations were made regarding the 1H NMR spectrum (Figure 3.9) of
the first less polar fraction (assigned as compound 2). The carbamate N-H proton
integrated for only half of those of compound 1 (Figure 3.6), signifying that mono acylation
had taken place. The introduction of one hexanoyl group was corroborated by high-field
aliphatic signals as well as a downfield (2.92 ppm) triplet for the protons adjacent to the
new carbonyl group (assigned as H -27), integrating for two protons. The dissimilarity
observed for the chemical shift pattern of the aromatic ring protons at δH = 6.98 - 7.29 (H -
9,11 ; H -15,19 and H -8,12 ; H -16,18) served as further evidence that disymmetrization
had taken place.
A downfield shift in the signal corresponding to the methylene protons (Ar2CH2) of
compound 2, from δH = 3.87 ppm (compound 1) to δH = 3.95 ppm (Figure 3.9), was
observed compared to compound 1 (Figure 3.6). This corresponds to an expected
downfield shift due to the stronger electron-withdrawing effect imparted by the latent
mono-acylated group.
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13C NMR (100MHz, CDCl3) δC 13.5, 13.7, 13.9 (C -1, 25, 31), 18.9, 19.1, 22.5, 24.4, 30.4, 30.9, 31.3 and 33.8 (C -2, 3, 23, 24, 27, 28,
29, 30), 40.8 (C -13), 65.1, 66.7 (C -4, 22), 118.7 (C -17), 125.4 (C -7), 128.2 – 129.6 (C -8, 9, 11, 12, 15, 16, 18, 19), 136.4, 136.6 (C
-10, 14), 141.2 (C –21), 154.2 (C -5), 176.0 (C -26)
Figure 3.10: 13C NMR spectrum of compound 2 showing assignment of signals
The signals of the 13C spectrum of compound 2 (Figure 3.10) were assigned and
found to be consistent with the proposed product. The correct number of aliphatic carbons
(14) was found to be present. The presence of a third carbonyl signal (assigned as C -26),
resulting from the introduction of the hexanoyl group, was also observed. The electronic
environments of the two respective aromatic rings were different, as is evident from the
observed signals at 128.2 - 129.6 ppm (when compared to compound 1 see Figure 3.7)
supporting dissymmetrization by mono-acylation. Minimal impurities (trace amounts of
compound 1) were found to be present and are due to imperfect separation.
SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 37#4:31 - 40#4:53. Sub=9#1:05 - 13#1:34. Entries=378. Base M/z=324.14143. 100% Int.=0.60408. EI. POS. 
High Resolution M/z
50 100 150 200 250 300 350 400 450 500
Int
en
sit
y (
%a
ge
)
0
10
20
30
40
50
60
70
80
90
100
43.05366
106.06605
132.04421
180.07847
224.09196
268.08527
324.14143
398.21528
496.29139
Figure 3.11: High-resolution mass spectrometry of compound 2
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The returned mass for compound 2 obtained from the HRMS (Figure 3.11) (HRMS:
496.29) was again within the allowable error range (error less than 4.7 ppm) when
compared with the theoretically calculated mass (C29H40O5N2 = 496.29).
1H NMR (400MHz, CDCl3) δH 0.82, 0.90 (12H, t, J = 7.3Hz, H -1, 25, 31, 37), 1.13 - 1.73 (20H, m, H -2, 3, 23, 24, 28, 29, 30, 34, 35,
36), 2.94 (4H, t, J = 7.5Hz, H -27, 33), 4.03 (2H, s, H -13), 4.11 (4H, t, J = 6.6Hz, H -4, 22), 7.00 (4H, d, J = 8.4Hz, H -9, 11, 15, 19),
7.20 (4H, d, J = 8.4Hz, H -8, 12, 16, 18)
Figure 3.12: 1H NMR spectrum of compound 3 showing structure and assignment of
signals
In the 1H NMR spectrum of the least polar fraction (Figure 3.12), the protons of the
carbamate nitrogen were completely absent, indicating full substitution of both nitrogen
atoms as a result of di-acylation. In accordance with this was the similarity of the ring
protons δH = 7.00 (H -9,11,15,19) and δH = 7.20 (H -8,12,16,18) due to restoration of
symmetry, i.e. both aromatic rings are now equivalent.
The observed downfield shift in the signal corresponding to the methylene protons (H
-13) of compound 3 (Figure 3.12) to δH = 4.03 ppm compared to those for both compound 1
(δH = 3.87 ppm) as well as mono-acylated compound 2 (δH = 3.95 ppm), due to the even
stronger electron-withdrawing effect imparted by the two acylated carbonate
functionalities, was further evidence for di-acylation.
The signals of the 13C spectrum of compound 3 (Figure 3.13) were assigned and the
signals observed at 13.9 ppm and 176.0 ppm attributed to the terminal methyl (C -31, 37)
and the amide carbonyl carbons (C -26, 32) of the newly introduced acyl functionality,
respectively. Once again, restoration of symmetry reduced the number of signals to 10 : 4 :
2 for aliphatic : aromatic : carbonyl.
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13C NMR (100MHz, CDCl3) δC 13.5, 13.9 (C -1, 25, 31, 37), 18.9, 22.5, 24.6, 30.4, 31.4 and 37.9 (C -2, 3, 23, 24, 27, 28, 29, 30, 33,
34, 35, 36), 41.0 (C -13), 66.7 (C –4, 22), 128.3 (C –8, 12, 16, 18), 129.7 (C –9, 11, 15, 19), 136.6, (C –10, 14), 140.4 (C –7, 17), 154.2
(C –5, 21), 176.0 (C –26, 32)
Figure 3.13: 13C NMR spectrum of compound 3 showing structure and assignment of
signals
High-resolution mass spectroscopy (Figure 3.14) returned an exact mass for
compound 3 (HRMS: 594.37) compared to the theoretically calculated mass  (C35H50O6N2 =
594.37).
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Figure 3.14: High-resolution mass spectrum of compound 3
The percentage yield (mole %) for each individual fraction was calculated for the
products of the reactions carried out with sodium hydride (25% molar excess) and n-
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butyllithium (25% molar excess), and presented in Table 3.6. The overall yield was found to
be 25.8% higher when n-butyllithium was used instead of sodium hydride.
The use of sodium hydride (solid) resulted in a heterogeneous reaction mixture, which
might not have been as effective when compared to the use of n-butyllithium (miscible
liquid). n-Butyllithium is also a stronger base than sodium hydride [11].  
Table 3.6: Calculated yields of individual fractions 2 & 3
Compound NaH n-BuLi
2
(mono-acylated) 36.5% 24.6%
3
(di-acylated) 35.0% 66.8%
Yield 53.3% 79.1%
In summary, the reaction between the model urethane compound (compound 1) and
hexanoyl chloride was shown to be successful. Full conversion (although not a primary
objective of this part of the study) was however not achieved, even when a strong base
like n-butyllithium was used. This phenomenon could be attributed to either the incomplete
deprotonation of compound 1 or side reactions with hexanoyl chloride, as indicated in
Scheme 3.7.
Scheme 3.7: Possible side reactions involving the pendant hexanoyl adduct of the
urethane group
3.5.2.2 Acylation using unsaturated acyl chlorides
In order to address the objectives of the project concept, as outlined in Chapter 1, a
number of acyl chlorides were then “screened” in trials to find one containing an acrylic or
a vinyl group that is unaffected during the N-acylation of compound 1, but capable of
crosslinking the modified material at a later stage.
No discernible product was, however, observed on a TLC plate when acryloyl
chloride was used, neither for the reactions when the nucleophilicity of the N-atom
(urethane nitrogen) was enhanced (using sodium hydride or n-butyllithium) or when an
attempt was made to increase the electrophilicity of acryloyl chloride by introducing
different acid acceptors and acyl-transfer agents. NMR analysis of the crude reaction
product revealed the unreacted model urethane compound (compound 1).
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It has been reported [14] that the use of a strong base (e.g. NaH) to de-protonate the
carbamate nitrogen (hence rendering it more nucleophilic) followed by the introduction of
acryloyl chloride results in the dimerization of the primary-formed product. Travnicek et al.
[14] used a Cu/Cu2Cl2 system in an attempt to prevent dimerization, but it proved to be
unsuccessful. Although they did not propose a possible mechanism by which the proposed
dimerization could be taking place [14], it is likely to involve the Michael-type addition
between the α,β-unsaturated latent acryloyl group and the carbamate anion (Scheme 3.8)
[11].
Scheme 3.8: Michael-type addition between the α,β-unsaturated latent acryloyl
group and the carbamate anion
From the foregoing results and discussion it is proposed that the successful
unsaturated acyl chloride candidate would have to be one lacking the α,β-unsaturated
arrangement and therefore have the generic structure as illustrated in Figure 3.15, in which
R1 would have to be at least one carbon in size (e.g. -CH2-).
Cl R1
O R2
R3
Figure 3.15: Proposed generic structure for candidate unsaturated acyl chloride
3.5.2.3 Acylation using 4-pentenoyl chloride
The author subsequently decided to study the reaction of 4-pentenoyl chloride with
the model urethane compound (compound 1). Scheme 3.9 shows the possible formation of
the mono- and di-acylated products. 4-Pentenoyl chloride was chosen in order to separate
the double bond from the carbonyl group, to prevent conjugation promoted by the basic
conditions.
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Scheme 3.9: Acylation of compound 1 with 4-pentenoyl chloride
As in the acylation of compound 1 using hexanoyl chloride (§3.5.2.1), acylation under
acyl-transfer conditions was first studied involving electrophilicity enhancement of the acyl
chloride and then reacting with the neutral carbamate. The best results (monitored with
TLC) were obtained when Hünig’s base was used with catalytic amounts of DMAP (10%)
in THF. TLC revealed two fractions: the starting material (compound 1) and one new, faintly
visible, less polar fraction. The latter was believed to be the monoacylated (compound 4)
urethane compound (later confirmed, see below). Several attempts were then made to try
to increase the conversion by increasing the reaction temperature and time of reaction, but
TLC results indicated little or no improvement. The best TLC results were obtained at room
temperature and a 24-h reaction time.
Attention was then directed at nucleophilicity enhancement of the carbamate anion
(using either sodium hydride or n-butyllithium). Promising TLC results were obtained,
revealing the formation of three spots: the starting material (compound 1) (faintly visible
fraction) and two distinctive, less polar fractions (4 & 5) (Figure 3.16). The reactions (using
sodium hydride or n-butyllithium) were then scaled up to produce suitable quantities of
product.
Numerous attempts were then made to separate the scaled-up reaction product into
its respective fractions using a gravity column packed with silica-gel. It was however not
possible to obtain pure fractions, either by reduction of the polarity of the mobile phase
(ethyl acetate/petroleum ether) or by increasing the silica to product ratio.
Figure 3.16: TLC plate of a mixture of compounds 1, 4 & 5
Compound 5
Compound 4
Compound 1
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The small difference in polarity between the three fractions, as is evident from the
TLC plate in Figure 3.16, also prevented successful separation by PTLC. The purified (but
unseparated) reaction product was analyzed by NMR and HRMS.
1H NMR (400MHz, CDCl3) δH 0.78 - 0.98 (m, H -1, 25), 1.10 - 1.71 (m, H -2, 3, 23, 24), 2.34 – 2.50 (m, H -27, 32), 3.02 – 3.11 (m,
H –28, 33), 3.88 (2H, s, “compound 1” H -13), 3.95 (2H, s, “compound 4” H -13), 4.03 (2H, s, “compound 5” H -13), 4.07 – 4.19 (m,
H –4, 22), 4.95 – 5.13 (m, H –30, 35), 5.76 – 5.95 (m, H –29, 34), 6.64 (s, H –6, 20), 6.96 – 7.32 (m, H –8, 9, 11, 12, 15, 16, 18, 19)  
Figure 3.17: 1H NMR spectrum of a mixture of compounds 1, 4 & 5
Although it was not possible to assign all of the individual signals of the returned 1H
and 13C NMR spectra (Figures 3.17 & 3.18) sufficient assignments could be made to enable
elucidation of the reaction product.
The introduction of a 4-pentenoyl unit resulted in the appearance of characteristic
signals between 4.95 - 5.13 ppm and 5.76 - 5.95 ppm in the 1H NMR spectrum (Figure 3.17).
These were attributed to the vinyl protons (H -30, 35) and (H -29, 34), respectively. The
acyl group further resulted in the appearance of extra high-field aliphatic signals (2.35 -
2.50 ppm) for the protons adjacent to the new carbonyl group (assigned H -27 and H -32),
integrating for four protons. The three singlet proton signals of the methylene protons
(Ar2CH2) corresponding to compounds 1, 4 and 5 were observed at 3.88, 3.95 and 4.03
ppm, respectively, and could be used to estimate relative amounts as approximately 1 : 2 : 2
for compound 1 : compound 4 : compound 5.
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13C NMR (100MHz, CDCl3) δC 13.7 (C -1, 25), 19.1 (C -2, 24), 28.9 - 36.6 (C -3, 23, 27, 28, 32, 33), 40.8 (C -13), 66.9 (C –4, 22),
115.8 (C –30, 35), 128.4 (C –8, 12, 16, 18), 129.7 (C –9, 11, 15, 19), 136.6 – 137.4 (C –7, 10, 14, 17, 29, 34), 154.2 (C –5, 21), 175.5
(C –26, 31)
Figure 3.18: 13C NMR spectrum of a mixture of compounds 1, 4 & 5
The presence of the terminal vinyl carbon signals (C -30, 35), assigned at 115.8 ppm
in the 13C spectrum (Figure 3.18), served as further evidence of successful acylation. The
presence of two carbonyl signals (assigned as C -26, 31) for the two amide carbonyl
carbons of compounds 4 and 5 (C -26 and C -26, 31) further supported the presence of the
mono- and di-acylated products.
The methylene proton signals attributed to compounds 1, 4 and 5 were integrated for
the respective reactions carried out with sodium hydride and n-butyllithium, and used to
calculate the following yields (see Table 3.7).
Table 3.7: Calculated yields of the mono- (compound 4) and di-acylated (compound
5) compounds
Compound NaH n-BuLi
4
(mono-acylated) 49.1% 39.1%
5
(di-acylated) 24.3% 43.5%
Yield 51.5% 63.1%
The overall product yield was found to be 11.6% higher when n-butyllithium was used
instead of sodium hydride. This is consistent with the results obtained with hexanoyl
chloride, and can be ascribed to the relative strength of n-butyllithium and the homogeneous
nature of the reaction mixture.
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Figure 3.19: HRMS of a mixture of compounds 1, 4 & 5
High-resolution mass spectroscopy (Figure 3.19) returned correct masses for the
individual compounds in the mixed sample when compared to the theoretically calculated
masses, as summarized in Table 3.8.
Table 3.8: Summary of the molecular masses of compounds 1, 4 and 5 obtained
from HRMS
Components Compound 1 Compound 4 Compound 5
Mass from HRMS
(g/mole) 398.22 480.27 562.31
Molecular formula C23.H30.O4.N2 C28.H36.O5.N2 C33.H42.O6.N2
Calculated mass
(g/mole) 398.22 480.26 562.31
Error
(ppm) 4.5 5.9 2.5
The spectrum obtained from MALDI analysis is presented in Figure 3.20. Although
MALDI is generally not a suitable analytical method for molecules with such low molecular
masses as the ones under investigation, useful results were obtained by optimization of the
assay conditions, as described earlier (§3.4.5.3).
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Figure 3.20: MALDI analysis of a mixture of compounds 1, 4 & 5
Compounds 1, 4 and 5 were observed at molecular masses of (421.685, 437.78),
(503.705, 519.86) and (585.738, 601.392) corresponding to the Na- and K- adducts
(inherent to the method used). The molecular masses of Na and K were deducted and the
results are presented in Table 3.9.
 Table 3.9: Summary of the molecular masses of compounds 1, 4 and 5 obtained
from MALDI analysis
Components Compound 1 Compound 4 Compound 5
Na-adduct
(g/mole) 398.69 480.72 562.74
K-adduct
(g/mole) 398.68 480.76 562.83
Molecular formula C23.H30.O4.N2 C28.H36.O5.N2 C33.H42.O6.N2
Calculated mass
(g/mole) 398.22 480.26 562.30
Although the MALDI results were not as accurate as the results obtained with HRMS,
they were nonetheless useful. The signals at molecular masses of 273.37, 365.35 and
397.57 are distinctive of the matrix used.
3.6 Conclusions
The conceptualized urethane model compound was successfully synthesized,
purified and then characterized by nuclear magnetic resonance and high-resolution mass
spectroscopy. The results (signals of NMR spectra and returned masses) were found to
be consistent with reported and theoretical values.
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Acylation of compound 1 with hexanoyl chloride was achieved by both nucleophilic
and electrophilic enhancement. The former was the more effective method, with the
stronger base n-butyllithium resulting in a significantly higher conversion. Separation of the
product fractions was achieved using preparative thin-layer chromatography. High-
resolution mass spectroscopy returned masses consistent with the mono- and di-acylated
compounds, while NMR data showed that the successful reaction site was indeed the
proposed carbamate nitrogen.
A range of reactions of compound 1 with acryloyl chloride proved to be
unsuccessful, most likely due to the promotion of oligomerization via Michael addition of the
primary formed product. This indicates the importance of the consideration in choosing a
suitable unsaturated acyl chloride.
The success of the hexanoyl chloride coupling could be emulated with 4-pentenoyl
chloride, thereby introducing a non-α,β-unsaturated C=C bond for potential future
crosslinking. Although the coupling could be achieved by either nucleophilic or electrophilic
enhancement, the former (especially when n-butyllithium was used) was again the more
effective method. Although pure products could not be isolated, spectroscopic analyses of
the mixed product (compound 1, 4 and 5) provided satisfactory support for their formation.
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Chapter 4
Polyurethane modification
Abstract
The acylation chemistry of a carbamate nitrogen, optimized in a model compound
study (Chapter 3), was transferred to Pellethane® 2363-80AE (academic
polyurethane standard) using 4-pentenoyl chloride (unsaturated acyl chloride),
sodium hydride (for nucleophilic enhancement of the unreactive carbamate
nitrogen) and an aprotic solvent, N,N-dimethylformamide (DMF), capable of
stabilizing the resulting polyanion. Treatment, using an initial sodium hydride
concentration of 10% molar equivalent to carbamate nitrogens (as suggested in
the literature) followed by the addition of 4-pentenoyl chloride, isolation and
purification, resulted in an average degree of modification of 4.5% (based on the
carbamate nitrogens), calculated using proton nuclear magnetic resonance
spectroscopy (1H NMR). The degree of modification was accurately and
reproducibly controlled (R2 = 0.99) between 4.5% - 20% (maximum determined)
by changing the sodium hydride concentration. Modification of a second,
technologically much more advanced polyurethane, PurSil® 35 80A, was also
achieved. A maximum degree of modification of 18.5% was calculated, based on
1H NMR, after successful deprotonation (using sodium hydride), purification and
isolation. The degree of modification was accurately and reproducibly controlled
(R2 = 0.99) between 11.5% - 18.5% by changing the sodium hydride
concentration. The novel modified, isolated and purified polyurethanes can be
used to study crosslinking reactions and to optimize their mechanical properties.
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4.1 Introduction
The modification of medical grade polyurethanes at the carbamate nitrogen with
unsaturated modification agents, rendering the polyurethanes (PUs) crosslinkable whilst
they remain stable during the modification and subsequent purification stages, is not a
trivial task.
The harsh reaction conditions that are required to effect nucleophilic addition
reactions of the relatively unreactive carbamate nitrogen of the respective polyurethanes
could result in in situ crosslinking reactions of the unsaturated pendent groups. Finding a
suitable unsaturated acyl chloride and optimizing the reaction conditions was thus crucial.
In the model compound study described in Chapter 3 the reaction site at which
acylation occurs, namely the carbamate nitrogen, was confirmed. 4-Pentenoyl chloride
was found to be an ideal modification reagent and sodium hydride could be used for
nucleophilic enhancement of the carbamate nitrogen. The knowledge gained in that section
of the work was now transferred to medical grade polyurethanes.
Pellethane® 2363-80AE (an academic polyurethane standard) was the first candidate
polyurethane that was selected with which to study the transfer of the chemistry
developed with the model compound. Reactions were carried out with Pellethane® 2363-
80AE and 4-pentenoyl chloride. A sodium hydride concentration equivalent to 10 molar
percentage of the carbamate nitrogens, as suggested in the literature [1], and an aprotic
solvent, DMF, capable of stabilizing the resulting polyanion [2] were used. Nuclear
magnetic resonance spectroscopy (NMR) was used to confirm the presence of vinyl
signals in the products of the acylation reactions.
The maximum degree of modification could then be determined by increasing the
sodium hydride concentration whilst maintaining a reaction temperature well below 0 0C ( 
-4 0C), as suggested by Adibi et al. [2]. The degree of modification was then studied by
varying the sodium hydride concentration.
Focus was then directed at using a technologically much more advanced medical
grade polyurethane PurSil® 35 80A (advanced in terms of synthetic chemistry and raw
materials used). The maximum degree of modification was determined after the presence
of vinyl signals was confirmed by NMR. Changing the sodium hydride concentration was
again used to alter or improve the degree of modification.
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4.2 Historical
4.2.1 Modification of existing polyurethanes for enhanced biocompatibility
N-alkylation reactions of polyurethanes have been extensively investigated (from as
early as 1949 [3]), initially to try and improve the fire resistance of the urethanes [3-10]. It
was however only much later that their medical use became evident [1, 11-13].
It is thus no surprise that there is a rich literature and patent reference database
available describing different reaction conditions, including the use of sodium hydride, to
enhance the nucleophilic character of the carbamate nitrogen, which is of specific interest
in this dissertation. Although improving the mechanical and chemical properties of the
polyurethanes was not the objective of this study, but rather enhancing the
biocompatibility, a brief summary of the most relevant work will be given here.
A number of investigations [3-10] have demonstrated the successful N-alkylation
(alkylhalogenides) of polyurethanes and polyamides (in the presence of a strong base e.g.
NaH), mainly to improve the fire resistance of these polymers. These reactions were
carried out at temperatures not exceeding 0 0C and using DMF as solvent.
In one such an investigation [4] the N-alkylation reaction of a polyurethane (based on
MDI) was studied using sodium hydride to first abstract the labile carbamate proton (at 0
0C in DMF). Hydrogen gas was immediately observed, whereafter the reported mixture
showed a green color, caused by the urethane polyanion - thus showing successful
deprotonation [4]. Diethyl 2-bromoethyl phosphate was used as alkylation reagent, as
illustrated in Scheme 4.1.
Scheme 4.1: N-alkylation of a polyurethane using diethyl 2-bromoethyl phosphate
[4]
In an effort to increase the biocompatibility of polyurethanes, molecules with reactive
groups (to which substituents can be added after polymer synthesis) have been
incorporated into the polymer backbone [14-16]. The molecular mass and mechanical
properties of the polymers obtained in this manner may however preclude their medical
use [1].
In an alternative approach to increase the biocompatibility [2], N-alkylation of
polyurethanes was considered. It has been demonstrated that the reaction of moderate
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grades of metallation of polyurethanes (based on MDI) and toluene diisocyanate (2,4-2,6)
(TDI)) with sodium hydride at temperatures not significantly exceeding 0 0C do not induce
significant polymer degradation [2]. According to Adibi et al. [2] the “polyanions” further
remain soluble in aprotic solvents, e.g. DMF.
The first application of this N-alkylation method to medical grade polyurethanes
involved N-alkylation of “sodium hydride-activated” polyurethanes using alkyl iodides to
attach C2 - C18 alkyl chains to the polymer backbone [12] in an effort to improve the blood
compatibility of the polymers. The polyurethanes were pretreated with sodium hydride at 0
- -5 0C and the reaction of the activated polymer with alkyl iodides was performed at a
temperature of 50 0C. The stability of the polyanion is however questionable at this
temperature, especially in the light of the work conducted by Adibi et al. [2].
Alferiev et al. [1, 11, 13] modified polyurethanes with pendant acylated thiol groups,
which resist oxidative crosslinking (often characteristic of molecules containing multiple
thiol groups), and thus managed to decrease the alkylation temperature. The resulting
polymer was prepared from a polyether-urethane pre-modified with bromobutyl groups,
which were reacted with an excess of thiolacetic acid (AcSH) in the presence of a
thioacetate ion (AcS-) (Scheme 4.2).
Scheme 4.2: Low temperature N-alkylation of a polyurethane with thiolacetic acid
(AcSH) in the presence of a thioacetate ion (AcS-) [11]
Although crosslinking of the polyurethanes was not one of the main objectives of the
aforementioned studies, valuable information was gained regarding the susceptibility of
the carbamate nitrogen to proton abstraction using sodium hydride. DMF was generally
used as solvent and it was shown that the polyanions of polyurethanes based on MDI
would remain stable in aprotic solvents (e.g. DMF). Adibi et al. [2] further demonstrated
that the resulting polyurethane anion would remain stable at temperatures below 0 0C.
4.2.2 Heat processing of existing polyurethanes with reactive monomers
The first evidence that was found involving the “crosslinking of polyurethanes” came
mainly from the patent literature, where heat processing (mainly extrusion) of
Jacobus Petrus Theron Chapter 4: Polyurethane modification
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prostheses 59
thermoplastic polyurethanes with “reactive” monomers is described. Some of the most
relevant references are briefly discussed below.
The technology described by the Babolat Sports Company (manufacturers of tennis
and badminton rackets, etc.) [17] involves the crosslinking of a semi-crystalline ester-
based polyurethane for the manufacturing of tennis and badminton racket strings with
enhance flow/creep resistance at room temperature.
The inventors [17] first developed a “two-step” process to achieve crosslinking
functionality, whereafter crosslinking was induced. The modification process involves use
of a “grafting agent” (e.g. TDI)) and a “crosslinking precursor” (e.g. hydroxy ethyl
methacrylate (HEMA)), which are mixed together with the thermoplastic polyurethane
(TPU) in an extruder. Crosslinking was induced during the extrusion process either using
irradiation or an ultraviolet light (UV) source.
In a second example the inventors [17] tried to use just a “grafting agent” (trimethylol
propane trimethylacrylate, (TMPTMA)), which they mixed together with a thermoplastic
polyurethane, in a single screw extruder. Crosslinking was achieved by irradiation (75
kGy).
No evidence could be found as to whether or where this technology had been
successfully used to modify other polyurethanes, or where a description is given to the
degree of reproducibility and control over the required degree of modification and
crosslinking. A possible limitation is that it does not offer much control over the degree of
modification.
Sardanopoli and Stonehouse [18] from BASF claim the use of an isocyanate-
terminated pre-polymer (based on e.g. MDI), which is then mixed in an extruder with the
TPU, whereafter crosslinking is induced by the heat in the extruder.
Table 4.1: Crosslinkers for enhance crosslinking [19]
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Beyer and Steckenbiegler [20] added a tri-functional methacrylate (5 – 15 phr) during
the synthesis of a polyether polyurethane and a polyester. Plates were then injection
molded, during which the films were irradiated with electrons of 150 kGy. No mention was
made as to how exactly it was incorporated into the polyurethanes, or the exact structure
of the polyisocyanates used.
Zamore [19] claimed to have improved the technology of Beyer and Steckenbiegler
[20] by using more “reactive crosslinkers”. A list of the crosslinkers used or suggested by
Zamore is included in Table 4.1. The TPU and the respective monomers were mixed in a
twin-screw extruder and crosslinked using irradiation.
Zamore [19] was unable to successfully modify and crosslink a TPU based on an
aromatic polyisocyanate including Pellethane® 2363-55D, one of the Pellethane® 2363-
80AE family, which is also based on the aromatic polyisocyanate, MDI.
The lack of evidence describing control over the degree of modification and
crosslinking during these heat-processing methods indicates that the usefulness in any
cardiovascular application is questionable. The versatility of this technology is also limited
to extrusion only.
Crosslinkability can alternatively be introduced in a post-polyurethane-synthesis step
(as will be followed in this dissertation), or during synthesis of the respective
polyurethanes, a brief discussion of which will follow.
4.2.3 Synthesis of novel crosslinkable polyurethanes
The literature describes three main approaches that have been followed during
polyurethane synthesis to introduce crosslink functionality i.e. to render the resulting novel
polyurethanes crosslinkable. It has been achieved either through the choice of isocyanate
[21-24], or chain extender or soft segment [25-29], or by the synthesis of novel urethane
oligomers [30].
Reitel and Goethlick [22] included an unsaturated isocyanate (vinyl isocyanate)
during the synthesis of a pre-polymer, whilst others like Muhfeld et al. [23] introduced
crosslink functionality using a multi-functional isocyanate (e.g. di- and triisocyanate) to
develop a polyurethane with improved light and temperature stability. Their method
involved mixing polycaprolactone, 1,6-hexane diol and 1,6-hexamethylene together in a
reaction vessel at 180 0C for 12 min [23], whereafter the polymer was processed into a
granular material. A triisocyanate (8% w/w) was then added and the resulting material
sintered according to the “conventional” powder-slush method in an open-heated mold at
225 0C, to form a 1-mm-thick crosslinked film. Only qualitative improvements, in light and
temperature stability, were reported in some cases.
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In a second approach the use of unsaturated [25, 28], hydroxy functional [29] or
hyperbrached pre-polymers [27] were investigated as possible chain extenders.
Le Roy and Pattein [28] developed novel crosslinkable polyurethanes using but-2-
ene-1,4-diol as chain extender. Crosslinking was achieved using a heat press or
extrusion process at temperatures and times ranging from 120 – 200 0C and 5 – 60 min,
respectively. The intended application was not mentioned, nor was any mention made
regarding improvements in either chemical or mechanical properties.
A novel poly(ether urethane amide) was synthesized by Stern et al. [25], by chain-
extending the prepolymer with fumaric acid, resulting in a polymer containing chemically
active derivatization sites, stemming from the fumaramide double bond. Although
crosslinking was not the main objective of this specific study, but rather the grafting of
polyethylene oxide onto the active double bond, the authors did however test the
reactivity of the double bonds by studying crosslinking reactions, using hexamethylene
diamine and diethylene triamine; crosslinking was only achieved at 60 0C overnight.
Gordon [29] aimed to develop latexes and aqueous polyurethane dispersions for use
in the manufacture of health care devices such as protective gloves, condoms,
tourniquets and dental dams. Crosslinking was achieved by means other than sulfur
vulcanization of double bonds. One of the patented methods is by means of including
crosslink functionality, using hydroxy functional diamines (e.g. 1,3-diamino-2-hydroxy
propane) as chain extenders. Multi-functional isocyanates are used as crosslinkers and
heat-induced crosslinking is then achieved at 260 0C. Amine-terminated AB2-type
hyperbranched polyamides (HBP) of different molecular masses (3516 – 13063 g/mole)
were prepared from 3,5-bis-(4-aminophenoxy)benzoic acid and used as crosslinkers in
the preparation of different polyurethanes [27]. The HBPs were mixed in different ratios
with 1,4-butanediol, which were then used as chain extenders. A control (no HBPs) and
nine other different polymers were prepared in this manner and the mechanical properties
(tensile strength and elongation) of only two of the nine were significantly improved,
when compared with the control.
In the third approach, vinyl-containing oligomers were synthesized [30] by reacting
TDI with 4-hydroxybutyl vinyl ether and three different diols, namely poly(ethylene glycol),
poly(propylene glycol) (PPG) and α-ω-hydroxy terminated organofunctional poly(dimethyl
siloxane) (PDMS). The resins were cationically polymerized by UV irradiation in the
presence of a diaryliodonium photoinitiator. Of the three, PDMS oligomers gave the highest
tensile strength and elongation and char yield when analyzed thermal gravimetrically.
Crosslink functionality has successfully been introduced during polyurethane
synthesis using unsaturated [22] or multi-functional [23] isocyanates. Although successful
crosslinking was achieved, only qualitative improvements were reported. Unsaturated [25,
28], hydroxy functional [29] and hyperbranched pre-polymers [27] have also been
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successfully used as chain extenders during polyurethane synthesis to incorporate
crosslink functionality. The derivation sites incorporated by Stern et al. [25] seemed
unreactive towards crosslinking reactions and this would not be a practical approach.
Although the synthesis of novel crosslinkable polyurethanes was not an objective of
this dissertation, but rather the modification and post-process crosslinking of existing
medical grade TPUs, a rich literature pertaining to the former is available, as is evident from
the aforementioned discussion.
4.2.4 Pellethane® 2363-80AE and PurSil® 35 80A
Pellethane® 2363-80AE (a polyether urethane) was developed by Dow Chemicals,
USA. Poly(tetramethylene oxide) glycol is used in the soft segment and the hard segment
consists of 4,4-methylenebis(phenylisocyanate), with 1,4-butanediol as chain extender
[31].
The extruded pellets are coated with a waxy extrusion processing aid [32-35]. In the
Fourier-transform infrared analysis the presence of peaks at 1635 cm-1, 1563 cm-1 and
1250 cm-1 refer to amide I, amide II and amide III vibrational modes, respectively, while the
peaks at 3302 cm-1, 2918 cm-1, 2850 cm-1 are related to the stretching mode vibration of
unbonded N-H groups and to the antisymmetric and symmetric stretching modes of
methylene groups, respectively. This data would support the assumption that the
extrusion processing aid is most likely an aliphatic amide (bis-stearamide) [32-34] and
could be removed by ethanol [32, 33].
PurSil® 35 80A (a silicone-polyether-urethane) was developed by the Polymer
Technology Group Inc. (PTG), USA. It is prepared by a multi-step bulk synthesis in which
35% polydimethylsiloxane is incorporated into the polymer soft segment with
poly(tetramethylene oxide) glycol. The hard segment consists of MDI, with a low molecular
mass glycol chain extender [36]. This very advanced and superior material (in terms of
chemical resistance and mechanical properties) could potentially be used in the
manufacturing of pacemaker leads.
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4.3 Experimental
4.3.1 Materials
Pellethane® 2363-80AE and PurSil 35-80A were obtained from Dow Chemicals
(USA) and Polymer Technology Group, Inc. (USA), respectively. Tetrahydrofuran (THF)
(Merck, Cat: AB009731) and N,N-dimethylformamide (Aldrich, Cat: 27,054-7) were used
as solvents and 60% (w%) sodium hydride (Fluka, Cat: 71620) served as strong base. 4-
Pentenoyl chloride (Aldrich, Cat: 46,847-9) was used as acylation reagent. Water, ethanol
(EtOH) (Merck, Cat: BB10107), n-hexane (Merck, Cat: 152496G), di-ethyl ether (Riedel-de
Haën, Cat: 32203), iso-propanol (Aldrich, Cat: 15,497-0) and cyclohexane (Aldrich, Cat:
15,474-1) were used as non-solvents.
4.3.2 Modification of Pellethane 2363-80AE
4.3.2.1 Purification
A 10% solution (w/w) of Pellethane® 2363-80AE and THF was slowly poured into a
glass beaker containing a 10-fold excess of vigorously stirring ethanol at room
temperature, as suggested in the literature [33, 35], to effect the precipitation of the
polymer. After decanting most of the ethanol, the remaining ethanol was removed from the
polymer by vacuum drying for 24 h at room temperature. This was repeated at least twice
or until the satisfactory removal of the processing aid was observed by FT-IR analysis.
The purified polymer was then vacuum dried at room temperature for 4 days and stored in
a dark bottle under an inert atmosphere (helium) for later use.
In an attempt to isolate the processing aid 300 ml of ethanol was added to 200 g of
Pellethane® 2363-80AE pellets and shaken on a laboratory shaker for 12 hours. The
resulting solution was then filtered, the solvent removed in vacuo on a rotary evaporator
and vacuum dried for 24 h. Samples were then submitted for FT-IR analysis.
4.3.2.2 Acylation using 4-pentenoyl chloride
Dried, purified Pellethane® 2363-80AE (hereafter referred to as Pellethane) was
weighed off and dissolved (under an inert atmosphere) in N,N-dimethylformamide (DMF)
(over night at 50 ºC). Helium was used to maintain an inert atmosphere in all experiments.
The formulation for a typical experiment is summarized in Table 4.1.
A 1000-ml round-bottomed reaction vessel was fitted with a septum, thermometer
and inert gas supply. Reactions were carried out under anhydrous conditions, using dry
solvents, under an inert atmosphere.
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Table 4.1: Typical formulation used for the modification of Pellethane
Reactants Mass (g)
Pellethane® 2363-80AE 25.00
Dimethyl formamide (DMF) 550.00
Sodium hydride (NaH) 0.40
4-Pentenoyl chloride (4-PCl) 1.77
The pre-dissolved Pellethane (25 g in 550 g DMF) was added to the reactor and
cooled down to below 0 0C, using a mixture of ice and ethanol. A suspension of NaH (0.4
g) in DMF (10 g) was then slowly added to the reactor over 20 min and the resulting
mixture was left for 60 min to allow the formation of the anion.
A 50% molar excess of 4-pentenoyl chloride (1.77 g) in DMF (10 g) was added drop-
wise over a period of 20 min, using a syringe. The resulting mixture was left for 30 min at
a temperature of below 0 0C, whereafter the ice-bath was removed and the reaction
mixture allowed to warm to room temperature (≈20 0C). The reaction was allowed to
continue for an additional 30 min. The reaction product was then isolated.
4.3.2.3 Isolation of the reaction product
The reaction mixture was slowly poured into a glass beaker (over a period of 10
minutes) containing a 10-fold excess of vigorously stirring water (non-solvent) at room
temperature to effect the precipitation of the modified polymer. After decantation of most
of the water, the remaining water was removed from the polymer by vacuum drying for
24 h in the dark, at room temperature. The dried polymer was re-dissolved in THF and re-
precipitated in a 10-fold excess of ethanol, and vacuum dried under the same conditions.
4.3.2.4 Changing the degree of modification
The modification of Pellethane was studied by first adding 5.0 mmol (0.20 g) NaH to a
pre-dissolved Pellethane solution (25 g in 550 g DMF) in an amount equal to 10 mole
percent (relative to the nominal molar amount of carbamate nitrogens) in the polymer
solution [1]. The molar amount of NaH was then increased to above 20.0 mmol (0.80 g)
(over a period of 60 min), while the temperature was kept well below 0 0C. This was done
in an effort to determine the maximum degree of modification possible for Pellethane.
Pellethane (25 g) was subsequently modified with different quantities of NaH, in six
separate reactions, as described in §5.3.2.2: 0.20 g (5.0 mmol), 0.30 g (7.5 mmol), 0.40 g
(10.0 mmol), 0.50 g (12.5 mmol), 0.60 g (15.0 mmol) and 0.80 g (20.0 mmol). After addition
of the 4-pentenoyl chloride followed by isolation and purification, the respective yields
were calculated and the samples submitted for NMR analyses.
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4.3.3 Modification of PurSil 35-80A
4.3.3.1 Acylation using 4-pentenoyl chloride
Dried PurSil 35-80A (hereafter referred to as PurSil) was weighed off and
dissolved (under an inert atmosphere) in DMF (overnight at 50 ºC). The formulation for a
typical experiment is summarized in Table 4.2.
Table 4.2: Typical formulation for the modification of PurSil
Reactants Mass (g)
PurSil® 35 80A 25.00
Dimethyl formamide (DMF) 550.00
Sodium hydride (NaH) 0.75
4-Pentenoyl chloride (4-PCl) 3.18
A 1000-ml round-bottomed reaction vessel was fitted with a septum, thermometer
and inert gas supply. Reactions were carried out under anhydrous conditions, using dry
solvents under an inert atmosphere.
The pre-dissolved PurSil (25 g in 550 g DMF) was added to the reactor and cooled
down to below 0 0C (0 - -4 0C), using a mixture of ice and ethanol. A suspension
consisting of NaH (0.75 g) in DMF (10 g) was then slowly added to the reactor over 20
min and the resulting mixture was left for 90 min to allow the formation of the anion.
A 50% molar excess of 4-pentenoyl chloride (3.18 g) in DMF (10 g) was added
dropwise over a period of 20 min, using a syringe. The resulting mixture was left for 30
min at a temperature of below 0 0C, whereafter the ice-bath was removed and the
reaction mixture allowed to warm to room temperature (≈20 0C). The reaction was allowed
to continue for an additional 30 min. The reaction product was then isolated.
4.3.3.2 Isolation of the reaction product
A number of non-solvents at different temperatures (-20 - +22 0C) were evaluated to
effect the precipitation of the modified PurSil (from the reaction solution). These included
water, ethanol, n-hexane, di-ethyl ether, iso-propanol and cyclohexane (see list of non-
solvents in Appendix A1). The polymer solution was added dropwise to the vigorously
stirring non-solvents (10-fold excess) and the recovered polymer dried and weighed.
After determination of a suitable non-solvent the reaction product could be
recovered by slowly pouring it into a glass beaker containing a 10-fold excess of the
vigorously stirring non-solvent. Remaining non-solvent was removed from the polymer by
vacuum drying. The dried polymer was re-dissolved in THF and different non-solvents
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again evaluated (as described above), after which the polymer could be recovered and
vacuum dried for 24 h in the dark at room temperature.
4.3.3.3 Changing the degree of modification
The modification of PurSil was studied by first adding 0.40 g (10.0 mmol) NaH to a
pre-dissolved PurSil solution (25 g in 550 g DMF). In an effort then to determine the
maximum degree of modification possible, up to 1.50 g NaH was added to the pre-
dissolved PurSil solution.
 PurSil (25g) was then modified in three different reactions with 0.75 g (18.8 mmol),
1.13 g (28.3 mmol) and 1.50 g (37.5 mmol) NaH. After isolation and purification, the
respective yields were calculated and the samples submitted for NMR analyses.
4.3.4 Analyses
4.3.4.1 Fourier-transform infrared spectroscopy
Samples were analyzed by means of photo acoustic FT-IR. The photo acoustic
detector (MTEC model 300) was coupled to a Thermo Nicolet Avatar 370
spectrophotometer. The parameters used for the determination of each spectrum were
the following:
Mirror velocity: 0.4 cm/s Spectral range: 400 - 4000 cm–1
Resolution: 8 cm –1 Number of scans: 512
Source aperture: maximum Detector gas: helium
A core sample (10 mm in diameter) was punched out from the pre-cast disk and
placed in the sample holder cup, allowing as little air into the sample compartment as
possible. A typical scan required fifteen minutes scan time. This allowed enough time for
the sample temperature to equilibrate, and hence, to obtain a quantitative measurement.
4.3.4.2 Nuclear magnetic resonance spectroscopy
Approximately 30 mg of product was dissolved in deuterated THF (d-THF). Proton
(1H) and carbon (13C) NMR spectra of the modified and control samples were obtained
from a Varian Unity 600 spectrometer at 600 and 100 MHz frequency respectively.
Chemical shifts are reported as δ (ppm) - values relative to tetramethylsilane (TMS) as
internal reference. The degree of modification was calculated as a fraction of the
integrated, vinyl proton signals (keeping in mind that it integrates for three protons) and the
total number of carbamate nitrogens (i.e. the unmodified carbamate protons plus those
modified (vinyl protons).
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4.4 Results and discussion
4.4.1 Modification of Pellethane 2363-80AE
4.4.1.1 Purification
 FT-IR analysis of the unpurified Pellethane pellets confirmed the presence of peaks
at 3302 cm-1(1), 2918 cm-1 (2) and 1635 cm-1 (3) (Figure 4.1, --blue), indicative of a bis-
stearamide processing aid [32-35]. Extractions carried out according to the literature [32,
33], using ethanol to remove the processing aid, however, highlighted a second impurity
that remained (Figure 4.1, --red) [37]. This impurity appears to be an imine [38] and is seen
together with many other peaks, typical of a urethane in Figure 4.2 to be short molecular
mass or cyclized isocyanate by-products [38].
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Figure 4.1: FT-IR analyses of (--) unpurified and (--) purified Pellethane
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Figure 4.2: FT-IR analyses of the recovered processing aid corresponding with the
peak numbers presented in Figure 4.2
The sensitivity was not strong enough to see the wax components in Figure 4.1, but
there is a much stronger evidence of the wax in Figure 4.2, especially in peak 2.
Approximately 0.35 g of processing aid was recovered from the 200 g Pellethane pellets
used.
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4.4.1.2 Acylation using 4-pentenoyl chloride
Evolution of hydrogen gas was immediately observed after the addition of the sodium
hydride (5.0 mmol). After 5 - 10 min the solution had a slight yellowish-green color caused
by the urethane polyanion, showing successful deprotonation. This observation was
consistent with the literature [2, 4].
After reaction with 4-PCl, followed by isolation and purification, the resulting polymer
was submitted, together with a Pellethane control sample, for 1H NMR analysis. The
results are presented in Figures 4.3 and 4.4 respectively.
1.01.52.0.2.53.03.54.04.55.05.56.0.6.57.07.58.08.59.09.510.0
Figure 4.3: 1H NMR spectrum of Pellethane (control)
1.01.52.02.53.03.5.4.04.55.05.56.06.57.07.5.8.08.59.09.510.0
Figure 4.4: 1H NMR spectrum of modified Pellethane
Figure 4.5: Partial structure of modified Pellethane
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The introduction of a 4-pentenoyl unit resulted in the appearance of characteristic
signals between 4.91 - 5.07 ppm and 5.81 - 5.92 ppm (Figure 4.4), when compared to
Figure 4.3 (Pellethane control). These are attributed to the vinyl protons (H -1) and (H -2),
respectively (Figure 4.5), indicating successful modification of Pellethane.
An average degree of modification of 4.5% was calculated, based on the proton-
NMR spectrum data (Figure 4.4). The degree of modification indicates the percentage of
carbamate hydrogens (at 8.5 - 8.7 ppm) substituted with the modification reagent.
Pellethane was thus successfully modified with 4-pentenoyl chloride after
deprotonation, using sodium hydride. Hence the chemistry was successfully transferred
from the model compound (Chapter 3) to a medical grade polyurethane (Pellethane® 2363-
80AE). This was considered significant and meaningful.
When the molar amount of NaH was increased to above 20.0 mmol NaH per 25 g
Pellethane the color of the mixture changed from a slight yellowish-green to a brownish
color, whereafter the polymer started precipitating out of solution, forming brown sludge
at the bottom of the reactor. It was not possible to recover the polymer after addition of 4-
pentenoyl chloride. At high sodium hydride concentrations it is believed that the polyanion
could become unstable, resulting in the degradation of the polymer chains [2].
Thereafter only 20.0 mmol NaH was added to a Pellethane solution, reacted with 4-
pentenoyl chloride, the product isolated and purified, and submitted for proton nuclear
magnetic resonance spectroscopy. The 1H NMR spectrum of the modified Pellethane is
presented in Figure 4.6.
1.01.52.02.53.03.5.4.04.55.05.56.06.57.07.5.8.08.59.09.510.0
Figure 4.6: 1H NMR spectrum of modified Pellethane
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The appearance of the characteristic vinyl proton signals between 4.90 - 5.07 ppm
and 5.81 - 5.91 ppm was once again evident. The maximum degree of modification was
found to be 20.0%, based on calculations of the 1H NMR spectrum (Figure 4.6).
Calculations from 1H NMR spectra revealed an increase in the modification extent
with increasing NaH concentration (Table 4.4). The yields (w/w), on the other hand,
randomly varied between 85 to 88% for the Pellethane samples.
Table 4.4: Control of extent of modification of Pellethane using different quantities
of NaH
NaH (mmol) 5.0 7.5 10.0 12.5 15.0 20.0
Modification (%) (Theoretical) 5.0 7.5 10.0 12.5 15.0 20.0
Modification (%) (Experimental) 4.7 7.0 10.1 11.7 14.7 19.8
The degrees of modification at the lower end (4.5% & 4.7%) as well as at the higher
end (20.0% & 19.8%) were found to be reproducible (n = 2). Very good correlation (R2 =
0.99) and a very tight 95% confidence interval (see Figure 4.7) were obtained between
the theoretically calculated (based on calculations assuming 1:1 reaction of NaH with
carbamate hydrogen) and experimentally (% modification indicates % of hydrogens on
carbamate substituted with modification reagent) obtained degrees of modification, for the
five reactions (as presented in Table 4.4) and the two repeat experiments (i.e. a total of
eight experiments). The Bland Altman plot (Figure 4.8) further shows a positive difference
between the theoretical and experimentally obtained degrees of modification (i.e.
experimental values always lower than theoretical values), probably due to trace amounts
of water present during the reaction.
Figure 4.7: Correlation between theoretical and experimental degrees of
modification of Pellethane
R2 = 0.99
.
.
.
.
.
.
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Figure 4.8: Bland Altman plot showing the differences between theoretically and
experimentally obtained degrees of modification of Pellethane
The relationship between the degrees of modification obtained experimentally (Table
4.4) was tested against the sodium hydride concentration using linear regression. A linear
regression coefficient (R2) equal to 0.99 was obtained, signifying linearity, the result of
which is shown in Figure 4.9. It was hence found to be possible to accurately control the
degree of modification (between 4.5% - 20%) by changing the molar amount of NaH.
Figure 4.9: Change in degrees of modification of Pellethane with change in NaH
concentration
4.4.2 Modification of PurSil 35-80A
4.4.2.1 Acylation using 4-pentenoyl chloride
Water (1 - 4 0C) was found to be the best non-solvent to effect the precipitation of
modified PurSil from the reaction mixture when DMF was used as solvent and in the
second precipitation, n-hexane (-20 0C) was best when tetrahydrofuran was used as
solvent.
Immediately after the addition of NaH (10.0 mmol) the solution showed a greenish
color. This, in addition to the evolution of hydrogen, indicated successful deprotonation,
and was consistent with the literature [2, 4].
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After addition of 4-PCl, isolation and purification, the resulting polymer was
submitted, with a PurSil control sample, for 1H NMR analysis. Spectra are shown in
Figures 4.10 and 4.11 respectively.
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
Figure 4.10: 1H NMR spectrum of PurSil (control)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
Figure 4.11: 1H NMR spectrum of modified PurSil
The introduction of a 4-pentenoyl unit resulted in the appearance of characteristic
signals between 4.90 - 5.07 ppm and 5.81 - 5.91 ppm in Figure 4.11, when compared to
Figure 4.10 (PurSil control). These signals are attributed to the vinyl protons, indicating
successful modification of a second medical grade polyurethane, PurSil 35-80A.
An average degree of modification of 8.1% (% modification indicates the % of
carbamate hydrogens (at 8.5 - 8.8 ppm) substituted with modification reagent) was
calculated based on the 1H NMR data (Figure 4.11).
PurSil 35-80A was thus successfully modified with 4-pentenoyl chloride, although
the degree of modification was slightly lower compared to modified Pellethane® 2363-
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5.005.205.405.605.806.00
80AE (using the same NaH concentration). This can be attributed to the difference in
chemical structure (and thus stoichiometry) between Pellethane® 2363-80AE and PurSil
35-80A.
It was found that increasing the molar amount of NaH beyond 37.5 mmol had very
little or no further effect on the degree of modification. The appearance of the
characteristic vinyl proton signals between 4.91 - 5.07 ppm and 5.81 - 5.91 ppm in Figure
4.12 was once again evident. The maximum degree of modification was thus found to be
18.5%, calculated from 1H NMR data (Figure 4.12).
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
Figure 4.12: 1H NMR spectrum of modified (18.5%) PurSil
The yields obtained after the treatment of PurSil with the range of NaH
concentrations (Table 4.5) varied randomly between 50 and 60%, which were much
lower than for the Pellethane samples. It was very difficult to effect the precipitation of
PurSil when drastic conditions (temperatures as low as –20 0C) were not used.
Calculations from 1H NMR spectra of the three modified PurSil samples revealed an
increase in the extent of modification with increasing NaH addition (Table 4.5).
Table 4.5: Control of extent of modification of PurSil with increase in NaH addition
NaH (mmol) 18.8 28.3 37.5
Modification (%) (Theoretical) 11.5 15.0 18.5
Modification (%) (Experimental) 11.7 15.2 17.9
The reproducibility of the reaction (n = 2) to obtain a theoretical degree of
modification of 18.5% was tested and found to be reproducible (18.7%). A very good
correlation (R2 = 0.99, see Figure 4.13) was obtained between the theoretically calculated
and experimentally obtained degrees of modification, for the three experiments (as
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presented in Table 4.4) and the repeat experiment (i.e. a total of four experiments). An
expected wider 95% confidence interval was obtained and can most likely be attributed to
the very small sample size (n = 4).
Figure 4.13: Correlation between theoretical and experimental degrees of
modification of PurSil with NaH
The relationship between the degrees of modification obtained experimentally (Table
4.5) was tested against the sodium hydride concentration using linear regression. A linear
regression coefficient (R2) equal to 0.99 was obtained, signifying linearity (see Figure
4.15). It is thus possible to accurately control the degree of modification (between 11.5 -
18.5%) by changing the molar amount of NaH.
The Bland Altman plot shows small random differences between the theoretical and
experimentally obtained degrees of modification. These differences could be due to
experimental and/or analytical errors.
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Figure 4.14: Bland Altman plot
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Figure 4.15: Change in degree of modification with change in NaH concentration
4.5 Conclusions
Pellethane® 2363-80AE could be purified by precipitation using ethanol at room
temperature and then successfully modified with 4-pentenoyl chloride. The model
compound chemistry could thus be successfully transferred to a medical grade
polyurethane. A maximum degree of modification of 20.0% could be obtained and the
degree of modification could be accurately (R2 = 0.99) and reproducibly (n = 2) controlled,
to between 4.5% and 20%, by changing the sodium hydride and 4-pentenoyl chloride
concentrations accordingly.
A second medical grade polyurethane, with a different chemical structure and
stoichiometry, namely PurSil 35-80A, could also be successfully modified with 4-
pentenoyl chloride. The maximum degree of modification was determined by proton-NMR
spectroscopy and found to be 18.5%. The degree of modification could accurately be
controlled to between 11.5% and 18.5% by changing the sodium hydride and 4-pentenoyl
chloride concentrations, respectively.
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Chapter 5
Crosslinking of novel modified polyurethanes
Abstract
A number of existing thermoplastic polyurethanes (TPUs) exhibit poor creep and
large hysteresis (energy losses) when subjected to static or dynamic loading. The
mechanical drawbacks of these existing TPUs have prompted the modification and
crosslinking of such materials, replacing weak hydrogen bonding with permanent
covalent crosslinks. Crosslinking of the two novel modified polyurethanes (Chapter
4) were studied using different initiation sources (ultraviolet light (UV), heat and
gamma irradiation), initiators and crosslinking enhancing monomers. The swelling
behavior (determined gravimetrically) of the crosslinked films allowed for the
calculation of the swelling index (Q) and, in turn, the molecular mass between
crosslinks. The mechanical properties (specifically hysteresis, creep and tan δ) of
the respective controls and crosslinked films were then evaluated using uniaxial
tensiometric testing and dynamic mechanical analysis. Successful UV and heat
induced crosslinking of the two novel modified polyurethanes (Pellethane and
PurSil) was achieved, using ω,ω-dimethoxy-ω-phenylacetophenone (DMPA) and
dicumyl peroxide (DCP), respectively, although only UV initiation was investigated
as a method of crosslinking for modified PurSil. The swelling index values, used to
calculate the molecular mass between crosslinks, were used to optimize the
initiator concentrations. The optimum initiator concentration, i.e. the smallest Q
value, was found to be between 1.5% and 2.0% (both for DMPA and DCP) for
modified Pellethane, and between 2.0% and 2.5% (DMPA) for modified PurSil.
The lowest Q value (i.e. the lowest molecular mass between crosslinks) was
obtained for the 15.0% and 18.5% modified and crosslinked Pellethane (Pell15.0)
and PurSil samples (Pur18.5), respectively. The best mechanical properties (e.g.
hysteresis) were also obtained for Pell15.0 and Pur18.5, with respective
improvements of up to 42.5% in hysteresis and 44.3% in creep for Pell15.0 and
improvements of up to 12.9% in hysteresis for Pur18.5. The use of the crosslinking
enhancing monomer, MBA, resulted in lower swelling index values, but had a
detrimental effect on the hysteresis. It was therefore not included in further
investigations.
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5.1 Introduction
The drawbacks associated with the mechanical and chemical properties of existing
medical grade polyurethanes (e.g. they may be prone to excessive dilation and still have
unproven long-term biostability) [1-10], prompted the modification and crosslinking of these
existing polyurethanes, replacing labile hydrogen bonding with permanent covalent
crosslinks.
Crosslinking of the two novel modified polyurethanes (Chapter 4) were evaluated
using different crosslinking systems (ultraviolet light, thermal and gamma irradiation) and
various initiators. In an attempt to further enhance crosslinking, the addition of a number of
crosslinking enhancing monomers was also investigated.
Quantification (i.e. the efficiency of crosslinking) of all the crosslinked films was first
determined using the swelling behavior (determined gravimetrically), which allowed for the
calculation of the swelling index (Q). The swelling index was specifically used as an
analytical tool to quantify the degree of crosslinking (i.e. the lowest Q results in the highest
crosslink density) and was not used to try and simulate in vivo behavior. The swelling index
values were then used to calculate the molecular mass between crosslinks [11-14]. Due to
complexity and uncertainty of the exact structure of the polymerized system only the films
where no monomer was added were considered in these calculations.
The mechanical properties of the controls and crosslinked polyurethane films were
then evaluated using uniaxial tensiometric testing and dynamic mechanical analysis (DMA)
to determine the effect of crosslinking on the energy losses. The parameters studied
included hysteresis, creep and tan δ. Correlation between the mechanical properties (e.g.
hysteresis) and swelling index values was then investigated.
5.2 Historical
Thermoplastic polyurethanes (TPU) are known to suffer from excessive plastic
deformation when subjected to cyclic loading. Due to their wide range of applications, the
mechanical properties of existing and new TPUs, when subjected to cyclic loading
(hysteresis) [3-6] or static loads (creep) [7-10], have been studied extensively.
A number of polyurethanes, comprising different hard and soft segments and chain
extenders, have been studied. In one such a study a poly(urethane urea) and three
polyurethanes were synthesized, comprising 4,4-methylenebis(phenylisocyanate) (MDI),
poly(tetramethylene oxide) glycol (PTMEG) and 1,4-butanediol (BDO) (in different ratios) [3].
The main objective of the study was to minimize the hysteresis. The lowest hysteresis
results were obtained with the TPU having an amorphous, well-dispersed hard segment
structure. This led to the development of a complex mathematical model [5] describing the
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important mechanical properties of the polyurethanes under investigation. In other studies,
large hysteresis of new poly(dimethylsiloxane) based segmented polyurea copolymers [4]
and dibenzyl-based polyurethanes [6] have also been reported.
The dynamic [7] and static [8] creep behavior of polyurethanes have also been
studied. The dynamic creep behavior of novel poly(aliphatic/aromatic-ester) urethanes was
compared with an existing medical grade polyurethane (Pellethane® 2363-80AE) [7].
Pellethane exhibited poor creep, especially when compared to the ester-based
polyurethanes. Unfortunately, the latter are known to be hydrolytically unstable (as
discussed in Chapter 2) and this precludes their use as biomaterial.
The crosslinking of polyurethanes has been achieved by various pathways, as
discussed in Chapter 4 (§4.2). Although the main objective of most of the studies was not
necessarily to improve the mechanical properties, many researchers used solubility and the
swelling index (Q) [11-13, 15-17] in the former to indicate successful crosslinking or in the
latter to optimize crosslinking.Swelling index values were then further used to calculate the
molecular mass between crosslinks [11-14] according to the well-known Flory-Rehner [16]
equation. As Q decreases, the molecular mass between crosslinks is reduced, resulting in
a more densely crosslinked structure [11, 13, 14, 16]. A complex theory, based on rubber
elasticity, has also been used to calculate the molecular mass between crosslinks [18].
In the Flory-Rehner equation the polymer solubility parameter (δ2) is however needed
to calculate the polymer-solvent interaction parameter (Χ1). The polymer solubility parameter
can be obtained by group contribution methods [11, 19] or by the method of Hansen [17, 19,
20] (also see Appendix C for a summary of the relevant theory and methods used).
Jayabalan and co-workers [13] made the assumption of mutual solubility (ideal scenario)
[13], in which it is assumed that the solvent (δ1) and polymer solubility parameters (δ2) are
equal, resulting in Χ1 being equal to 0.34 (Eq. 5.4). This was done due to the sensitivity in
the calculation of the polymer-solvent interaction parameters to uncertainty in the
determination of the polymer interaction parameter.
5.3 Theoretical considerations in crosslinking reactions
5.3.1 Initiation systems
The modification agent used in this study, 4-pentenoyl chloride, has a pendent vinyl
group, and in order to induce crosslinking of the modified polyurethane a suitable free
radical initiation source was required. Possible initiation methods include thermal,
photochemical, and gamma irradiation methods. The following discussion is based on the
very comprehensive book by Moab et al. [21].
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5.3.1.1 Thermal initiation
Azo-compounds and peroxides are generally used as initiators in thermal induced
polymerization reactions. The initiator decomposes into free radicals, resulting in the
evolution of nitrogen gas (Scheme 5.1). The decomposition rate is highly dependent on the
reaction temperature and the solvent used [21].
Scheme 5.1: Illustration of the decomposition of an azo-compound [21]
Azo-compounds can be subdivided into dialkyldiazenes, which are a high-temperature
(65 - 200 0C) source of alkyl radicals, and dialkyl hyponitrites, which are a low-temperature
(40 - 70 0C) source of alkoxy or acyloxy radicals. In the former, 2,2-azobis(2-
methylpropanenitrile) (AIBN) is commonly encountered, while dialkyl hyponitrites have not
found wide application due to difficulties associated with their synthesis and commercial
availability.
The most commonly used peroxide initiators include: diacyl peroxides, dialkyl
peroxydicarbonates, peresters, dialkyl peroxides, hydroperoxides and inorganic peroxides.
The decomposition of the peroxide molecule is illustrated in Scheme 5.2.
R C
O
O O C
O
R1 R C
O
O2 + CO2
Scheme 5.2: Illustration of the decomposition of the peroxide molecule [21]
Dialkyl peroxydicarbonates and peresters (e.g. di-t-butyl peroxalate (DBPOX)) are
used in low temperature (35 - 550C) applications and diacyl peroxides (e.g. benzoyl
peroxide, BPO and dilauroyl peroxide, LPO) in moderate reaction temperature ranges (35 -
800C). Dialkyl peroxides, e.g. dicumyl peroxide (DCP), are a high-temperature source of
alkoxy radicals. In general, the decomposition rate of dialkyl peroxides is not sensitive to the
solvent when compared to most other peroxides. Persulfates are primarily used in emulsion
polymerization.
5.3.1.2 Photochemical initiation
Photochemical initiation is commonly used in curing or crosslinking processes and in
initiating graft copolymerization [21]. The initiators used are often aromatic carbonyl
containing compounds, including benzoin derivatives.
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Scheme 5.3: Decomposition of an acetophenone chromophore [21]
The acetophenone chromophore absorbs in the near UV (300 - 400 nm) and usually
decomposes by α-scission, as presented in Scheme 5.3. Benzoin ethers (R = alkyl; R1 = H)
and the α-alkyl benzoin derivatives (R = H, alkyl; R1 = alkyl) (e.g. ω,ω-dimethoxy-ω-
phenylacetophenone, DMPA) are primarily used. The α-scission process is extremely facile
and is not quenched by oxygen, which means it can be used for UV-curing in air.
5.3.1.3 Gamma irradiation
Gamma rays are ultra-short electromagnetic waves. They involve the transfer of
sufficient energy to a bound electron located in an atomic or molecular orbital of the
irradiated material so that the electron becomes free [22]. Polymerization initiated by gamma
rays most often occurs via a free radical mechanism [22].
5.3.2 Determination of crosslinking density
5.3.2.1 Swelling index determination
The swelling index is determined by Eq. 5.1 [13, 14, 16, 23].
€ 
Q = V1
V2
(5.1)
where V1 and V2 are the volumes of solvent in the swollen gel and the polymer,
respectively, which can be obtained using a gravimetrical method (§5.3.3.1) [13, 16, 23,
24].
5.3.2.2 Molecular mass between crosslinks
The most widely used, and essentially the standard, method for determining crosslink
density of crosslinked polymers (3-D networks) depends upon knowledge of their swelling
properties [14], i.e. the swollen volume of the crosslinked polymer is measured and used to
calculate the crosslink density.
 When the crosslinked polymer sample is placed in contact with a suitable solvent,
imbibition of the solvent takes place, resulting in swelling of the polymer. The three-
dimensional network is extended until, due to deformation stresses, the rate of imbibition of
solvent equals the rate of expulsion. This equilibrium swelling can be related to the well-
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known Flory-Rehner equation to calculate the number of effective network chains per unit
volume of crosslinked polymer [14]. The modified form of this equation is [14]:
€ 
1
Mc
−
2
Mr
= −
ln(1−υ 2) +υ 2 + X1υ 2
2
ρ2v1(υ 2
1 3 −υ 2 2)
(5.2)
where Mc is the molecular mass between crosslinks; Mr, the molecular mass of the linear
polymer; υ2, the volume fraction of the polymer in the swollen gel; X1, the polymer-solvent
interaction parameter; and v1, the specific volume of solvent. The volume fraction of the
polymer in the swollen gel (υ2) can be calculated by the reciprocal of the swelling (Q).
€ 
υ 2 =
1
(1+Q)
(5.3)
X1 is obtained from the solubility parameters by the following equation:
€ 
X1 ≈ 0.34 +
V1
RT
(δ1 −δ2)
2 (5.4)
where δ1 and δ2 are the solubility parameters of the solvent and polymer respectively; R is
the universal gas constant; T is the temperature. The polymer solubility parameter is often
not known, but can be estimated using the well known group contribution methods of
Hansen, Hoy, and Hoftyzer and Van Krevelen (HVK). The relevant theory is summarized in
Appendix C.
Newer theory of rubber elasticity could potentially be used in the interpretation of
swelling [11, 24]. However, network parameters such as cycle rank, entanglement
constraints, the average junction functionality, the number of chains and the molecular
mass of chains between two junctions are required. Due to the complexities of these
methods, as described by others [11, 24], this was considered outside the scope of this
dissertation.
5.4 Experimental
5.4.1 Materials
The following polyurethanes were used, Pellethane® 2363-80AE (Pellethane), modified
Pellethane (degree of modification ranging from 4.5 – 15%, Chapter 4), PurSil 35-80A
(PurSil) and modified PurSil (degree of modification ranging from 11.5 – 18.5%, Chapter 4).
Tetrahydrofuran (THF) (Merck, Cat: AB009731) was used as solvent and ω,ω-dimethoxy-
ω-phenylacetophenone (DMPA) (Aldrich Cat: 19,611-8) as UV initiator. The thermal initiators
that were evaluated included 2,2’-azobisisobutyronitrile (AIBN) (Aldrich Cat: 44,109-0),
benzoyl peroxide (BPO) (Aldrich Cat: 17,998-1), cumene hydroperoxide (Aldrich Cat:
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24,750-2), dicumyl peroxide (DCP) (Aldrich Cat: 32,954-1) and lauroyl peroxide (Aldrich Cat:
29,078-5).
A number of crosslinking enhancing monomers were used, including ethylene glycol
dimethacrylate (EDGM) (Aldrich Cat: 33,568-1), trimethylolpropane trimethacrylate
(TMPTMA) (Aldrich Cat: 24,684-0), trimethylolpropane triacrylate (TMPTA) (Aldrich Cat:
24,680-8) and N,N’-methylenebisacrylamide (MbA) (Aldrich Cat: 14,607-2). n-Hexane was
obtained from Merck (Cat: 152496G).
5.4.2 Methods
5.4.2.1 Sample preparation for crosslinking
The crosslinking of modified Pellethane (degree of modification ranging from 4.5 –
15%, Chapter 4) and modified PurSil (degree of modification ranging from 11.5 – 18.5%,
Chapter 4) was studied. The following abbreviations will hereafter be used:
Pellm Modified Pellethane(uncrosslinked) Purm
Modified PurSil
(uncrosslinked)
Pellm15.0 15% modified Pellethane(uncrosslinked) Purm15.0
15% modified PurSil
(uncrosslinked)
Pellx Modified and crosslinkedPellethane Purx
Modified and crosslinked
PurSil
Pell15.0 15% modified and crosslinkedPellethane Pur15.0
15% modified and crosslinked
PurSil
The three polyurethanes Pellethane (control), Pellm and Purm were dissolved in
tetrahydrofuran, and the PurSil (control) in cyclohexanone (10% solution (w/w). To the
novel modified polyurethanes (Pellm and Purm) different initiators (e.g. DCP and DMPA) and,
in selected experiments, crosslinking enhancing monomers (e.g. BA, MbA and TMPTMA),
were added.
Solid films were cast from the solutions by standard solvent casting and evaporation
techniques and dried in vacuo for at least 18 hours. Crosslinking of the dried films (≈0.5 mm
thick) using an ultraviolet light (UV initiation), a heat source (thermal initiation) or gamma
irradiation, respectively, were studied.
5.4.2.2 Ultraviolet light induced crosslinking
The films were exposed to a 315 - 400 nm UV light source (Sylvania, 100 W) at a
distance of 500 mm for a period of 5 - 20 min (depending on the size of the samples and the
film thickness) to induce crosslinking (see Figure 5.1). After crosslinking, the samples were
dried for an additional 72 hours in vacuo, before any mechanical tests were performed.
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Figure 5.1: Illustration of UV initiation set-up used
5.4.2.3 Heat induced crosslinking
The films were placed between two plates of a heat press (Figure 5.2), fitted with
two spacers, equal to the required film thickness, which ensured a constant film thickness
when a pressure of approximately 30 MPa was applied to the plates.
Figure 5.2: Illustration of thermal initiation set-up used
The films were exposed to temperatures ranging between 60 - 180 0C for time periods
of 0.5 - 6 h, depending on the specific initiator in the film sample used. The heat press was
then switched off and the film allowed to slowly cool down to room temperature (22 0C).
The average rate of cooling over the higher temperature ranges used (>100 0C), was
approximately 15 - 20 0C/h. The cooling rate was relatively constant due to the construction
of the heat press (large, thick heating blocks). After crosslinking, the samples were dried
for an additional 72 hours in vacuo, before any mechanical tests were conducted.
5.4.2.4 Gamma irradiation
Films were exposed to a Co60 source with a half-life of 5.3 years (HEPRO, South
Africa). Irradiation dosages ranging between 10 - 250 kGy were used to impart
crosslinking.
5.4.2.5 Optimization of initiator and monomer concentrations
First the initiator concentration used in the crosslinking reaction was varied between 0
- 3% (max). The swelling indexes (Q) of the crosslinked films were determined and an
optimum (lowest Q) found, which was desirable in this dissertation to illustrate the highest
degree of crosslinking. The different crosslinking-enhancing monomers were then included
separately, using the optimum initiator concentration as determined above and was then
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varied between 0 - 3% (max). Q was determined and an optimum (lowest Q) found. This
was repeated for the whole range of novel modified Pellethane® 2363-80AE (Pellx) and
PurSil 35-80A (Purx) samples.
5.4.3 Analyses
5.4.3.1 Swellling index determination
The swelling index (Q) was determined (n = 3) using a gravimetrical method [13, 16,
23, 24]. Round disks (15 mm diameter) were punched from the dried films, their weight
measured in air (mass 1) and as submerged in n-hexane (non-solvent immiscible with DMF
[14]) (mass 2) (Figure 5.3) and the dry volume (V2) determined according to Eq. 5.5, where
ρair and ρn-Hexane are the densities of air and n-hexane, respectively. The films were then
allowed to swell in dimethylformamide (DMF) (for at least 18 hours) and weighed again in
air (mass 3) and as submerged in n-hexane (mass 4) and the swollen volume determined
(V3) (Eq 5.6). DMF was used as solvent to achieve the sufficient swelling required,
minimizing the possible experimental error [14]. The swelling index (Q) was calculated
according to Eq. 5.7 [13, 14, 16, 23]:
€ 
V2 = (Mass1−Mass2) (ρn−Hexane − ρair) (5.5)
€ 
V3 = (Mass3−Mass4) (ρn−Hexane − ρair) (5.6)
€ 
Q = (V3 −V2) V2 =V1 V2 (5.7)
Figure 5.3: Illustration of the procedure used to obtain the swelling index (Q)
5.4.3.2 Calculation of molecular mass between crosslinks
Although the exact molecular structures of Pellethane® 2363-80AE or PurSil 35-80A
are not known, some limited knowledge of Pellethane® 2363-80AE enabled an estimation of
its polymer solubility parameter (δ2), not only experimentally using the method by Hansen
(as in the case of PurSil 35-80A), but also theoretically, using the group contribution
methods of Hoy, and Hoftyzer and Van Krevelen (HVK). The calculated molecular mass
between crosslinks (Mc) was then compared with that of the “ideal”, where it is assumed
that the solvent (δ1) and polymer solubility parameters are equal (δ1 = δ2 resulting in Χ1 =
0.34) (Eq. 5.4), i.e. mutual solubility [19].
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The solubility parameter of Pellethane® 2363-80AE and PurSil 35-80A, respectively,
(as described by Hansen, Appendix C) was determined by placing 0.10g of dried
polyurethane in ampoules with 1.00 ml of solvent and then shaking for 7 days at room
temperature. The liquids were then classified as good solvents, good swelling agents, poor
swelling agents, and non-solvents, by visual assessment. The polymer interaction was
then also estimated using the group contribution methods (outlined in Appendix C). The
Flory-Rehner equation was then ultimately used to calculate Mc (Eq 5.2).
5.4.3.3 Tensile testing
Test specimens (≈0.5 mm thick) were cut from the dried films using an ASTM D638
(Type V) cutter. The tensile testing was performed at room temperature (20 - 22 0C) using
an Instron model 5544, equipped with a 1 kN load cell. Each test was repeated at least
three times (n ≥ 3). Testing was performed on the dry films to gain basic knowledge first,
which allowed for direct comparisons with published results. The results could be slightly
influenced by the absorption of moisture in vivo [26].
(A) Tensile stress and strain at break
Once a preload of 0.005 N was achieved at a crosshead speed of 2 mm/min, samples
were pulled to failure at a crosshead speed of 200 mm/min. The tensile stress and strain at
break were recorded (n = 4).
 (B) Cyclic tensile testing
Once a preload of 0.005 N was achieved at a crosshead speed of 2 mm/min, samples
(n = 4) were subjected to four extension cycles to an extension of 200% of the samples’
original length (200 mm/min). The second cycle was consistently used throughout [4] to
calculate the hysteresis and non-recovered strain (NRS), as illustrated in Figure 5.4.
Figure 5.4: Illustration of cyclic tensile testing calculations
a
b
c d
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The areas (a and b), as illustrated in Figure 5.4, were numerically integrated
(trapezium rule) and the hysteresis calculated as the energy loss (a) per total input energy
(a+b) (Eq. 5.8) [4, 6].
€ 
Hysteresis = a a + b( ) (5.8)
Non-recovered-strain (NRS) (also called instantaneous residual strain [4]) was
calculated according to Eq. 5.9 [4].
€ 
NRS = d − c( ) (5.9)
(C) Creep
The samples (n = 3) were pulled at a crosshead speed of 50 mm/min to a tensile
stress of 8 MPa (t0), where the tensile strain of Pellethane and Pell15.0 are comparable, and
the stress maintained for a period of 90 min (t90). The creep was calculated according to
Eq. 5.10 (see Figure 5.5) as the ratio between the difference between measured strains at
t90 and t0 (e) and the strain measured at t0 (f).
€ 
Creep = e f (5.10)
Figure 5.5: Illustration of variables used to calculate the creep
5.4.3.4 Dynamic mechanical analysis
Dynamic mechanical analyses (n = 1) were performed with a Perkin Elmer DMA 7e
equipped with a parallel plate measuring system and 3-mm disc probe. A temperature scan
mode was used and the temperature was ramped at a rate of 5 0C/min from -100 to 220 0C
under a nitrogen atmosphere. Scans were performed at a frequency of 1 Hz with initial
static and dynamic forces of 110 mN and 100 mN, respectively. A static tension control
(120%) and amplitude dynamic control of 10 µm were used.
The transition temperatures (T1 and T2) were obtained from the tan δ curves [4, 18], at
the onset of the respective peaks. The storage moduli will be reported at 37 0C
(physiological temperature).
e
f
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5.3.4.5 Statistical analysis
Statistical analyses were performed using either (a) student t-test (unpaired 2-tailed,
assuming equal variance), (b) 1-way analysis of variance (ANOVA) and (c) 2-way
ANOVA. Bonferroni corrections were applied in cases of multiple comparisons. A
significance level of 0.05 or less was accepted as being statistically significant. Standard
assumptions of normality were made, but in cases were it was suspected that the
assumptions were violated the results were verified using non-parametric (bootstrap)
techniques (see Appendix H for a summary).
5.5 Results and discussion
5.5.1 Crosslinking of modified Pellethane® 2363-80AE
5.5.1.1 Swelling index
Successful UV induced crosslinking was achieved after 5 - 20 min, using DMPA or,
alternatively, using DCP at 120 0C for 5 hours. The evolution of nitrogen gas during thermal
initiation produced bubbles in the polyurethane films, which rendered the azo-containing
initiators (e.g. 2,2’-azobisisobutyronitrile) unusable. Crosslinking was not achieved in the
temperature range (60 - 180 0C) and time range (0.5 - 6 h) studied when benzoyl peroxide,
cumene hydroperoxide or lauroyl peroxide were used.
The change in Q ± standard deviation with change in initiator (DMPA and DCP)
concentration (0 - 2%) for a typical example (Pell8.5) is presented in Figure 5.6.
Figure 5.6: Change in Q ± standard deviation (n = 3) with change in DMPA and DCP
concentration for Pell8.5 using UV and heat induced crosslinking, respectively
Crosslinking was not achieved without using initiator (“0%”, Figure 5.6), even after the
samples were subjected to the UV source for 30 min or the heat source (150 0C) for up to
6 hours. This finding was consistent over the whole range of Pellx samples.
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The swelling index at a DCP concentration of 1.5% (w/w) was found to be
significantly lower compared to a concentration of 1.0% (p<0.01), but did not change
significantly when compared to a concentration of 2.0% (p=1.0). Similarly, the swelling
index at a DMPA concentration of 1.5% (w/w) was found to be significantly lower than at a
concentration of 1.0% (p=0.01), but did not change significantly (p=0.28) when compared
to 2.0%. The swelling indices obtained for the UV initiation system were significantly lower
than the heat induced initiation system (p<0.01) for all the samples in the initiator range. The
lowest swelling index (optimum initiator concentration) was thus achieved at an initiator
concentration of 1.5% (w/w) (in this specific example) using either DMPA or DCP as
initiator.  The DMPA and DCP concentrations were similarly optimized for the range of Pellx
samples (i.e. Pell4.5, Pell6.5, etc.), the swelling indices of which are presented in Figure 5.7
and summarized in Table 5.1.
Figure 5.7: Change in Q ± standard deviation (n = 3) for Pell8.5 with optimized
initiator concentration
Table 5.1: Optimized initiator concentrations for the Pellx range
Pellx Pell4.5 Pell6.5 Pell8.5 Pell12.5 Pell15.0
[DMPA] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
Q ± std dev 7.17 ±0.31 5.85 ±0.15 3.77 ±0.01 3.39 ±0.12 2.82 ±0.05
[DCP] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
Q ± std dev 9.44 ±0.50 6.99 ±0.38 6.24 ±0.27 4.58 ±0.20 3.20 ±0.03
The Pellethane control samples (“Pellethane”) did not crosslink after subjection to
either the UV or heat sources. As expected, a decrease in the swelling index was
observed with an increase in the degree of modification (in the range tested, i.e. Pell4.5 –
Pell15.0) for both UV and heat induced crosslinking (Figure 5.7 and Table 5.1). The lowest
swelling index was obtained for Pell15.0 (when compared to Pell12.5, Pell8.5, Pell6.5 and
Pell4.5) for both UV (p<0.02) and heat (p<0.01) initiation. This was expected, as a higher
degree of modification (e.g. Pell15.0) would lead to a more densely crosslinked structure
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(i.e. the molecular mass between crosslinks would be lower, see §5.4.1.2), thus increasing
the elastic response and limiting the solvent uptake in the resulting tighter three-dimensional
polymer structure, resulting in the lowest swelling index [14].
This finding was consistent for both UV and thermal induced crosslinking although the
swelling index was consistently significantly higher in the latter (p<0.03) (Table 5.1), except
for Pell6.5 where the difference was found to be non-significant (p=0.11). Heat induced
crosslinking was achieved at the onset of the melt region of Pellethane (see Figure 5.19,
DMA) most probably resulting initially in free chain movement and “pre-mature” crosslinking,
which in turn then restricted full micro-phase separation. This is in contrast to UV induced
crosslinking, which was achieved at room temperature and thus after complete micro-
phase separation.
In a control study of the influence of the respective initiators (ranging in concentration
between 0 - 2%) on the swelling index of Pellethane it was found that neither DMPA nor
DCP (at concentrations as high as 2%) resulted in crosslinking reactions, even after
exposure of the films to the UV light source for more than 30 min or temperatures of 1200C
for periods of up to 6 hours.
Gamma irradiation induced crosslinking was only achieved at very high radiation
dosages (250 kGy) for Pellm12.5 and Pellm15.0. The samples swelled excessively in
solvent (e.g. DMF) and unfortunately the mechanical integrity of the resulting crosslinked
structures was so weak that it was not possible to determine the swelling indices. Pellm
films were also prepared with a wide range of initiators (as listed in §5.4.1), at different
concentrations, but crosslinking using gamma irradiation was not achieved in any of the
samples. In a control study, Pellethane did not crosslink, even after being subjected to the
very high irradiation dosages. This is most likely due to a combination of the low degree of
modification of the other samples and scission that occurs during the irradiation process.
Table 5.2: Swelling index ± standard deviation of Pell8.5 with variation in initiator (I)
and monomer (M) concentrations
Pell8.5 0.0%I 0.5%I 1.0%I 1.5%I 2.0%I
0.0%M - 6.39 ±0.72 4.29 ±0.11 3.76 ±0.05 3.84 ±0.01
0.5%M - 4.60±0.41 4.22±0.16 3.58±0.04 3.65±0.08
1.0%M - 4.51±0.05 4.10±0.04 3.45±0.07 3.61±0.08
1.5%M - 4.47±0.13 3.78±0.04 3.05±0.06 3.33±0.25
2.0%M - 4.45±0.32 4.16±0.31 3.93±0.12 3.96±0.15
Although a number of potential crosslinking enhancing monomers was originally
evaluated it was decided to proceed with MbA, because of its long and proven history in
the field of biomedical polymers.
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To illustrate the effect that the DMPA and MbA concentrations (with UV initiation) have
on the swelling index of Pell8.5, a matrix consisting of the swelling index results (Q ±
standard deviation) (n = 3) for the full initiator (I) (DMPA, 0 - 2%) and monomer (M) (MbA, 0
- 2%) ranges is presented in Table 5.2, and illustrated in Figure 5.8.
Figure 5.8: 3-D plot of swelling index (I:0-2%, M:0-2%) results obtained for Pell8.5
Again no crosslinking was achieved without initiator (“0.0%I”). A small decrease in Q
with an increase in monomer concentration (M) was observed for the full initiator
concentration (I) range studied. A decrease in Q was further observed with an increase in
initiator concentration, for the monomer concentration range studied. The lowest swelling
index was observed with both monomer and initiator concentrations at 1.5%.
Figure 5.9 compares Q ± standard deviation (n = 3) values obtained with both optimum
initiation systems, both with (Table 5.3) and without optimized monomer (MbA)
concentration.
Figure 5.9: Effect of modification percentage of crosslinked Pellethane on swelling
index for UV and thermal initiation, both with and without MbA monomer (n = 3)
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Similarly, a decrease in Q (when using either UV or heat) was observed with the
additional inclusion of the crosslinking enhancing monomer MbA (i.e. “UV(I+M)” &
Heat(I+M)”, Figure 5.9). A significant reduction in the swelling index was observed when
monomer was included compared to the cases when only initiator was included, using
either UV (p<0.01) or heat (p<0.02), over the whole range (i.e. Pell4.5 - Pell15.0). The only
significant difference between the UV and heat initiation systems, when monomer was
added, was found between Pell12.5 (p=0.03) and Pell15.0 (p<0.01). The inclusion of the
MbA molecule presumably reduced Q by forming “linking bridges” between the spaced
reactive 4-pentenoyl pendent groups during their polymerization.
When the swelling indices of samples (n = 3) initiated using UV (DMPA) are compared
with those initiated using heat (DCP) (Table 5.3) (when MbA was included), those of the
former were found to be significantly lower for Pell8.5, Pell12.5 and Pell15.0.
Table 5.3: Q ± standard deviation (n = 3) for optimized initiator and MbA
concentrations for Pellx
Pellx Pell4.5 Pell6.5 Pell8.5 Pell12.5 Pell15.0
[DMPA] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
[MbA] (w/w) 0.5% 1.5% 1.5% 2.0% 2.0%
Q ± std dev 4.35 ±0.09 3.32 ±0.10 3.05 ±0.06 2.47 ±0.05 2.35 ±0.03
[DCP] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
[MbA] (w/w) 0.5% 1.5% 1.5% 2.0% 2.0%
Q ± std dev 4.65 ±0.38 3.46 ±0.24 3.21 ±0.11 3.13 ±0.14 2.86 ±0.07
In the following section the swelling index values will be used to calculate the
molecular mass between crosslinks for Pellx. Swelling index results obtained with MbA will
not be considered due to the complexity and uncertainties involved in the degree of
polymerization and possible other side reactions involving MbA.
5.5.1.2 Molecular mass between crosslinks
The calculation of the polymer solubility parameter (δ2) using the group contribution
method of Hoy [19] was found to be the closest to mutual solubility (“Ideal”, Table 5.5),
where the solubility parameter of the solvent (DMF) (δ1 = 24.8 MPa1/2) is equal to the
solubility parameter of the polymer (δ1 = δ2 = 24.8 MPa1/2). This equates to a polymer-solvent
interaction parameter (Χ1) equal to 0.34 (Eq. 5.4). Table 5.4 compares this result with those
obtained using the methods of Hoy, Hansen, and of Hoftyzer and Van Krevelen (HVK)
(Table 5.4).
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Table 5.4: Calculation of the polymer and polymer-solvent interaction parameters by
various methods
Ideal Hoy Hansen HVK
δ2 (MPa1/2) 24.80 24.01 21.80 19.11
Χ1 ( ) 0.34 0.36 0.62 1.36
The polymer-solvent interaction parameter (Χ1) is very sensitive to changes in δ2 (and
thus the differences between δ1 and δ2) as it is a quadratic function of the latter (Eq. 5.4).
The sensitivity of Χ1 to changes in δ2, ranging between 0 - 15%, on the solubility parameter
of the polymer is shown in Figure 5.10.
Figure 5.10: Sensitivity of the solvent-polymer interaction parameter (Χ1) to changes
in the polymer solubility parameter (δ2)
Figure 5.11 shows the effect of the sensitivity of Χ1 on the molecular mass between
crosslink (Mc) determinations for Pellx.
Figure 5.11: Change in Mc with change in Χ1 for Pellx
 in δ2 ( )
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The calculated molecular masses between crosslinks (Mc) are relatively stable for
changes in Χ1 only between values of 0.34 and 0.39, which equates to a change in δ2 of
5%. This was found to be consistent over the whole range of Pellx (i.e. Pell4.5, Pell6.5,
etc.) presented in Figure 5.11.
Only the method of Hoy was thus found to be useful in the determination of the
polymer interaction parameter (δ2). The calculated molecular mass between crosslinks for
mutual solubility (“Ideal”), and using the method of Hoy for both the UV and heat initiation
systems, is presented in Figure 5.12, with a summary of the exact values in Table D.1
(Appendix D).
Figure 5.12: Comparison of Mc ± standard deviation (n = 3) for UV and heat initiation
of Pellx
A decrease in Mc was observed with an increase in the degree of modification (in the
range tested, i.e. Pell4.5 - Pell15.0) for both the UV and heat induced crosslinking (Figure
5.12). The trends in the Mc values for both the UV and heat initiation systems are consistent
with those obtained for the swelling indexes, as presented in Figure 5.7 (see Table D.1,
Appendix D, for the exact values), which was expected, since the swelling index values
were used to calculate Mc.
There will still be an uncertainty because of the microphase separation and since
crosslinking is only in the hard phase. As the soft phase is not crosslinked a certain
swellability must persist. At present, there is no method to take this variability of block
crosslinking into account.
5.5.1.3 Tensile properties
The hysteresis for Pellethane (control) and for Pell8.5 (typical example) and as a
function of initiator (DMPA and DCP) concentration (0 – 2%) is presented in Figure 5.13.
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Figure 5.13: Hysteresis ± standard deviation (n = 4) of Pell8.5 as function of DMPA
and DCP concentrations
A decrease in the hysteresis was observed with an increase in initiator concentration
(DMPA and DCP) , over the initiator concentration range studied. The hysteresis for the UV
and heat initiation systems were found to be a minimum at an initiator concentration of 1.5%
(w/w), for both DMPA (p=0.04) and DCP (p=0.03), when compared to initiator
concentrations of 1.0%, but with no significant change when compared to initiator
concentrations of 2.0%. The lowest hysteresis (optimum) was thus achieved at initiator
concentrations of 1.5% (w/w) (for both UV and heat). This is in good agreement with
swelling index values, where the lowest Q value for Pell8.5 (§5.4.1.1) was also obtained at
initiator concentrations of 1.5% (w/w).
The DMPA concentration was similarly optimized for Pell15.0. The initiator
concentrations (DMPA and DCP) as optimized for Pell8.5 (Figure 5.13), and the DMPA
concentration as optimized for Pell15.0, compared well with the swelling results. The
hystereses ± standard deviation (n = 4) of Pellethane (control) and Pellx (Figure 5.14) are
summarized in Table 5.5 at the initiator concentrations, as optimized in the swelling
experiments, and verified for the selected ones, as mentioned above.
Figure 5.14: Change in hysteresis with change in degree of modification of Pellx
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A decrease in hysteresis was observed with an increase in the degree of
modification for both thermal and UV initiation, with a minimum obtained for Pell15.0
(p<0.01), when compared to their respective controls, i.e. a marked improvement of more
than 40% in hysteresis was achieved over the Pellethane control. The difference between
UV and heat initiation on the hysteresis (Figure 5.14) was found to be non-significant
(p>0.05) over the Pellx range tested.
Table 5.5: Measured and calculated mechanical properties ± standard deviation for
Pellx (n = 4)
Pellx Pellethane Pell4.5 Pell6.5 Pell8.5 Pell12.5 Pell15.0
[DMPA] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
Hysteresis (-) 0.36±0.01 0.32±0.02 0.28±0.01 0.28±0.01 0.24±0.01 0.21±0.01
% Change 11.0% 21.4% 23.3% 33.6% 42.5%
NRS (-) 16.74±0.97 16.30±0.77 13.31±0.61 12.70±0.68 11.78±1.11 8.75±0.88
% Change 2.6% 20.5% 24.1% 29.6% 47.7%
Stress (MPa) 46.97±2.44 42.63±1.96 35.81±3.13 38.70±1.07 31.07±1.58 29.23±1.92
% Change 9.2% 23.8% 17.6% 33.9% 37.8%
Strain (%) 571.6±19.3 488.6±15.1 498.1±25.1 475.5±15.4 435.5±5.2 411.5±18.4
% Change 12.8% 12.9% 16.8% 23.8% 28.0%
[DCP] (w/w) 1.5% 1.5% 1.5% 2.0% 2.0%
Hysteresis (-) 0.36±0.11 0.31±0.01 0.31±0.02 0.29±0.00 0.24±0.00 0.21±0.01
% Change 13.0% 14.2% 19.9% 32.0% 40.2%
NRS (-) 21.70±0.83 14.34±0.75 14.84±0.96 14.42±1.18 11.88±0.48 9.16±0.68
% Change 33.9% 31.6% 33.5% 45.2% 57.8%
Stress (MPa) 47.82±3.13 46.66±2.74 43.79±4.93 36.34±4.44 35.12±1.18 29.43±4.27
% Change 2.4% 8.4% 24.0% 26.6% 38.5%
Strain (%) 619.9±21.4 550.5±18.3 566.5±36.6 445.9±34.2 491.1±14.0 402.1±32.1
% Change 11.2% 8.6% 28.1% 20.8% 35.1%
Figure 5.15 shows the linear correlation between the swelling index and hysteresis
for Pellx (UV initiation).
Figure 5.15: Correlation between the swelling index and hysteresis of Pellx
r = 0.90
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A linear correlation coefficient (r) equal to 0.90 was calculated, indicating (from table
of correlation coefficients with degree of freedom equal to 13) that the swelling index and
hysteresis are positively correlated (p=0.01).
A decrease in NRS (i.e. improvement in recovered strain) was also observed with an
increase in the degree of modification, for both UV and heat initiation, when compared to
the Pellethane control sample (Table 5.5). As expected, a decrease in the strain at break
was observed, due to the restriction of chain movement caused by the resulting
crosslinked network [12]. A decrease in the stress at break was also observed with an
increase in the degree of crosslinking, with the lowest value obtained for Pell15.0. Similar
observations have been made in the literature [12, 14]. According to Ania and Calleja [25],
the wide angle X-ray scattering analysis of Pellethane and Pell15.0 (Figure D.1, Appendix
D) shows no clear evidence of crystalline peaks in any of the two polymers. It means that,
from the point of view of X-ray scattering, the crystallinity is negligible [25]. See Appendix G
for Ania and Calleja’s comments). Crosslinking through the 4-pentenoyl pendent group is the
main changing variable. Figure 5.16 shows the stress-strain curves (typical) for Pellethane
(control) and Pell15.0.
Figure 5.16: Tensile stress and strain at break for Pellethane and Pell15.0
The introduction of the pendent groups during the polyurethane modification step
would not replace the existing hydrogen bonds in a stoichiometrical ratio but would rather
have a more disruptive effect, possibly due to the size of the pendent group. Weak
hydrogen bonds are however replaced by strong and permanent covalent crosslinks,
resulting in a drastic improvement (>40%) in reducing energy losses (hysteresis), due to
flow. The uncrosslinked Pellethane control will, under large strain and large stress, show
deformation (large) of the hard segments. The crosslinked Pellx will begin to show
deformation of the hard segment but this will obey the law of a crosslinked material, which
will restrict the flow (causing less strain at break) and more rapidly increase stress on the
sample (lower flow is less accommodating to relieve stress), as seen in Figure 5.16. This
Jacobus Petrus Theron                        Chapter 5: Crosslinking of novel modified polyurethanes
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prostheses 99
100
120
140
160
180
200
0 15 30 45 60 75 90
Time (min)
Te
ns
ile
 s
tr
ai
n 
(%
)
Pellethane Pell15.0
will also start crack formation sooner (i.e. lower stress at break, typical of increased
crosslinking of the blocked domains [12]).
Typical creep results for Pellethane and Pell15.0 are presented in Figure 5.17 and the
calculated values (Eq. 5.7) summarized in Table 5.6.
Figure 5.17: Creep results for Pellethane and Pell15.0
Table 5.6: Calculated creep values ± standard deviation (n = 3) obtained for
Pellethane and Pell15.0
Pellethane Pell15.0
Creep ±stdev 0.65 ±0.01 0.36 ±0.01
Improvement (%) 44.3%
The tested Pell15.0 samples showed a 44.3% reduction in creep when compared to
Pellethane (p<0.01).
Table 5.7 summarizes the hysteresis results (hysteresis ± standard deviation)
obtained for the full initiator (I) (DMPA, 0 - 2%) and monomer (M) (MbA, 0 - 2%)
concentration ranges for Pell8.5 (typical example). This is illustrated in Figure 5.18.
Table 5.7: Hysteresis ± standard deviation of Pell8.5 for variation in monomer (M)
and initiator (I) concentrations
Pell8.5 0.0%I 0.5%I 1.0%I 1.5%I 2.0%I
0.0%M 0.32 ±0.02 0.30 ±0.02 0.30 ±0.00 0.28 ±0.01 0.28 ±0.00
0.5%M 0.34 ±0.00 0.31 ±0.01 0.31 ±0.01 0.29 ±0.01 0.29 ±0.01
1.0%M 0.34 ±0.01 0.30 ±0.01 0.30 ±0.01 0.29 ±0.00 0.30 ±0.01
1.5%M 0.35 ±0.03 0.32 ±0.01 0.31 ±0.00 0.30 ±0.01 0.30 ±0.02
2.0%M 0.37 ±0.02 0.34 ±0.02 0.31 ±0.01 0.33±0.01 0.32 ±0.01
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Figure 5.18: 3-D illustration of hysteresis for Pell8.5
The introduction of the crosslinking-enhancing monomer had a detrimental effect on
the hysteresis. An increase in hysteresis with increase in monomer concentration (M) was
observed for the full initiator (I) concentration range studied. The best result, i.e. the lowest
hysteresis, was still obtained when no monomer (“0.0%M”) was used (Figure 5.18), thus
as optimized and presented in Figure 5.13. Although the swelling indices were lower when
crosslinking-enhancing monomer was used (Figure 5.3), an increase in the hysteresis (i.e.
greater energy losses) was however observed. This was consistent over the entire Pellx
range and use of the crosslinking enhancing monomer (MbA) was therefore not further
considered in this dissertation.
The following hypothesis is offered to explain this seemingly contradictory result. The
crosslinking monomer forms a stable radical, which does not easily add to the pendent vinyl
bond, i.e. it shows a propensity to homopolymerize and produce long bulky crosslinked links
between pendant modification groups. This defeats the purpose of achieving short-range
crosslinks, even if more crosslinks are achieved.
5.5.1.4 Dynamic mechanical analysis
Typical tan δ curves obtained for Pellethane and Pell15.0, and storage moduli (G’) for
Pellethane and Pell15.0 are presented in Figures 5.19 and 5.20, respectively.
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Figure 5.19: Tan δ curves obtained for Pellethane and Pell15.0
Figure 5.20: Storage moduli (G’) for Pellethane and Pell15.0
The DMA behavior corresponds to a distinct two-phase elastomeric structure, as
opposed to a network structure [11], as is evident from the two main transitions at an onset
temperature in the first phase at approximately –48 0C to –55 0C (transition temperature, T1,
of the amorphous PTMEG) and in the second phase 85 0C to 132 0C (transition temperature,
T2, of hard block) (Figure 5.19 & 5.20) [26, 27].
Pell15.0 has a significantly higher T1 and much lower T2 (Figure 5.19), coinciding with
a much smaller but broader second transition temperature, compared to Pellethane.
Table 5.9 compares the two transition temperatures, as well as the storage moduli, of
Pellethane (control) with Pell4.5, Pell8.5 and Pell15.0.
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Table 5.8: Summary of DMA results of Pellethane and Pell4.5, Pell8.5 and Pell15.0
Pellethane Pell4.5 Pell8.5 Pell15.0
T1 (0C) -55.1 -54.9 -51.8 -48.6
∆T1 (0C) 0 0.2 3.3 6.5
T2 (0C) 131.9 111.5 110.7 84.7
∆T2 (0C) 0 -20.4 -21.2 -42.7
T2 (width) (0C) 48.7 71.8 86.2 144.0
G’ (Pa) 5.0x107 5.0x107 4.8x107 3.9x107
The increase in the first transition temperature with an increase in the degree of
crosslinking is clearly illustrated in Table 5.8, with Pell15.0 showing an increase of 6.5 0C
when compared to Pellethane. In general, crosslinking minimizes the sliding of polymer
chains past one another (viscous flow) (i.e. it restricts the mobility of the chains), with a
resulting increase in T1 [11, 14, 16]. Yet the crosslinking is in the hard phase, not the soft
phase, therefore the only way the soft phase can change transition temperature or can
increase in storage modulus is if part of the crosslinked hard phase becomes compatible in
the soft phase. The T1 of a mixture is the sum of the volume fractions of individual T1 values
of mixing components, (i.e. adding higher the T1 components increases the T1 of mixture).
Since the hard phase will consist of small to large domains it may be possible that many of
the smaller phases mix after crosslinking. Conversely, the outer sheaths of the hard
phases may become compatible and, by mixing into the soft phase, show the behavior
seen in the tan δ and storage moduli curves.
A significant decrease in the onset of the second transition temperature, coinciding
with an increase in the peak width, with an increase in the degree of crosslinking, was
observed for Pell4.5, Pell8.5 and Pell15.0, when compared to Pellethane.
The storage moduli of the crosslinked polymers compared well with that of Pellethane,
although a slightly lower value was obtained for Pell15.0 at 37 0C. Similar observations with
an increase in degree of crosslinking have been described in the literature [14, 16]. If the
argument above is accepted, then the integrity of the hard phases must be compromised
(they will change from a hard phase to a crosslinked domain that would be softer, more
compatible). Then the storage modulus decreases significantly on crosslinking. This can be
seen for Pell15.0 at 150 0C where it has a storage modulus of approximately zero, showing
no remaining hard phase as was present in Pellethane.
5.5.2 Crosslinking of modified PurSil 35-80A
The crosslinking of the second novel modified polyurethane (PurSil) (Chapter 4) was
investigated using a UV initiation system.
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5.5.2.1 Swelling index determination
Ultraviolet light (UV) induced crosslinking was achieved after 5 - 20 min using DMPA.
The initiator concentration was varied over the range 0 - 3% (w/w). The swelling indices
were determined and results for a typical example (Pur18.5) are presented in Figure 5.21.
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Figure 5.21: Change in Q ± standard deviation (n = 3) with change in DMPA
concentration for Pur18.5
Crosslinking was not achieved without initiator (“0%”, Figure 5.21), not even after the
samples were subjected to the UV source for 30 min. This finding was consistent for the
PurSil control and the whole range of modified PurSil (Purm) samples.
The swelling index was found to be the lowest at an initiator concentration of 2.5%.
The swelling index at this concentration was found to be significantly lower compared to
the swelling index at initiator concentrations of 2.0% (p=0.03) and 3.0% (p<0.01),
respectively. The DMPA concentration was similarly optimized for all the Purx samples (i.e.
Pur11.5, Pur15.0 and Pur18.5), the swelling indexes of which are presented in Figure 5.22
and summarized in Table 5.10.
Figure 5.22: Q ± standard deviation (n = 3) for PurSil and Purx samples with
optimized DMPA concentrations
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Table 5.9: Optimized DMPA concentration for Purx range (Q ± standard deviation)
Purx Pur11.5 Pur15.0 Pur18.5
[DMPA] (w/w) 2.0% 2.0% 2.5%
Q ± std dev 8.91 ±0.08 7.35 ±0.23 5.64 ±0.18
As expected, a decrease in the swelling index was observed with an increase in the
degree of modification (Figure 5.22 and Table 5.9) in the Purx range studied. Pur18.5 had
the lowest swelling index when compared to Pur15.0 (p<0.01) and Pur11.5 (p<0.01). A
higher degree of modification (e.g. Pur18.5) leads to a more densely crosslinked structure
(i.e. lower molecular mass between crosslinks), limiting swellability [14].
In a control study to illustrate the influence of the DMPA (ranging in concentration from
0 – 3%) on the swelling index of PurSil it was found that DMPA  (at concentrations as high
as 3%) did not result in crosslinking reactions, even after exposure of the films to the UV
light source for more than 30 min.
5.5.2.2 Molecular mass between crosslinks
The molecular mass between crosslinks for the Purx samples are presented in Figure
5.23, with the exact values presented in Table D.2, Appendix D.
The interaction between the methods of Hansen and assuming mutual solubility
(‘Ideal”) were found to be non-significant (p=0.65). There is a decrease in the Mc (i.e.
increase in crosslinking density) with an increase in degree of modification of Purx, for both
the methods of Hansen and assuming mutual solubility (‘Ideal”). The lowest Mc was
calculated for Pur18.5 (p<0.01) when compared to Pur15.0 and Pur11.5.
Figure 5.23: Molecular mass between crosslinks ± standard deviation (n = 3) for
Purx samples
Jacobus Petrus Theron                        Chapter 5: Crosslinking of novel modified polyurethanes
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prostheses 105
0.20
0.25
0.30
0.35
0.40
0.45
0.50
PurSil 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0%
Initiator concentration (%)
H
ys
te
re
si
s
0.00
0.15
0.30
0.45
PurSil Pur11.5 Pur15.0 Pur18.5
H
ys
te
re
si
s
5.5.2.3 Tensile properties
An example (Pur18.5) of the hysteresis of polyurethane samples as a function of
initiator (DMPA) concentration (0 – 3%) is presented in Figure 5.24.
Figure 5.24: Hysteresis ± standard deviation (n = 4) of Pur18.5 as function of DMPA
concentration
The lowest hysteresis was achieved at an initiator concentration of 2.5% (w/w). The
hysteresis at the latter concentration was found to be significantly lower compared to
hysteresis values at initiator concentrations of 2.0% (p<0.01) and 3.0% (p=0.02),
respectively
The DMPA concentration was similarly optimized for each Purx sample (i.e. Pur11.5
etc.), the hysteresis of which is presented in Figure 5.25. A summary of all the other
measured (stress and strain at break) and calculated (non-recovered strain, NRS)
mechanical properties is presented in Table 5.10.
Figure 5.25: Change in hysteresis ± standard deviation (n = 4) with change in degree
of modification for Purx
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Table 5.10: Measured and calculated mechanical properties ± standard deviation  
(n = 4) for Purx
Purx PurSil Pur11.5 Pur15.0 Pur18.5
[DMPA] (w/w) 2.0% 2.0% 2.5%
Hysteresis (-) 0.43 ±0.01 0.43 ±0.00 0.40 ±0.00 0.38 ±0.01
% Change 1.0% 7.2% 12.9%
NRS (-) 26.77 ±1.14 24.53 ±0.03 23.18 ±1.57 20.33 ±1.17
% Change 8.3% 13.4% 24.0%
Stress (MPa) 28.34 ±0.99 29.04 ±0.85 29.53 ±1.72 21.39 ±1.72
% Change 2.4% 1.7% 27.6%
Strain (%) 469.7 ±5.57 288.3 ±12.91 305.8 ±8.69 311.9 ±28.16
% Change 38.6% 34.9% 33.6%
A decrease in hysteresis (Figure 5.25) and non-recovered strain (Table 5.11) was
observed with an increase in the degree of modification when compared to the PurSil
control sample. The lowest hysteresis and non-recovered strain was obtained for Pur18.5.
The hysteresis for Pur18.5 (Figure 5.25) was found to be significantly (p<0.01) the lowest
when compared to Pur15.0, Pur11.5 and the PurSil control.
These results are in accordance with the measured swelling index (Q) for Purx,
where the lowest swelling indexes were obtained at similar initiator concentrations for the
whole range of Purx.
As expected a decrease in the strain at break was observed, due to the restriction of
chain movement imparted by the crosslinking. A similar decrease, as with Pellx, in the
stress at break was observed, with an increase in the degree of modification. The same
explanation offered earlier (§5.5.1.3) is given here.
5.5.2.4 Dynamic mechanical analyses
Typical tan δ curves and storage moduli (G’) obtained for PurSil and Pur11.5 are
presented in Figures 5.26 and 5.27, respectively.
Figure 5.26: Tan δ curves obtained for PurSil and Pur11.5
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Figure 5.27: Storage moduli (G’) for PurSil and Pur11.5
Two main transitions are again observed from the results presented in Figure 5.26,
showing the typical two-phase structure of polyurethanes [11]. The storage modulus of
Pur11.5 (Figure 5.27) was found to be significantly higher than that of PurSil over the
temperature range of -10 to 1400C. The DMA results are summarized in Table 5.11.
Table 5.11: Summary of DMA results of PurSil and Purx
PurSil Pur11.5 Pur15.0 Pell18.5
T1 (0C) -50.6 -33.9 -31.4 -30.0
∆T1 (0C) 0 16.7 19.2 20.6
G’ (Pa) 2.8x107 5.0x107 5.3x107 2.5x107
The increase in the first transition temperature with an increase in the degree of
crosslinking is again clearly illustrated in Table 5.11, with Pur18.5 showing an increase of
20.6 0C compared to PurSil. Here the possible explanation needs a modification compared to
Pellx, as the 35% siloxane soft block will be less likely to mix with a modified hard block.
This would imply less change to storage modulus at low temperature but more change in
the intermediate zone between T1 and T2 (as was found).
A substantial increase in storage modulus was obtained for Pur11.5 and Pur15.0,
compared to PurSil, while the value obtained for Pur18.5 was found to be comparable with
the PurSil control. Concerning the storage modulus, if the degree of compatibilization with
the soft block is severely restricted by the siloxane segments then the higher temperature
tan δ will not diminish; it will be modified, and can either increase (better flow), become
more spread (less homogeneous phase after crosslinking), or decrease (less hard phase
due to mixing with soft phase). The results point to minor mixing with part of the soft phase.
The results also show typical expectations for a crosslinked hard phase that loses
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stiffness, gaining flow and increased tan δ, but does not loose integrity (will not mix with
siloxane block).
5.6 Conclusions
Successful crosslinking of two novel modified polyurethanes (Pellm and Purm)
(Chapter 5) could be achieved using an ultraviolet light source and the initiator DMPA, a heat
source (1200C) and the initiator DCP, and gamma irradiation
The swelling indices, used to calculate the molecular mass between crosslinks, could
be used successfully to optimize the initiator concentrations for the Pellx and Purx samples,
respectively. The lowest swelling indexes (i.e. lowest molecular mass between crosslinks)
were obtained for Pell15.0 and for Pur18.5.
The best mechanical properties (in terms of hysteresis and NRS) were obtained for
Pell15.0 and Pur18.5, with respective improvements in hysteresis (up to 42.5%) and creep
(44.0%) for Pell15.0. The hysteresis and swelling indexes of Pellx are positively correlated
(r=0.90, p=0.01).
The use of crosslinking enhancing monomers (e.g. MbA) resulted in lower swelling
index values, but had a detrimental effect on the hysteresis. They were therefore not
included in further investigations.
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Chapter 6
In vitro chemical stability assay
Abstract
Laboratory experiments (in vitro) involving aggressive reagents and high
temperatures (exceeding physiological) are generally first used to evaluate the
chemical stability of new or modified polyurethanes, before such materials are
evaluated in animals (in vivo). In such a study, the chemical stability of Pellethane®
2363-80AE (control) was compared to Pell15.0 using silver nitrate, hydrogen
peroxide and a phosphate buffer solution at 65 0C for periods ranging from 4 to 8
weeks. Changes in mechanical properties of the respective polyurethanes,
(determined using tensile testing and dynamic mechanical analysis (DMA)) and
chemical properties (determined using Fourier transform infrared spectroscopy (FT-
IR), scanning electron microscopy (SEM) and X-ray photoemission spectroscopy
(XPS)) were subsequently compared. Degradation of the two respective
polyurethanes was already evident after 4 weeks, as evident from their measured
tensile properties (e.g. hysteresis and non-recovered strain (NRS)). The hysteresis
and NRS of Pell15.0 was better by at least 27.5% and 21.0%, respectively, when
compared to Pellethane® 2363-80AE. The latter also showed a decrease in the
hard phase integrity when compared to Pell15.0 (DMA) due to the absence of the
imparted oxidative stable crosslinks. FT-IR results mainly confirmed the
degradation of the “more vulnerable, less ordered” soft segment, in both
Pellethane® 2363-80AE and Pell15.0. XPS results confirmed the degradation of
the ether soft phase in both Pellethane® 2363-80AE and Pell15.0, although this
effect was more pronounced in the former, because the hard phases are more
free to rearrange. Pellethane® 2363-80AE showed much more surface
degradation (SEM), in both silver nitrate and hydrogen peroxide, when compared
to Pell15.0, although the difference was statistically significant only for the
samples incubated in silver nitrate. It can finally be concluded, from the extensive
in vitro degradation study, that Pell15.0 generally showed a higher resistance
toward degradation because of the imparted, stable covalent crosslinks. The soft
phases of both polyurethanes are however vulnerable towards degradation, but
this is not as pronounced in Pell15.0, mainly due to the restriction of chain
movement, resulting from crosslinking.
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6.1 Introduction
Time, cost and moral issues necessitate that the chemical stability of new biomaterials
first be tested in the laboratory (in vitro) before they are evaluated in animals (in vivo).
Aggressive reagents (e.g. hydrogen peroxide and silver nitrate) and temperatures
exceeding physiological temperature (>37 0C) are often used to accelerate possible
chemical degradation reactions (see Appendix E) in the former case.
The chemical stability of Pellethane® 2363-80AE (control) was compared to Pell15.0
(modified and crosslinked as described in Chapters 4 & 5, using ω,ω-dimethoxy-ω-
phenylacetophenone and an ultraviolet light source) in such an in vitro degradation study.
Samples were placed separately in silver nitrate, hydrogen peroxide (to simulate metal ion
induced oxidation and oxidation reactions, respectively) and phosphate buffer solutions
(PBS) and incubated at 650C for periods ranging from 4 to 8 weeks.
Tensile testing of the specimens was performed after 4 weeks to accommodate
cyclic testing. Dynamic mechanical analysis (DMA), Fourier-transform infrared
spectroscopy (FT-IR), scanning electron microscopy (SEM) and X-ray photoemission
spectroscopy (XPS) analyses were performed at the end of the degradation study (8
weeks). Changes in mechanical and chemical properties of the respective polyurethanes
were subsequently compared.
6.2 Historical
From the almost infinite number of possible polyurethane compositions, relatively f ew
have demonstrated successful performance in implantable devices [1]. In the 1960’s
published clinical reports of implantable polyurethanes described excellent initial properties
but severe chemical breakdown in the body within months. It was then believed that
polyurethanes were not suitable for implantation, but this erroneous attitude was mainly
based on the lack of appreciation of the tremendous number of chemical polyurethane
formulations possible.
Since then, there has been a widespread investigation into finding polyurethanes that
are chemically stable, as well as in vitro testing methods that could simulate in vivo
conditions. This has lead to a much better understanding of the sensitivity of the method of
processing and the sensitivity of certain raw materials to chemical degradation. Some of
these studies will now be briefly discussed (also see Table E.1, Appendix E for a more
complete list).
Polyurethanes, especially the Pellethane family, have been extensively used in the
manufacturing of the first pacemaker leads [1, 2]. It was however not until the first reported
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clinical failure that in vitro test methods had to be devised in order to create an
understanding of the possible mechanisms involved in order to prevent such occurrences.
A. Coury and K. Stokes were the pioneers in evaluating the chemical stability of
especially pacemaker leads, and have published widely. Whole pacemaker leads [2, 3], pre-
stressed tubing [1, 2] and flat sheets [1, 2, 4, 5] were incubated in different oxidative metal
ion solutions (metals typically used in the manufacture of the wires inside the leads, such
as platinum, silver, ferrous chloride, copper, nickel and cobalt) and other oxidative media
such as hydrogen peroxide. The samples were typically kept at temperatures ranging
between 37 - 90 0C for periods of up to 6 months and then analyzed mainly using Fourier
transform infrared spectroscopy and tensile testing.
Severe cracking of Pellethane 80A (Dow Chemicals, USA) was observed after a 30-
day incubation period in hydrogen peroxide at 37 0C [3]. Pellethane 80A was compared with
Pellethane 55D (Dow Chemicals, USA), Techoflex EG80A (Thermedics, USA), Biomer
(Ethicon, USA) and Cardiothane-51 (Avcothane, USA). It was found that the susceptibility
to degradation is directly proportional to the oxidative potential of the metal ions present and
the ether content of the respective polyurethanes, with Pellethane 80A (highest ether
content) performing significantly the worst [2].
This inspired the syntheses of “custom-made” polyurethanes, using different raw
materials (especially different soft segments) and at different concentrations, to
subsequently create an understanding of the underlying degradation mechanisms involved.
In efforts to improve commercially available polyurethanes, Takahara [6], Santerre, [7,
8], Petrovic [9], del Guerra [10], Labow [11], Schubert [12] and their co-workers
synthesized polyurethanes containing different soft segments, such as poly(ethylene
oxide), poly(tetra methylene oxide), poly(butane) diol and poly(dimethyl siloxane).
Polyurethane samples were incubated in various media, including metal ion solutions
and other oxidative media e.g. cholesterol esterase at physiological temperatures (37 0C),
for periods of up to 30 days. Flat films were formed either by solvent casting techniques or
extruded to thicknesses of up to 0.3 mm.
Degradation of the surface of polyurethanes with high ether soft segment content,
resulting from an autoxidation mechanism, was again observed. Much less degradation
was observed in the polyurethanes synthesized from e.g. poly(dimethyl siloxane) and
hydrogenated poly(butadiene), respectively. It was concluded that high resistance could be
obtained from highly linear aliphatic polyol soft segments with a saturated hydrocarbon
content and siloxanes.
Due to the high number of formulations possible and their great versatility as
biomaterial, the demand for chemically stable polyurethanes increased in the late 1980s.
This resulted in a change of focus in terms of the methods of in vitro chemical stability
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evaluation, from the use of mainly metal ions and oxidative media to in vitro degradation
media that could more accurately simulate physiological conditions [13-25].
Technologically more advanced commercially available polyurethanes (e.g. Corethane
80A, Biospan, Techoflex and MyoLink) were subsequently used in comparative studies.
Flats sheets, tubing (strained and unstrained) and even porous grafts [16, 20] were
evaluated at physiological temperatures (for up to 4 months) in a wide range of media.
These included: cholesterol, steroids (e.g. cortisone), different enzymes (e.g. papain),
human macrophages, human plasma, mouse fibroblast cells and immunoglobulin. Differential
scanning calorimetry, gel permeation calorimetry, dynamic mechanical analyses, atomic
force microscopy (AFM) and environmental scanning electron microscopy were commonly
used to evaluate degradation.
It was found that although poly(carbonate) urethanes are less susceptible to oxidative
degradation than poly(ether) urethanes, they are more prone to hydrolytic degradation [16,
22]. Polar steroids (e.g. cortisone) have strong interactions, especially with Pellethane 55D
(as opposed to Pellethane 80A), and environmental stress cracking was observed at
moderate strains [24]. Poly(urea) urethanes showed higher calcification and white blood
cell consumption when compared to poly(ether) urethanes [18].
It is clear from the summary presented in Table E.1 (Appendix E) and the discussion
above that polyurethanes are strongly influenced by the aging media, raw materials that
constitute the urethane, temperature and incubation time. The most commonly used in vitro
degradation conditions (from the extensive list, in Appendix E) were chosen and used in
this study.
6.3 Experimental
6.3.1 Materials
Pellethane was obtained from Dow Chemicals, while Pell15.0 was synthesized and
crosslinked as described in Chapters 4 & 5. Tetrahydrofuran (THF) (Merck, Cat: AB009731)
was used as solvent and ω,ω-dimethoxy-ω-phenylacetophenone (DMPA) (Aldrich Cat:
19,611-8) as UV initiator
The following reagents were used to prepare the degradation media: silver nitrate
(Aldrich Cat: 20,913-9), hydrogen peroxide (30% wt%) (Riedel-de Haën cat: 31642), di-
sodium hydrogen orthophosphate (Saarchem, Cat: 5822900), potassium dihydrogen
orthophosphate (Saarchem, Cat: 5043600), potassium chloride (Aldrich, Cat: 20,800-0),
sodium chloride (Aldrich, Cat: 22,351-4) and double-distilled ultra-pure water (17 µΩ).
Jacobus Petrus Theron Chapter 6: In vitro chemical stability assay
Development of crosslinkable, thermoplastic polyurethanes for cardiovascular prostheses 114
6.3.2 Methods
6.3.2.1 Preparation of degradation solutions
The degradation solutions were prepared to volumes of 1500 ml, with concentrations
and pH values as presented in Table 6.1.
Table 6.1 Reactants used in degradation study
Reactants Concentration
Silver nitrate (AgNO3) 0.1 mol/l
Hydrogen peroxide (H2O2) 20% (w/w)
Phosphate buffer solution (PBS) pH = 7.4
The phosphate buffer solution was prepared by dissolving di-sodium hydrogen
orthophosphate (14.48 g), potassium dihydrogen orthophosphate (1.00 g), potassium
chloride (1.00 g) and sodium chloride (40.00 g) in 1400 ml of double-distilled ultra-pure
water (17 µΩ) and adjusting the pH to 7.4. Hydrogen peroxide was diluted with water to
obtain the required concentration, while 25.48 g of silver nitrate was dissolved in 1500 ml
water to obtain a concentration of 0.1 mol/l.
6.3.2.2 Film casting
Pellethane and Pellm15.0 were dissolved in tetrahydrofuran to obtain 10% (w/w)
solutions. To the Pellm15.0 solution 2.0% DMPA was added. Solid films were cast of all the
polymer solutions (to thicknesses of 0.5 mm) by standard solvent casting and evaporation
techniques, then dried in vacuo for 12 h. Pellm15.0 was subsequently crosslinked (Pell15.0)
using a 315 - 400 nm ultraviolet light source (UV initiation) for 15 min, whereafter all the
films were dried for an additional 72 h in vacuo.
6.3.2.3 Sample preparation
Dumbbell samples for tensile testing (≈0.5 mm thick) (ASTM D638, Type V) (n = 4) and
a strip (10-mm wide) were cut from the dried polymer films as prepared in §6.3.2.2 and
placed in 30 ml glass tubes filled with the three respective solutions (see Table 6.1).
The tensile samples were placed in a constant-temperature laboratory oven at 65 0C
for 4 weeks, while the other samples were left at 65 0C for 8 weeks. The solutions were
replaced twice weekly. After the respective study periods the samples were thoroughly
washed with double distilled water, slowly air dried overnight and then dried in vacuo for 4
days (room temperature).
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6.3.3 Analyses
6.3.3.1 Tensile testing
Cut samples were tested for tensile behavior, as described in §5.4.3.3 (Chapter 5).
6.3.3.2 Dynamic mechanical analysis
Dynamic mechanical analyses (DMA) were performed as described in §5.4.3.4
(Chapter 5).
6.3.3.3 Fourier-transform infrared spectroscopy
The degraded and control samples were analyzed by means of photo acoustic
Fourier-transform infrared spectroscopy (FT-IR), as described in §4.3.4.1 (Chapter 4).
Ratios of peaks at wavelengths of: 1075 cm-1 (urethane ether), 1105 cm-1 (aliphatic
ether), 1175 cm-1 (new peak), 1220 cm-1 (Amide III), 1703 cm-1 (bonded carbonyl), 1730  
cm-1 (unbonded carbonyl), 2860 cm-1 (asymmetrical PTMEG CH2 stretch) and 2940 cm-1
(symmetrical PTMEG CH2 stretch) were studied and compared.
6.3.3.4 X-ray photoemission spectroscopy
The surface chemistry of the test samples, subjected to the degradation study for 8
weeks, and their respective controls (Pellethane and Pell15.0) were analyzed using XPS.
Samples (n = 1) were analyzed using a Quantum 2000 (PHI) scanning X-ray microprobe,
which employs a monochromate AL Kα source. The X-ray gun was operated at a take-off
angle of 450 and at 20 W with pass energy of 118 eV for the wide scans and 23 eV for the
narrow scans. All calculations (e.g. integration) were performed by the built-in software.
6.3.3.5 Scanning electron microscopy
The surfaces of the samples subjected to the degradation study for 8 weeks and
control samples of Pellethane and Pell15.0 were investigated using a LEO (1450EP)
scanning electron microscope (SEM). Test pieces (n = 3) were cut from each sample with
a sharp blade, mounted on aluminum stubs, sputter coated with gold-palladium (AuPd), and
viewed in the SEM at an accelerating voltage of 7 kV.
Complete areas were investigated and captured at different magnifications (x2000 &
x5000). Representative images (n = 5) from the different treatment groups were then
compared at similar positions (e.g. close to the edges) and magnification (x2000) and
scored by seven independent blinded observers. The control samples (not subjected to the
degradation media) were used as references and scores of between 0 and 5 were given
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depending on the degree of degradation, where 5 indicated a sample that was most
degraded (i.e. deep, open cracks).
6.3.3.6 Statistical analysis
Statistical analyses were performed using either (a) student t-test (unpaired 2-tailed,
assuming equal variance, (b) Kruskal-Wallis (non-parametric test) (c) 1-way analysis of
variance (ANOVA) and (d) 2-way ANOVA. Bonferroni corrections were applied in cases
of multiple comparisons. A significance level of 0.05 or less was accepted as being
statistically significant. Standard assumptions of normality were made, but in cases were it
was suspected that the assumptions were violated the results were verified using non-
parametric (bootstrap) techniques (see Appendix H for a summary).
6.4 Results and discussion
6.4.1 Tensile testing
The measured and calculated tensile properties of the controls (Pell & Pell15.0) and
samples degraded in the various degradation media are presented in Table 6.2.
Table 6.2: Summary of tensile properties ± standard deviation (n = 3) of Pellethane
and Pell15.0 degraded in the various media
Controls AgNO3 H2O2 PBS
Pell Pell15.0 Pell Pell15.0 Pell Pell15.0 Pell Pell15.0
Hysteresis
(-) 0.36±0.01 0.21±0.01 0.38±0.01 0.27±0.01 0.38±0.01 0.26±0.01 0.37±0.01 0.20±0.01
p p < 0.01 p < 0.01 p < 0.01 p < 0.01
Δ (%) 42.5% 27.5% 30.9% 45.3%
NRS
(%) 16.74±0.97 8.75±0.88 18.70±2.78 14.79±1.26 8.90±2.12 14.52±1.88 17.91±1.33 9.17±0.75
p p < 0.01 p = 0.06 p = 0.02 p < 0.01
Δ (%) 47.7% 21.0% 23.3% 48.8%
Stress
(MPa) 46.97±2.44 29.23±1.92 56.84±4.75 16.73±1.20 41.63±4.07 27.80±2.84 50.45±1.16 32.88±1.57
p p < 0.01 p < 0.01 p < 0.01 p < 0.01
Δ (%) 37.8% 70.6% 31.1% 34.8%
Strain
(%) 571.6±19.3 411.5±18.4 665.3±43.0 527.0±51.7 618.8±49.3 537.3±45.6 630.4±14.6 522.9±34.5
p p < 0.01 p < 0.01 p = 0.04 p < 0.01
Δ (%) 28.0% 20.8% 13.2% 17.0%
An increase in hysteresis was observed for Pellethane and Pell15.0 samples all
treated in the degradation media except in PBS (Figure 6.2). The increase was significant
for Pellethane (p=0.02) and Pell15.0 (p<0.01) degraded in silver nitrate, and for Pell15.0 in
hydrogen peroxide (p<0.01). The hysteresis of all the degraded Pell15.0 samples was
significantly lower (at least 27.5%) than the degraded Pellethane (p<0.01) samples.
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Figure 6.2: Hysteresis ± standard deviation (n = 3) of Pellethane and Pell15.0 in the
various degradation media
A similar trend was observed for the non-recovered strain (Figure 6.3). Here,
however, the NRS of the Pell15.0 samples was at least 21.0% better compared to the
Pellethane control sample. The differences between Pellethane and Pell15.0 were
significant for the samples degraded in hydrogen peroxide (p=0.03) and PBS (p<0.01).
Figure 6.3: NRS ± standard deviation (n = 3)of Pellethane and Pell15.0 with change
in degradation media
The apparent slower degradation of Pellethane in silver nitrate and hydrogen peroxide
compared to Pell15.0 may be a result of re-ordering of the polyurethane’s conformation and
better phase separation, due to the absorption of the degradation media [26]. The oxidation
attack is said to be at the ether linkage of the soft section [1, 27, 28]. However, it is also
known that amide and urethane groups are susceptible to oxidation [3, 28] and one of two
effects could occur: either loss of crosslinks at the carbamate coupling or the introduction
of the modification making the hard segment more penetrable to the oxidants, allowing chain
scission at nascent urethane groups. In the authors view, the latter would be more
plausible and in keeping with the findings of the above references.
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This effect is clearly illustrated in Figures 6.4 and 6.5, where an unexpected
significantly higher stress (p<0.01) and strain at break (p=0.04) was obtained for
Pellethane incubated in silver nitrate, compared to the Pellethane control.
Figure 6.4: Comparison of stress at break ± standard deviation (n = 3) of Pellethane
with Pell15.0
These results are consistent with tensile results obtained by Stokes et al. [26], where
Pellethane initially showed very little loss in stress and strain at break in a silver nitrate
medium (Figure 6.5), but dramatically degraded after a longer period of time.
The stress at break (Figure 6.4) remained fairly constant for Pell15.0 (except for the
decrease in AgNO3, p<0.01), but degradation was clearly evident for Pellethane incubated
in hydrogen peroxide, where a decrease in stress at break was observed (Figures 6.4),
compared to the Pellethane control. This is probably due to localized chain scission in the
soft segment of Pellethane, possibly near the interphase bonding, as was reported by
Pinchuk [27].
Figure 6.5: Change in strain at break ± standard deviation (n = 3) with change in
degradation medium
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A significant increase (p<0.01) in strain at break was observed for the degraded
Pell15.0 samples, compared to the Pell15.0 control. As discussed earlier, the increase in
strain at break was only significant for the Pellethane sample degraded in silver nitrate
(p=0.04).
Although results obtained under these accelerated in vitro degradation conditions, are
not directly translatable to the in vivo environment, they have been extensively used [1-6] to
compare the degradation resistance of polyurethanes and to offer a certain degree of
prediction of the long-term behavior in the body.
The hysteresis and non-recovered strain of Pell15.0, compared to Pellethane, was still
better on average by between 21.0% to 48.8%, even after the 4-week incubation period in
the various degradation media. The stress and strain at break of Pell15.0 remained relatively
constant, although a slight decrease in stress at break was observed for Pell15.0 in silver
nitrate. On average, the tensile properties of Pell15.0 remained superior to Pellethane even
after subjection of the samples to the harsh conditions.
6.4.2 Dynamic mechanical analysis
Figures 6.6a and 6.6b exhibit the mechanical loss tangents (tan δ) for Pellethane and
Pell15.0 control samples and degraded samples in silver nitrate.
a) Tan δ of Pellethane (control) and a Pellethane sample
degraded in silver nitrate
b) Tan δ of Pell15.0 (control) and a Pell15.0 sample degraded in
silver nitrate
Figure 6.6: Comparison of tan δ for control and degraded samples
c) Storage modulus (G’) of Pellethane (control) and a
Pellethane sample degraded in silver nitrate
d) Storage modulus (G’) of Pell15.0 (control) and a Pell15.0
sample degraded in silver nitrate
Figure 6.7: Comparison of storage modulus (G’) for control and degraded samples
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The storage moduli (G’) for typical samples degraded in silver nitrate with their
respective controls, are presented in Figures 6.7a and 6.7b.
The distinct two-phase polyurethane elastomeric structure is still clearly evident for
Pell15.0 (Figure 6.6b), even after exposure of the sample to silver nitrate. This result was
consistent for Pell15.0 samples exposed to all the respective degradation media. If scission
occurs in the polyether this would not affect phase separation, while scission in the hard
polyurethane domain would. However, the tan δ data in Figure 6.6b shows that the
crosslinking keeps this phase intact. The author therefore suggests that the crosslinks are
impervious to the silver nitrate, but that the urethane groups can still be attacked on the
periphery of the hard segments, leading to scission and some compatibility with the soft
segment, as is seen in the increased storage modulus, Figure 6.7d [20]. A small decrease in
T1 was further observed for the degraded sample (Figure 6.6b and Table 6.3) when
compared to the control (Pell15.0), indicative of scission in the soft segment. A decrease in
storage modulus in the temperature range of 0 - 1000C (Figure 6.7d) was also observed.
This is in keeping with scission at the periphery of the hard segments.
The tan δ of the Pellethane sample degraded in silver nitrate (Figure 6.6a) exhibited
polyphase properties. The second transition is evident, indicating degradation of part of the
polyurethane hard segment. There also is a very slight lower onset of the first transition
temperature when compared to the Pellethane control (Table 6.3), which indicates chain
scission in the soft segment (more chain ends lower T1) [15, 17, 29]. The lower storage
modulus reinforces the concept of chain scission in both phases (Figure 6.7c).
Table 6.3: Summary of DMA results of Pellethane and Pell15.0
Controls AgNO3 H2O2 PBS
Pell Pell15.0 Pell Pell15.0 Pell Pell15.0 Pell Pell15.0
T1 (0C) -55.1 -48.8 -59.1 -51.6 -61.5 -59.1 -57.1 -50.8
d T1 (0C) +6.5 +7.5 +2.4 +6.3
T2 (0C) 131.9 84.7 124.4 116.3 118.9 93.6 134.7 113.5
d T2 (0C) -47.2 -8.1 -25.3 -21.2
G’ (Pa) 5.0x107 3.9x107 4.0x107 1.3x107 5.2x107 2.8x107 4.8x107 2.0x107
d G’ (Pa) 1.1x107 2.7x107 2.5x107 2.8x107
The data presented in Table 6.3 clearly show the slight decrease in T1 for both
Pellethane and Pell15.0 samples after degradation. The first transition temperature of the
Pell15.0 samples is however a few degrees higher (Table 6.3), possibly due to the
restriction of the mobility of the polymer chains imparted by the covalent crosslinking.
The decrease in hard segment integrity (T2) for Pellethane degraded in silver nitrate
and hydrogen peroxide, also described by Tanzi et al. [17], is proposedly caused by
chemically induced disruption of the hard segment domains [17]. The opposite effect was
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observed for the Pell15.0 samples, and can be attributed to the restriction of chain
movement, again as a result of the imparted oxidatively stable crosslinks.
6.4.3 Fourier-transform infrared spectroscopy
FT-IR analysis may not be the best analytical method by which to investigate degraded
surfaces, as the beam penetrates the sample, averaging between very thin degraded
material on the surface and underlying non-degraded polymer [26]. A summary of some
important ratio of absorbances (cm-1/cm-1) for Pellethane (Pell) and Pell15.0 is however
given in Table 6.4, with graphical illustrations of selected ratios in Figures 6.8 - 6.11.
Table 6.4: Ratios of absorbance (cm-1/cm-1) ± standard deviation (n = 4) for
Pellethane (Pell) and Pell15.0
Controls AgNO3 H2O2 PBS
Pell Pell15.0 Pell Pell15.0 Pell Pell15.0 Pell Pell15.0
1703/1730 2.280 1.611 2.715 2.285 3.147 4.529 1.913 1.848
Stdev 0.331 0.418 0.645 0.559 0.279 0.744 0.219 0.230
1175/1220 0.000 0.000 0.158 0.230 0.028 0.000 0.000 0.000
Stdev 0.000 0.000 0.026 0.029 0.021 0.000 0.000 0.000
- -
1105/1220 0.447 0.457 0.406 0.458 0.398 0.381 0.438 0.417
Stdev 0.025 0.025 0.031 0.020 0.041 0.035 0.030 0.013
1075/1220 0.133 0.147 0.268 0.272 0.182 0.225 0.137 0.179
Stdev 0.005 0.007 0.025 0.013 0.004 0.028 0.008 0.010
1105/1075 3.368 3.226 1.530 1.688 2.191 1.726 3.205 2.336
Stdev 0.249 0.269 0.301 0.130 0.207 0.373 0.218 0.191
2860/2940 1.060 1.072 1.002 1.058 1.050 1.006 1.124 1.063
Stdev 0.034 0.044 0.020 0.113 0.033 0.051 0.045 0.038
1075 cm-1 Urethane ether 1703 cm-1 Bonded carbonyl
1105 cm-1 Aliphatic ether 1730 cm-1 Unbonded carbonyl
1175 cm-1 New peak (carbonyl containing) 2860 cm-1 Asymmetrical PTMEG CH2 stretch
1220 cm-1 Amide III 2940 cm-1 Symmetrical PTMEG CH2 stretch
Figure 6.8: Ratios of absorbance ± standard deviation (n = 4) (1703 cm-1/1730 cm-1)
for Pellethane and Pell15.0
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A minor decrease in asymmetrical PTMEG CH2 stretch compared to symmetrical
PTMEG CH2 stretch (2860 cm-1/2940 cm-1) (Table 6.4) was observed, with a concomitant
increase in the hydrogen-bonding index (ratio of bonded to unbonded carbonyl, 1703 cm-
1/1730 cm-1) for all degraded specimens (except samples degraded in PBS) compared to
their control samples (Figure 6.8) (only significant (p<0.01) for Pell15.0 degraded in
hydrogen peroxide). This finding was consistent with that of Stokes et al. [26]. The
hydrogen-bonding index of Pell15.0 was also found to be consistently slightly lower than
that of Pellethane, except in hydrogen peroxide where that of Pell15.0 was significantly
higher (p=0.01) than Pellethane. This is consistent with the removal of carbamate
hydrogens and substitution of 4-pentenoyl pendent groups. The ratios of the aliphatic ether
(1105 cm-1) to amide III (1220 cm-1) are presented in Figure 6.9.
Figure 6.9: Ratio of absorbance ± standard deviation (n = 4) (1105 cm-1/1220 cm-1)
for Pellethane and Pell15.0
On average, the ratios (1105cm-1/1220 cm-1) remained relatively constant for both
Pell15.0 and Pellethane when compared to each other and to their control samples. It seems
therefore that the aliphatic ether and amide III changed simultaneously and consistently
during degradation when compared to their controls. This has been reported by Stokes at
al. [26] to be a result of permanent re-ordering of the polyurethanes’ conformation due to
the absorption of the degradation media and degradation occurring in both phases (see
discussion in §6.4.1).
The ratios of the urethane ether (1075 cm-1) to amide III (1220 cm-1) are presented in
Figure 6.10. The ratios of Pell15.0 were significantly higher than those of Pellethane, for the
samples degraded in hydrogen peroxide (p=0.01) and in PBS (p=0.02). An increase in the
ratios was observed throughout for both degraded Pellethane and Pell15.0 compared to
their controls, although it was only significant in the case of hydrogen peroxide and silver
nitrate (p<0.01).
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Figure 6.10: Ratios of absorbance ± standard deviation (n = 4) (1075 cm-1/1220 cm-
1) for Pellethane and Pell15.0
It appears that oxidative degradation by silver nitrate leads to better hydrogen bonding
and more carbonyl formation in deference to hydrogen peroxide degradation. Degradation
in Pell15.0 was slightly greater; diffusion into the hard segments is facilitated, indicating that
much of the ratio is due to changes in the hard segment, especially at the periphery.
Figure 6.11: Ratio of absorbance ± standard deviation (n = 4) (1105 cm-1/1075 cm-1)
for Pellethane and Pell15.0
The ratios of the aliphatic ether (1105 cm-1) to urethane ether (1075 cm-1) are
presented in Figure 6.11. A significant decrease (p<0.01) in this ratio was observed in all
the samples, when compared to their respective controls, with the exception of Pellethane
degraded in PBS. This observation was found to be consistent with the results obtained by
Stokes [26], who attributed it to ether soft segment oxidation. It is however interesting to
note though that the loss in aliphatic ether compared to urethane ether (1105 cm-1/1075 cm-
1) was lower for Pell15.0 for all but one sample (AgNO3) when compared to Pellethane,
although only significantly lower for Pell15.0 degraded in PBS (p<0.01) (Figure 6.8). This is
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also in agreement with the findings of Stokes et al. [26], who concluded that the primary
site of attack must be the “more vulnerable, less ordered” soft segment.
The appearance of a new carbonyl-containing peak at 1175 cm-1, which was
observed for Pellethane, degraded in silver nitrate (AgNO3) and hydrogen peroxide (H2O2),
but only in one case for Pell15.0 (AgNO3). It has been suggested [26, 30] that this is a result
of coordination of the ether oxygen with a metal ion (although the author is not in full
agreement with this explanation), although it has been reported [26] also to occur in an in
vitro study with hydrogen peroxide. This finding is consistent with the suggested oxidation
mechanism proposed by Stokes et al. [26] and the author suggests that it stems from
competitive oxidation occurring in both phases.
Stokes et al. [26] observed significant changes on the surfaces of his samples, but
finally concluded that the changes are due to reversible changes in the polyurethane
conformation and should not be confused with irreversible changes due to degradation.
6.4.4 X-ray photoemission spectroscopy
Polyurethanes are very mobile polymers and XPS may not be the most suitable
analytical technique, due to the surface rearrangement in the high vacuum environment
[28]. This technique was never the less used (although results cannot be directly
extrapolated to the biological environment) to provide additional/supportive information.
A summary of the XPS results obtained for degraded Pellethane and Pell15.0 is
presented in Table 6.5. The high-resolution C1S spectra (narrow scans) could be
deconvoluted into two major peaks, at 284.7 eV (hydrocarbon, C-C) and 286.2 eV (ether,
C-O) [6, 22, 30], as well as a small but broad peak at 288.4 - 289.4 eV (C=O). The O/C and
N/C ratios of Pellethane (control) were found to be consistent with reported values [30].
Table 6.5: Summary of XPS results for Pellethane and Pell15.0
Controls H2O2 PBS
Conc (%) Pellethane Pell15.0 Pellethane Pell15.0 Pellethane Pell15.0
C 88.6 82.7 85.2 78.9 83.6 80.7
O 9.4 14.0 12.9 17.2 13.3 16.3
N 1.4 2.0 0.8 2.9 1.7 1.5
Si 0.6 1.3 1.1 1.0 1.4 1.5
O/C 0.11 0.17 0.15 0.22 0.16 0.20
N/C 0.02 0.02 0.01 0.04 0.02 0.02
Area (%) Pellethane Pell15.0 Pellethane Pell15.0 Pellethane Pell15.0
C-C 79.74 72.50 87.95 73.80 88.78 80.85
C-O 18.78 24.10 7.54 22.72 6.97 15.10
C=O 1.48 3.40 4.51 3.48 4.26 4.05
Since the 286.2 eV peak is indicative of the soft segment, and the small, broad tail
near 288.4 - 289.4 eV is primarily related to the hard segment, their ratio represents the
relative contribution from the soft and hard segments [22]. It was apparent that the
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polyether soft segment was enriched at the surfaces of the control samples (Pellethane &
Pell15.0). This was confirmed by the very small surface N/C atomic ratio observed.
A significant increase in the O/C ratio (more severe in Pellethane) was observed after
the respective polyurethane samples were subjected to hydrogen peroxide degradation,
indicating either oxidation of the surface [6, 22, 30] or rearrangement of the polar phases to
the surface aqueous media. From the calculated percentages for the 286.2 eV (C-O) peak
area tabulated in Table 6.5, a significant disappearance of ether from the surface was also
noted, especially for Pellethane samples, when compared to their control. The same
observations were made when samples were incubated in PBS. Here previous mechanical
data showed very little change, therefore this must be mainly attributed to surface
rearrangement to higher polarity.
Thus it was concluded from the XPS results that rearrangement occurred at surfaces
with probable degradation as well in the oxidized samples. This effect was generally more
pronounced in Pellethane samples incubated in both hydrogen peroxide and PBS, because
the hard segments are freer to rearrange.
6.4.5 Scanning electron microscopy
Significant surface degradation of Pellethane in both silver nitrate and hydrogen
peroxide was seen within 8 weeks (Figure 6.12).
AgNO3, x5000 AgNO3, x5000
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H2O2, x4000 H2O2, x4000
Figure 6.12: Scanning electron micrographs for Pellethane showing severe surface
degradation in the presence of silver nitrate and hydrogen peroxide after 8 weeks
The cracks had rough, often “spiculated” walls, suggestive of a craze origin [31].
Severe cracking (deep cracks that have opened up) was especially observed in the
Pellethane samples degraded in hydrogen peroxide.
Typical SEM images of Pellethane and Pell15.0 (non-degraded controls and samples
incubated in the various media) are presented in Figure 6.13 at x2000 (above) and x5000
(below) magnifications, respectively.
The smooth surfaces of the control samples (a & b) are clearly evident at x2000 and
at x5000 magnifications. The surface of the Pell15.0 sample (d) incubated in silver nitrate
has a “wrinkled” appearance (only in a few cases was the onset of small cracks
observed), while the surface of the Pellethane sample (c) shows severe surface
degradation (formation of deep cracks) [31]. It is proposed that degradation of the Pell15.0
sample is mostly as a result of internal degradation of the hard segment, while the
degradation of Pellethane is accelerated by rearrangement.
Hydrogen peroxide incubation resulted in the degradation of the Pellethane sample (e)
with the very distinct appearance of shallow “mud” cracks [27, 31-33]. This is especially
evident at the higher magnification (x5000). The Pell15.0 sample shows some degree of
cracking and some pit formation. This could be a result of a leaching product [31], or
possibly low molecular mass degradation products. The author suggests further that this is
due to degradation-assisted rearrangement of the phases to give hydrophilic surfaces.
Visually no distinct difference could be detected between the Pellethane (g) and
Pell15.0 (h) samples incubated in PBS, apart (possibly) from the onset of some “wrinkles” in
the former. No cracks were observed in any of the samples incubated in PBS, which
suggests that a necessary requirement for crack formation is both an oxidative/hydrolyses
medium and rearrangement.
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a) Pellethane (Control) x2000(above), x5000(below) b) Pell15.0 (Control) x2000(above), x5000(below)
c) Pellethane (AgNO3) x2000(above), x5000(below) d) Pell15.0 (AgNO3) x2000(above), x5000(below)
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e) Pellethane (H2O2) x2000(above), x5000(below) f) Pell15.0 (H2O2) x2000(above), x5000(below)
g) Pellethane (PBS) x2000(above), x5000(below) h) Pell15.0 (PBS) x2000(above), x5000(below)
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Figure 6.13: Scanning electron micrographs for Pellethane and Pell15.0, degraded
and control samples, at x2000 and x5000 magnification
Figure 6.14 shows the average scores for the degraded Pellethane and Pell15.0
samples with the 95% confidence interval for the average, calculated from the scores
given by the independent blinded observers.
Figure 6.14: Scoring results ± the 95% confidence interval of SEM images of
degraded and control samples of Pellethane and Pell15.0
Significantly higher degradation was observed for the Pellethane sample degraded in
silver nitrate (p<0.01) and hydrogen peroxide (p=0.05) when compared to the Pell15.0
samples. Although the difference between the Pellethane and Pell15.0 samples degraded in
hydrogen peroxide is bordering on statistical significance on a 95% level there is a clear
trend that Pell15.0 performed much better than Pellethane. No significant difference was
observed between the Pellethane and Pell15.0 samples incubated in PBS. These results,
and as presented in Figure 6.13, were verified using a non-parametric test method
(bootstrap) and similar results were obtained.
The results suggest that rearrangement alone cannot form cracks, and that
crosslinking of the hard phase restricts rearrangement. This implies that degradation of the
hard phase enhances rearrangement (surface analysis) while there is also a contribution
from the hard section peripheral and soft section oxidative degradation. Such degradation
is essential to form surface cracking.
6.5 Conclusions
Degradation of both the Pellethane and the Pell15.0 samples was evident from their
measured tensile properties (e.g. hysteresis and NRS) when compared to their respective
controls. Pellethane and Pell15.0 samples degraded in silver nitrate, hydrogen peroxide and
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PBS resulted in an increase in the hysteresis and NRS, although PBS had the least
influence on the afore-mentioned mechanical properties. The hysteresis and NRS of
Pell15.0 was better by at least 27.5% and 21.0%, respectively, when compared to
Pellethane.
Chemically induced disruption (degradation) of Pellethane, incubated in silver nitrate
and hydrogen peroxide, is clearly evident from the decrease in hard phase integrity (T2).
The opposite effect was observed for the Pell15.0 samples. It can be concluded that it is
due to the restriction of chain movement (and thus melting) as a result of the imparted
oxidative stable crosslinks.
FT-IR results confirmed the degradation of the “more vulnerable, less ordered” soft
phase in both the Pellethane and Pell15.0 samples when compared to their respective
controls. It can further be concluded from the FT-IR results that the formation of the new
carbonyl containing peaks observed for both Pellethane (2 cases) and Pell15.0 (1 case)
sterns from competitive oxidation occurring in both the soft and hard phases.
XPS results confirmed the degradation of the surface ether soft phase in both
Pellethane and Pell15.0 although this effect was more pronounced in the former, because
the hard phases are freer to rearrange.
Significant surface degradation of Pellethane in both silver nitrate and hydrogen
peroxide was seen within 8 weeks. The surface degradation was significantly higher for
Pellethane when compared to Pell15.0, degraded in the above-mentioned solutions,
although it was found not to be statistically significant for samples degraded in hydrogen
peroxide, although there is a clear trend.
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Chapter 7
Electrospinning of tubular constructs
Abstract
Electrospinning offers a method by which to produce structures suitable to mimic
extracellular matrices, and form tissue-engineered scaffolds. This has become a
key manufacturing method in the engineering of cardiovascular devices.
Pellethane® 2363-80AE and the novel modified polyurethane, Pellm15.0 (Chapter
4) was used to study the electrospinning of tubular constructs. An ultraviolet light
(UV) initiator, ω,ω-dimethoxy-ω-phenylacetophenone, was included in the
Pellm15.0 solution. A suitable set-up was devised and the polymer successfully
crosslinked, in situ, by a “reactive electrospinning” method, whereby the fibers are
crosslinked during the electrospinning process. The fiber and wall thicknesses of
the tubes manufactured using Pellethane were accurately controlled by changing
the concentration of the polymer solution and spinning times. Tubular constructs
(n = 4) with comparable fiber and wall thicknesses (3.1 ±0.7 µm and 80.7 ±12.0
µm) for Pellethane and (3.3 ±1.1 µm and 78.1 ±9.0 µm) for Pell15.0 were obtained
respectively. The measured porosity for Pellethane (69.8% & 63.4%), determined
by gravimetrical and apparent volume methods, was however significantly higher
than for Pell15.0 (44.7% & 40.0%). In conclusion, a novel “reactive
electrospinning” technique was used to manufacture crosslinked tubular constructs
with fiber and wall thicknesses comparable to those of scaffolds manufactured
from Pellethane using a standard electrospinning technique.
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7.1 Introduction
The design and manufacture of artificial matrices or scaffolds that mimic the
supramolecular structure and biological functions of the extracellular matrix (ECM) is a
pivotal issue in tissue engineering and the development of artificial organs [1].
The process of electrospinning has received much attention in biomedical engineering,
especially over the last few years, because of the ability it offers to fabricate a wide
variety of artificial extracellular matrixes and scaffolds [2] consisting of fibers ranging in
thickness from several microns to 100 nm or less.
Electrospinning was therefore chosen as the method of choice for polyurethane
processing in this study. Pellethane® 2363-80AE and Pellm15.0 were used to electrospin
tubular constructs (ID = 1.6 mm). A set-up had first to be devised to initiate in situ
crosslinking of Pellm15.0, while simultaneously electrospinning on a rotating/translating
mandrel.
Constructs with similar fiber and wall thicknesses could be obtained by changing the
polyurethane concentration and spinning times, respectively. The resulting porosities of the
scaffolds could be determined using well-known techniques, including the Archimedes and
apparent volume methods [3].
7.2 Polyurethane processing
The type of processing and processing conditions have a significant influence on the
eventual chemical stability of the polyurethane-based prostheses. Processing is an
important consideration, as residual stresses imparted during e.g. extrusion processing by
inappropriate stretching could accelerate in vivo surface micro-fissuring [4]. A number of
processing techniques (solvent casting, extrusion etc.) will briefly be discussed here,
categorized according to the dimensionality of the resulting product.
Coatings and adhesives are defined as one-dimensional (1-D) processes because the
most important dimension is usually the thickness of the respective coating or adhesive [5].
Coatings may be applied using solution-dip or spray-coating techniques (at room
temperature) or hot-melt, fluidized bed and electrostatic powder coating (at elevated
temperatures) or, alternatively, solvent coating techniques. Solvent casting is another
example of 1-D processing.
Two-dimensional (2-D) fabrication processes include extrusion, laminations, and the
production of fibers. During extrusion the polyurethane is forced through a die that shapes
it into a long shape of constant cross section. Pacemaker leads are commonly
manufactured by extrusion. Lamination techniques are used to produce composite
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materials, which can be formed during extrusion or by forming the structure around a
mandrel. Fibers can also be produced by melt and solvent spinning.
Three-dimensional (3-D) fabrication processes include sheet forming, vacuum
forming, post forming, cold forming, weaving, knitting and machining [5]. Some of these
processes are used to form polyurethanes into foams, tubing, balloons, and bladders. Non-
porous tubing is formed by extrusion or solvent casting, in which the latter is used to e.g.
produce anisotropic vascular prosthesis. Porous tubing, used as vascular grafts, is
fabricated by electrospinning a polymer from solution onto a rotating/translating mandrel or
by phase inversion and extraction techniques. Solvent casting methods have also been
used for the processing of intra-aortic balloons [5].
Attention will now be focused on electrospinning and in the following section more
background information will be given, followed by a summary of some achievements in
applications in the medical industry to date.
7.3 Electrospinning
Electrospinning is not a new process; the application of a static electric field to move
fluids is over 500 years old, with patents dating back to as early as the beginning of the
20th century [6].
Polymeric fibers ranging in thickness from 100 nm - 30 µm are produced, which is at
least one or two orders of magnitude smaller than the ones obtained through conventional
fiber production methods like melt or solution spinning [2]. It is therefore no wonder that
electrospun materials have found wide application in the medical field, where they are used
in the manufacturing of vascular grafts and prosthetic blood vessels.
The polymeric material is usually fed from a small reservoir (e.g. a syringe) through a
capillary (often polyethylene or Teflon) with a conducting tip. This tip forms the one
electrode and the target, which can be a mandrel or flat plate, forms the other electrode.
When the high-voltage direct current (DC) supply is turned on, the electrode imparts an
electric charge to the polymer solution and a jet is ejected from the suspended liquid
meniscus (Taylor cone) at the capillary-end when the applied field strength overcomes the
surface tension of the liquid [7].
Process parameters, such as the strength of the applied electric field, flow rate,
polymer concentration, distance between the capillaries and the target have been found to
influence the average fiber diameter, but these parameters are highly dependent on the
polymer under investigation [2, 8-12].
Set-ups using one polymer solution or blends of polymer solutions are common
practice. More recently however, electrospinning devices have been developed where two
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or more polymer solutions have been electrospun simultaneously, in a side-by-side fashion
[7].
Accomplishments in the electrospinning of medical devices, including materials and
procedures, have been pronounced; especially achievements gained over the last 2 - 3
years. Some will briefly be discussed in the next section (see also Table F.1, Appendix F
for a non-exhaustive list of the most recent advances in electrospinning).
7.4 Historical
A variety of natural and synthetic materials, each containing examples of degradable
and non-degradable materials, have been electrospun into flat sheets or tubular scaffolds.
Flat sheets were spun mainly to investigate human biocompatibility [8, 13-18] for
general wound dressing applications [17, 19-23] and, more specifically, facial [24], liver
[25], neural [24], bone [26-29] and cardiac applications [30, 31], in which case the collecting
set-ups were simple flat areas or rotating disks.
A number of different materials, both natural (collagen type 1, gelatin type B, alpha-
elastin, tropo-elastin and chitosan) and synthetic (poly(caprolactone), poly(ethylene glycol),
poly(lactide), poly(glycolic acid), poly(D,L-lactide-co-glycolide) and poly(ethylene oxide)),
have been electrospun using different voltages (10 - 20 kV), flow rates (1 - 10 ml/h),
average distance between electrodes (150 mm), and mainly using 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) as solvent, to obtain flat sheet structures with a wide range of fiber
thicknesses (40 nm - 10 µm). A number of different cells (e.g. human embryonic palatal
mesenchymal, interstitial, endothelial and smooth muscle cells) were seeded onto these flat
sheet structures and the attachment and proliferation of the cells were investigated.
In general, the scaffolds supported the attachment, proliferation and infiltration of the
cells used in the respective studies [8, 13-18]. In one specific study [13] however,
interstitial and endothelial cells did not infiltrate or attached to the electrospun scaffolds
fabricated from poly(glycolic acid) and poly(lactide).
A number of authors have also electrospun flat sheet scaffolds for general use in
wound-dressing applications [17, 19-23], while others have investigated their use in more
specific applications, e.g. facial [24], liver [25], neural [24], bone formation [26-29] and
cardiac [30, 31].
Silk, a natural and non-degradable material, has been used by some researchers [19,
20, 26] with great success in wound-healing applications, while the fabrication of
degradable scaffolds has been extensively investigated using both natural (collagen type 1
and fibrinogen) [21, 22] and synthetic (e.g. poly(caprolactone), poly(D,L-lactide-co-
glycolide) and poly(ethylene-b-lactide)) [17, 21-25, 27-31] polymers.
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A wide range of process conditions and solvents has been used, depending on the
specific polymer and its application. The flat sheets were again seeded with different cells
(e.g. cardiac myocytes, smooth muscle and endothelial cells) and the attachment and
proliferation studied.
The release of DNA [17], an antibiotic (Mefoxin) [23] and Ibuprofen from electrospun
flat sheets [32, 33] has also been studied. A composite poly(lactide-co-glycolide)/DNA
scaffold was fabricated for therapeutic application in gene delivery for tissue engineering
[17]. The release of plasmid DNA was sustained over a period of 20 days, with maximum
release occurring at 2 hours. Results indicated that DNA released directly from these
electrospun scaffolds was indeed intact, capable of cellular transfection, and successfully
encoded the protein β-galactosidase.
Kim et al. [23] demonstrated the successful incorporation and sustained release of an
antibiotic (Mefoxin) from a electrospun poly(lactide-co-glycolide) scaffold without the loss
of structure and bioactivity. The morphology and porosity of the electrospun flat sheet was
found to be dependent on the drug concentration, which was attributed to the change in
ionic strength of the polymer solution.
Alternative electrospinning techniques used to manufacture tubular scaffolds [1, 34-
37], comprising one or more layers [1, 34] have been much more complicated, consisting of
rotating and translating mandrels or even “side-by-side” spinning set-ups [37].
Mainly synthetic materials, degradable (e.g. poly(caprolactone) and poly(D,L-lactide-
co-glycolide)) and non-degradable materials (e.g. poly(vinyl chloride and poly(ethylene
oxide)) including non-degradable polyurethanes (Cardiomat 610 and Estane® 5750). In a
selected case [1] the synthetic polymers were used in combination with natural polymers
(e.g. collagen type 1 and gelatin).
Inoguchi et al. [35] fabricated vascular grafts using poly(L-lactide-co-ε-caprolactone)
with an inner diameter of 2.5 mm and wall thicknesses ranging between 50 - 340 µm in an
effort to determine a correlation between wall thickness (controlled by spinning time) and
mechanical response (e.g. compliance). The compliance increased with a decrease in wall
thickness, approaching that of a native artery [35].
Vaz et al. [34] fabricated a bi-layered tubular scaffold composed of a stiff and
oriented poly(lactide) outside fibrous layer and a pliable and randomly oriented
poly(caprolactone) fibrous inner layer. Control over the level of fiber orientation of the
different layers was achieved through the rotation speed of the collecting mandrel.
Simultaneous electrospinning of poly(vinyl chloride) and a polyurethane (Estane®
5750), in a “side-by-side” fashion, was also demonstrated [37]. The two solutions were
placed in separate syringes, but in one syringe pump. The tips of the respective syringe
needles were however connected to form one end of the electrode, thus mixing the
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solutions just before it was electrospun. Fibers (0.1 - 5 µm) were obtained at a working
distance of 150 mm and a voltage of 14 kV.
Kidoaki et al. [1] fabricated a bi-layered tubular construct composed of a thick
polyurethane (Cardiomat 610) outer layer and a thin type 1 collagen inner layer as a
“prototype scaffold of artificial grafts”. Cardiomat and collagen were dissolved in
tetrahydrofuran and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), respectively, and then spun
at distances and voltages of 150 - 300 mm and 9 - 16 kV to produce fibers with
thicknesses in the range of 0.2 - 2 µm.
7.5 Theoretical
The structure and architecture of scaffolds are crucial parameters in the design of
cardiovascular prostheses as those features have a great influence on the healing
response. The mechanical and biological functionality of the scaffolds are influenced by
architectural parameters such as porosity, pore size, surface area to volume ratio, cross
sectional area, strut/wall thickness and permeability [38]. A number of techniques can be
used to evaluate and calculate these parameters, including theoretical assessment,
scanning electron microscopy (SEM) analysis, flow and mercury porosimetry, gas
pycnometry, adsorption and, more recently, micro computed tomography (CT) [3].
7.5.1 Determination of porosity by apparent volume method
In this method, scaffolds are weighed and the volumes (Vg) of the material obtained
by dividing the mass by the material density. The apparent scaffold cube volume (Va) on the
other hand is calculated from its linear measurements (wall thickness and length), and the
porosity is then calculated using Eq. 7.1 [3].
€ 
Porosity = 1−Vg Va( ) ×100% (7.1)
7.5.2 Determination of porosity by Archimedes method
In the gravimetric method, a scaffold is pre-weighed (Mdry), then soaked in water,
under vacuum (to remove trapped air), then submerged under water (at ambient pressure)
and weighed (Msub). After the sample is removed from the water it is weighed again (Mwet)
and the porosity then calculated according to Eq. 7.2 [3].
€ 
Porosity = Mwet −Mdry( ) Mwet −Msub( ) (7.2)
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7.6 Experimental
7.6.1 Materials
Pellethane® 2363-80AE (Pellethane) was obtained from Dow Chemicals (USA).
Modified Pellethane (15%) was synthesized as described in Chapter 4 and dissolved in
tetrahydrofuran (THF) (Merck, Cat: AB009731). ω,ω-Dimethoxy-ω-phenylacetophenone
(DMPA) (Aldrich Cat: 19,611-8) was used as UV initiator in selected experiments.
7.6.2 Methods
7.6.2.1 Electrospinning set-up
The electrospinning apparatus (see Figure 7.1) consisted of a high-voltage power
supply (maximum voltage potential of 35 kV), an infusion pump (Vial medical SE 400B), a
syringe fitted with a stainless-steel blunt-ended 15G needle, and a circular mandrel (1.6-mm
diameter) which was made to rotate and translate during fabrication of the grafts to ensure
even deposition of fibers.
An ultraviolet light source (315 - 400 nm) was fixed at a distance of 500 mm directly
above the rotating mandrel, to initiate the crosslinking reaction of Pell15.0 (Figure 7.1). Note
that the syringe is actually orthogonal to the mandrel (current depiction is for clarity only).
Figure 7.1: Illustration of electrospinning set-up
A 1-ml syringe was horizontally fixed on the infusion pump and the polymer solution
pumped through a polyethylene tube and the needle. The polymer solution was
electrostatically drawn from the tip of the needle by applying a high voltage between the
rotating mandrel and the tip of the needle. The flow rate of the solution, applied voltage and
distance between the needle tip and the mandrel were set to 0.7 ml/h, 15 kV and 11 and 15
cm for Pellethane and Pell15.0, respectively. The distance to the ground of the rotating
mandrel and the tip of the nozzle were set at 185 mm.
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7.6.2.2 Electrospinning procedure
Pellethane and Pellm15.0 were dissolved in THF to obtain solutions ranging in
concentration from 16.5% to 18.0% (wt%). DMPA (2.0 wt%) was pre-dissolved in THF and
then added to the Pell15.0 solution to obtain a final polymer concentration of 18.0% (wt%).
The polyethylene tubing was primed and the syringe then completely filled with
polymer solution. The distance between the tip of the nozzle and the ground was then set
to 185 mm. The distance between the nozzle tip and mandrel was then set to either 110 mm
(Pellethane) or 150 mm (Pell15.0). The ultraviolet light, syringe pump and rotating/translating
mandrel were then switched on. The high-voltage power supply was switched on last and
carefully set to the desired setting (15 kV). The wall thickness was achieved by spinning
for times ranging between 5 - 30 min.
The tubular constructs (40 mm in length) were then left in ethanol for approximately 1
- 2 min to swell, which allowed their successful removal from the mandrel. They were then
dried in vacuo for 24 h at room temperature and analyzed.
Test pieces were cut off the electrospun Pellethane (control) and Pell15.0 grafts and
placed in 50 ml of tetrahydrofuran to test whether crosslinking had been achieved.
7.6.2.3 Scanning electron microscopy
A macroscopic evaluation of the electrospun tubes was conducted using a scanning
electron microscope (SEM) (Yeol, JSM 5200). Test pieces were cut with a sharp blade,
mounted on aluminum stubs, sputter coated with gold-palladium (AuPd) and viewed in the
SEM at an accelerating voltage of 25 kV.
7.6.2.4 Architectural and structural evaluation
The concentricity along the length of the tubes was inspected using a light
microscope (Leica, MZ 75). Two pieces (3 mm in length) were then cut off on both ends
and used to determine the average fiber and wall thicknesses, respectively, using SEM
analyses. Three areas were randomly selected on both end pieces for fiber thickness
determination while the other two pieces were used, as a whole, to determine the wall
thickness of the respective grafts.
The SEM images were analyzed using ImageJ (v1.36) software. At least 300 counts
were made per tube and the average fiber thickness calculated, while the wall thickness
was measured on at least 30 places on the circumference of the tube, at both ends.
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7.6.2.5 Porosity determination
Two non-destructive methods (a gravimetric and a volume method) were used to
determine the porosity of the scaffolds.
(A) Archimedes method
The dry mass (Mdry) of the tube (n = 4) was recorded. It was then placed in a small
test tube filled with water, and the entrapped air removed under vacuum. The tube was
removed from the test tube and placed in water, and the submerged mass (Msub) recorded
(Figure 7.2). It was subsequently taken out of the water, quickly dab-dried and weighed
(Mwet). The measured values were used to compute the porosity (Eq. 7.2).
Figure 7.2: Illustration of gravimetrical method used for porosity determination of
electrospun grafts
(B) Apparent volume method
The length and diameter of each tube (n = 4) were recorded and used with the
average fiber and wall thickness (obtained as described in §7.3.2.4) to calculate the volume
of the polymer scaffold (Vg) and the apparent scaffold cube volume (Va). Eq. 7.1 was used
to calculate the porosity.
7.7 Results and discussion
Pellethane and Pellm15.0 were successfully electrospun on a 1.6-mm
rotating/translating mandrel. Tubes, at least 35 - 40 mm in length, and of even concentricity,
were obtained. The control samples of Pellethane immediately dissolved when placed in 50
ml THF, while the one manufactured from Pell15.0 only swelled slightly, indicating
successful crosslinking.
Pellm15.0 was thus successfully crosslinked in situ by a “reactive electrospinning”
technique. To the best of the authors’ knowledge this is the first time that a polyurethane
material has ever been electrospun in such a manner, to date.
0.0045 g 0.0011g 0.0175 g
Step 1 Step 2 Step 3
Mdry Mwet
Msub
m
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7.7.1 Fiber and wall thickness
It was found possible to electrospin Pellm15.0 at a polymer concentration of 18.0%
(w/w) and an average fiber thickness of 3.3 ±1.1 µm (n = 4) was obtained. A typical
scanning electron microscope image, showing fiber thickness and orientation, is presented
in Figure 7.3. A fairly even fiber thickness distribution was obtained.
Figure 7.3: SEM (x1500) analysis of outer wall of electrospun Pell15.0
Pellethane at a concentration of 18.0% resulted in a much larger average fiber
thickness when compared to Pell15.0. The fiber thickness could however be controlled, by
changing the polymer concentration, as is illustrated in Figure 7.4, with the exact values
tabulated in Table 7.2
Table 7.2: Change in fiber thickness of Pellethane with change in polymer
concentration
Concentration (%) 18.00% 17.00% 16.65% 16.58% 16.50% 16.00%
Fiber thickness (µm) 7.9 ±4.0 7.4 ±3.6 3.7 ±1.2 3.1 ±0.7 2.8 ±0.9 1.9 ±0.8
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Figure 7.4: Change in fiber thickness with change in Pellethane concentration
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At the higher Pellethane concentrations (>17.0%) thicker fibers were obtained with
much wider fiber thickness distributions when compared to fibers obtained from lower
concentrations (<16.6%). Similar nonlinear increases in fiber thickness and distributions
with an increase in polymer concentration, using different polymers (e.g. poly(L-lactide-co-
ε-caprolactone and Gelatin) and solvents (e.g. acetone and HFIP), have been reported [8,
12, 13, 31, 39].
A Pellethane concentration of 16.58% (w/w) resulted in fibers with a comparable
average fiber thickness and standard deviation (3.1 ±0.7 µm) (Figure 7.4) to that of Pell15.0.
Figure 7.5: SEM (x1500) analysis of outer wall of Pellethane
A visual inspection of the SEM pictures obtained indicated that the tubes obtained from
Pell15.0 might be more densely packed (i.e. lower porosity) compared to the tubes obtained
from Pellethane (Figure 7.5). Porosity calculations confirmed this initial qualitative
observation, and will be discussed further in §7.4.2.
Concentric tubes were obtained using Pellethane and Pell15.0. See Figure 7.6a for a
typical result.
Figure 7.6(a)&(b): SEM analysis showing (a) concentricity (x50) of the tube and (b)
part of Pell15.0 tube wall (x150)
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Pell15.0, electrospun for 30 min, resulted in tubes (n = 4) with an average wall
thickness of 78.05 ±9.0 µm (Figure 7.6b).
The thickness of the wall of the tubes electrospun using Pellethane was found to be
very sensitive to the time of spinning. Tubes with much thicker walls compared to tubes
electrospun using Pell15.0 were obtained at a spinning time of 6.5 min (Table 7.3).
Table 7.3: Change in wall thickness of Pellethane with spinning time
Time (min) 6.5 min 5.5 min 5.0 min
Wall thickness (µm) 125 .1 ±13.8 83.3 ±16.3 80.7 ±12.0
Tubes electrospun for 5 min had wall thicknesses of 80.7 ±12.0 µm (Figure 7.7),
which was comparable to those obtained using Pell15.0. See Table 7.4 for a summary of
the fiber and wall thicknesses for grafts (n ≥ 4) electrospun using Pellethane and Pell15.0,
respectively.
Figure 7.7: SEM (x150) analysis of wall cross section of electrospun Pellethane
Tubes with very similar fiber and wall thicknesses were obtained. The fairly high
standard deviation in wall thickness calculated for the tubes electrospun using Pellethane
can be mainly attributed to the sensitivity to spinning times, and is thus a result of slight
tube-to-tube variation.
Table 7.4: Summary of fiber and wall thicknesses of tubular scaffolds electrospun
from Pellethane and Pell15.0
Pellethane Pell15.0
Fiber thickness (µm) 3.1 ±0.7 3.3 ±1.1
Wall thickness (µm) 80.7 ±12.0 78.1 ±9.0
100 µm
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7.7.2 Porosity evaluation
The results obtained from the two methods used to determine the porosities of the
electrospun constructs, namely Archimedes and apparent volume, compared reasonably
well. The tubes electrospun using Pell15.0 had a significantly lower porosity than the ones
manufactured using Pellethane (Table 7.5).
Table 7.5: Summary of measured and calculated porosities of electrospun
constructs
Pellethane Pell15.0
Archimedes (%) 69.8 44.7
Apparent volume (%) 63.4 40.0
The difference in porosity between the electrospun Pellethane and Pell15.0 constructs
can be explained by the dielectric properties of Pell15.0. These are different to Pellethane
as a result of the introduction of the pendent groups. Secondly, the addition of DMPA in the
Pellm15.0 solution could also slightly change the viscosity and surface tension of the
solution [23], while the resulting change in conductivity (presence of the ionized DMPA
molecules) will change the charge density of the jet, resulting in changes in the fibrous
morphology [23].
7.8 Conclusions
Pellm15.0 could be successfully crosslinked by a “reactive electrospinning” technique.
The concentration and spinning time of Pellethane could be used to control the fiber and
wall thicknesses very accurately. Tubular constructs (1.6 mm ID) with comparable wall and
fiber thicknesses could be obtained, but the porosity of the Pellethane tubes were found to
be much higher compared to the tubes electrospun using Pell15.0, most probably due to
differences in dielectric properties of the polyurethanes and ionic strength of the solutions.
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Chapter 8
Conclusions and recommendations for future
research
8.1 Introduction
The main goal of this project was to chemically modify existing medical grade
polyurethanes using functional groups capable of undergoing crosslinking reactions, in
order to improve their chemical stability and mechanical properties. A model compound, with
the same hard segment structure of an academic standard polyurethane (Pellethane® 2363-
80AE), was first used to find a suitable pendant group, and then to optimize the chemistry.
The process variables involved in the modification and crosslinking reactions of the
polyurethanes were optimized and the chemical stability evaluated in an in vitro degradation
assay. Porous tubular constructs were subsequently successfully electrospun and
crosslinked.
8.2 Conclusions
There were seven major objectives, as set out in Chapter 1, and to which the
following conclusions were drawn.
8.2.1 Background and theoretical considerations of polyurethanes as
biomaterial
After carrying out a literature survey of polyurethanes as biomaterial the following
were found:
• Thermoplastic polyurethanes offer a great variety in terms of chemical and
physical properties and are therefore attractive candidate biomaterials.
• Polyurethanes have however not yet demonstrated long-term biostability, and they
also suffer from large energy losses (hysteresis) when subjected to continuous
cyclic loading, due to the weak nature of virtual crosslinking.
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8.2.2 Potential modification of the carbamate nitrogen with an acyl chloride
• The carbamate nitrogen of polyurethanes is a weak nucleophile. The lone electron
pair is compromised by back donation into the aromatic p system and because of
delocalization into the carbonyl.
• Acyl chlorides of the type R(CO)X (where X is a leaving group) are very reactive
towards nucleophilic substitution.
The following model compound was proposed, with which to study the proposed
reaction between the carbamate nitrogen and an acyl chloride
8.2.3 Model compound synthesis and optimization of acylation chemistry
• A urethane model compound, based on the same hard segment structure as
Pellethane® 2363-80AE, was successfully synthesized, purified and
characterized.
• Acylation of the model compound with hexanoyl chloride was achieved by either
nucleophilic or electrophilic enhancement. Higher conversions were obtained
using the former.
• Characterization of the resulting product showed successful acylation at the
proposed reaction site (the carbamate nitrogen).
• The success of hexanoyl chloride coupling could be emulated with 4-pentenoyl
chloride, thereby introducing an unsaturated C=C bond for potential future
crosslinking.
• Although the coupling could be achieved by either nucleophilic or electrophilic
enhancement, the former was again found to be the more effective method.
• The formation of the desired acylated product was confirmed by spectroscopic
analyses.
8.2.4 Modification of existing polyurethanes
• Pellethane was purified (using ethanol at room temperature) and then successfully
modified with 4-pentenoyl chloride.
• The chemistry was successfully transferred from the model compound to a
medical grade polyurethane.
• A maximum degree of modification of 20.0% was obtained. It was also found
possible to accurately (R2 = 0.99) and reproducibly control the degree of
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modification between 4.5% to 20% by changing the sodium hydride and 4-
pentenoyl chloride concentrations, respectively.
• PurSil 35-80A, a second medical grade polyurethane, with a different chemical
structure and stoichiometry to that of Pellethane, was also successfully modified
with 4-pentenoyl chloride.
• The degree of modification was accurately (R2 = 0.99) controlled between 11.5%
and 18.5% (maximum) by changing the sodium hydride and 4-pentenoyl chloride
concentrations, respectively.
8.2.5 Optimization of the degree of modification and crosslinking
• Successful crosslinking of two novel modified polyurethanes (so-called Pellx and
Purx) was achieved using an ultraviolet light (UV) source, a heat source (120 0C)
and gamma irradiation (only UV was investigated as method of crosslinking for
Purx).
• The swelling indices, used to calculate the molecular weight between crosslinks,
were used to optimize the initiator concentrations used in the crosslinking
experiments.
• The lowest swelling indices, i.e. lowest molecular weight between crosslinks,
were obtained for Pell15.0 and Pur18.5, respectively.
• The best mechanical properties (lowest hysteresis and creep) were also obtained
for Pell15.0 and Pur18.5, with respective improvements of up to 42.5% in
hysteresis and 44.0% in creep for Pell15.0.
• The use of crosslinking enhancing monomers (e.g. MbA) resulted in lower swelling
index values, but had a detrimental effect on the hysteresis due to long linking
groups (bridges) and even more disruption of the hydrogen bonding in the hard
phase.
8.2.6 In vitro chemical stability assay
• Degradation of both Pellethane and Pell15.0 was evident from the measured and
determined mechanical (e.g. tensile and dynamic mechanical analysis) and
chemical properties (Fourier infrared spectroscopy, X-ray photoemission
spectroscopy and environmental scanning electron microscopy).
• The hysteresis and non-recovered strain of Pell15.0 was better by at least 27.5%
and 21.0%, respectively, when compared to Pellethane.
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• It is concluded that Pell15.0 retained hard phase integrity due to the oxidative
stable crosslinks when compared to Pellethane.
• Degradation of the “more vulnerable, less ordered” soft phases of Pellethane and
Pell15.0 was confirmed by Fourier-transform infrared spectroscopy and X-ray
photoemission spectroscopy.
• Significant surface degradation of Pellethane incubated in silver nitrate and
hydrogen peroxide was confirmed by environmental scanning electron
microscopy. Less surface degradation was observed for Pell15.0 in both the
above-mentioned degradation media, and significantly so lower in silver nitrate.
8.2.7 Manufacturing of tubular constructs
• Pellm15.0 was successfully crosslinked by a “reactive electrospinning” technique.
• The concentration and spinning time of Pellethane was used to control the fiber
and wall thicknesses very accurately.
• Tubular constructs (1.6 mm ID) with comparable wall and fiber thicknesses, but
with different porosities, were obtained.
• The difference in porosity can be attributed to, differences in dielectric properties
of the polyurethanes and ionic strength of the spinning solutions.
8.3 Major contributions
In summary, the major contributions of this study are:
• A model urethane compound could be used to find a suitable modification reagent
(4-pentenoyl chloride), confirm the intended carbamate nitrogen as successful
reaction site, and to optimize the chemistry.
• The chemistry could be successfully transferred and two medical grade
polyurethanes, Pellethane® 2363-80AE and PurSil 35-80A, were subsequently
modified with 4-pentenoyl chloride. The degree of modification could be accurately
controlled (R2 = 0.99) between 4.5% to 20.0% and between 11.5% to 18.5% for
the respective polyurethanes.
• Crosslinking of the two novel modified polyurethanes could be achieved, using an
ultraviolet light source, a heat source and gamma irradiation, resulting in
improvements in hysteresis and creep of up to 42.5% and 44.3%, respectively, for
Pell15.0.
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• It could be concluded from an in vitro degradation study that Pell15.0 exhibited
significant resistance to surface degradation, as studied with scanning electron
microscopy, and retained hard phase integrity due to the oxidative stable
crosslinks, when compared to Pellethane.
• Small-diameter tubular constructs, with similar fiber and wall thicknesses, could be
electrospun from Pellethane and the 15% modified Pellethane using a standard
electrospinning technique in the case of the former and, in the latter, a novel
“reactive” electrospinning technique for the in situ crosslinking of the novel
material, while simultaneously forming the tubular constructs.
Patent and presentation emanating from this research:
1. D. Bezuidenhout, J.P. Theron, P. Zilla, Modification of thermoplastic polyurethanes,
U.S. Patent application Serial No. 11/388 and U.S. Provisional Patent Application
Serial No. 60/664,767.
2. J.P. Theron, D. Bezuidenhout, J.H. Knoetze, R.D. Sanderson, P. Zilla, Modification
of polyurethanes with latent crosslinkable groups for use in cardiovascular
prostheses, 8th UNESCO/IUPAC conference on macromolecules, Mauritius, 2005
Results of this very extensive research conducted in to the development of
crosslinkable, thermoplastic polyurethanes should certainly make a meaningful contribution
in the field of the manufacturing of new synthetic cardiovascular prostheses.
8.4 Recommendations for future research
On completion of this study, certain recommendations can be made:
• The scale up of the modification reactions should be studied. A bench-scale pilot
plant with different size reactors could be designed and built to accommodate such
a study. Successful scale-up would ensure that more material would be available,
as required for extrusion.
• Pacemaker leads could then be extruded and evaluated subcutaneously in a sheep
model.
• Tubular constructs could be implanted in a rodent model, and/or tubes with larger
inside diameter (e.g. 4.4 mm) could be electrospun and optimized in vitro,
whereafter they could be evaluated in vivo in a circulatory model, e.g. a femoral
arterial baboon model.
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Appendix A
Raw materials and properties of polyurethanes
Table A.1: List of commonly used raw materials in polyurethane synthesis [1]
Structure of compound Name Abbreviation
Diol extenders
HO-R-OH generic diol DO
HO-(CH2)2-OH ethane diol EDO
HO-(CH2)4-OH butane diol BuDO
HO-(CH2)6-OH hexane diol HDO
Diamine extenders
H2N-R-NH2 generic diamine DA
H2N-(CH2)2-NH2 ethylene diamine EDA
Aromatic diisocyanates
O C N R1 N C O
R1 = aromatic
generic aromatic diisocyanate ArDI
C
N
O
C
N
O methylene bis(p-phenyl isocyanate) MDI
C
N
OC NO     
C
N
O
C
N
O
2,4 toluene diisocyanate
2,6 toluene diisocyanate
2,4 TDI
2,6-TDI
CN O
C NO
1,5-naphthalene diisocyanate NDI
NCO
N C O methylene bis (toluene isocyanate) TODI
Aliphatic diisocyanates
O C N R2 N C O
R2 = aliphatic
generic aliphatic diisocyanate AlDI
C
N
O
C
N
O methylene bis(4,4-cyclohexyl isocyanate) HMDI
C
N
O
C
N
O 1,4-cyclohexane diisocyanate CHDI
C
N
O CN O
3-isocyanatomethyl-3,5,5-
trimethylcyclohexyl isocyanate
(isophorone diisocyanate)
IPDI
Polyester diols
HO R C
O
O R'
n
O H generic polyester diol PesD
HO (CH2)5 C
O
O (CH2)2 O C (CH2)5
O
OH
n n
polyethylene adipate glycol PEA
HO (CH2)4 O C (CH2)4 O C H
O
n
O
polycaprolactone PCL
Polyether diols
HO R O H
n
generic polyether diol PED
HO CH2 CH2 O Hn
poly(ethyleneoxide) glycol
poly(oxyethylene) glycol PEO
HO CH2 CH O Hn
CH3 polypropylene oxide glycol
poly(oxypropylene) glycol POPG
HO CH2 CH2 CH2 nCH2 O H
poly(oxytetramethylene) glycol
poly(tetramethylene oxide) glycol PTMEG
Polycarbonate diols
HO (CH2)6 O C O
O
(CH2)6 OHn
polyhexamethylene carbonate glycol PHMC
Polysiloxane diols
HO (CH2)4
n
Si O
CH3
CH3
Si
CH3
CH3
(CH2)4 OH
hydroxybutyl terminated
poly(dimethylsiloxane) PDMS
Hydrocarbon diols
HO C CH2 OH
n
CH3
CH3
hydroxy-terminated polyisobutylene PIB
HO CH2 CH2 CH2
n
CH2 mCH2 CH OH
CH2
CH3
hydrogenated polybutadiene PBD
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Table A.2: Listing and properties of medical grade polyurethanes [1]
AROMATIC POLYETHER URETHANES
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Pellethane® 2363
55D
55DE
65D
75D
80A
80AE
90A
90AE
Dow MDI PTMEG BDO 90A-55D
55D
53D
62D
76D
81A
85A
90A
90A
-42
-47
-30
-33
156 81
35-48
47.5
44.8
44.5
40.0
35.8
28.9
40.3
41.3
87
13.2
390
450
450
380
550
650
500
550
17.2
15.9
20.0
6.1
6.1
11.7
10.2
1.15
1.15
1.15
1.17
1.21
1.13
1.12
1.14
1.14
[2-6]
2 Vialon® 510X Becton Dickenson MDI PTMEG BDO [3, 4]
3 Cardiomat®  610 Kontron MDI PED DO 80A 27.6 8.1* 500 [4]
Corplex® [4]
4 Erythrothane® Biosearch ArDI PED DO [4]
5 Renathane® Renal Syst’s ArDI PED DO [4]
6 SRI series Stanford Res.
Inst.
MDI PED DO [4]
7 Estane® 5714 BF Goodrich MDI PED DO [3, 4]
8 Texin® Mobay (Bayer) MDI PED DO [4]
9 Techothane®
TT-1074A
TT-1085A
TT-1095A
TT-1055D
TT-1065D
TT-1069D
TT-1072D
TT-1075D
Thermedics MDI PTMEG
75A
85A
94A
54D
64D
69D
74D
75D
81
-51
220 100 41.3
48.2
62.1
66.1
68.9
60.7
62.1
57.2
550
450
440
350
300
310
275
150
3.4
5.5
9.0
17.2
19.3
22.1
25.5
24.8
1.10
1.12
1.15
1.16
1.18
1.18
1.18
1.19
[7, 8]
10 Tecoplast® TP-470 Thermedics 82D 68.9 50 [8]
11 Elasthane®
55D
75D
80A
PTG MDI PTMEG BDO
55D
74D
85A
55.1
55.8
39.9
490
220
795
14.9
5.8
1.16
1.19
1.12
[9]
12 Chronothane® 80A CT Biomaterials MDI PTMEG
80A
35.2 550 5.9 [10]
13 Elast-Eon® 1 Elastomedic ArDI PHMO 80A-75D 31±2 54.5±6 580±45 9.1±0.2 [11]
AROMATIC POLYETHER URETHANE UREAS
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Biomer® SolG Ethicon MDI PTMEG EDA/DAC 75A -73 295 157 31-41 2.8-5.5 600-800 [3, 12, 13]
2 Biomer® ExtG Ethicon MDI PTMEG water 75A 28-35 12.4Flx [4]
3 Mitrathane® Polymedica MDI PTMEG EDA [3, 14]
4 Surethane® Cardial Con Sys MDI PTMEG DA [4]
5 SRI series Stanford Res MDI PED DA [4]
6 Mod.PUU Mercor ArDI PED DA/Surf. [4 ]
7 Univ. Utah Univ. Utah MDI POPG EDA [4]
8 Lycra DuPont MDI PTMEG DA [4]
9 Biospan®
70A
PTG MDI PTMEG DA
70A -65 180 180 41 41.3 5.9 850
[3, 9]
10 TM5 Toyobo MDI PTMEG PDA [3, 9]
AROMATIC POLYCARBONATE POLYURETHANES
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Chronoflex® AR
75A
Cardiotech Inc.
(Polymedica)
MDI PCDO EDA/DAC
75A 86 -34 240 140 51.7 500
[3, 7,
10, 12]
2 Bionate®
(Corethane)
80A
90A
55D
75D
PTG (Corvita) MDI PHECD BD
80A
90A
55D
75D
81
96
-18
-78.3
240
140
130
75
45-52
48-59
48-63
48.1
53.7
62.0
68.9
400-490
365-440
255-320
570
420
380
260
6.8
12.6
18.3
37.9
1.19
1.20
1.21
1.22
[3, 5, 7, 9]
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3 Chronoflex® C
80A
55D
75D
Cardiotech Inc.
(Polymedica) 80A
55D
75D
37.9-44.8
41.4-51.7
48.3-55.2
400-490
365-440
255-320
secant
5.3-8.6
12.8-15.2
36.5-39.3
[10]
ALIPHATIC POLYETHER URETHANES
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) ε1 0 0 (MPa) ρ (g/cm3) Ref
1 Tecoflex®
EG-80A
EG-85A
EG-93A
EG-100A
EG-60D
EG-65D
EG-68D
EG-72D
Thermedics HMDI PTMEG BDO
72A
77A
87A
94A
51D
60D
63D
72D
81 -70
42
55
40.0
42.7
53.1
56.5
57.2
57.2
57.2
55.8
580-800
660
550
390
370
360
360
350
310
2.1
4.1
6.9
11.0
12.4
15.2
17.9
23.4
1.04
1.05
1.08
1.09
1.09
1.10
1.10
1.11
[3, 4, 7, 8]
2 Techophilic®
HP-60D-20
HP-60D-35
HP-60D-60
HP-93A-100
Thermedics
43D
42D
41D
83A
Dry/wet
61.3/35.1
53.7/33.7
57.1/21.3
15.1/9.6
Dry/wet
430/390
450/390
500/300
1040/620
1.12
1.12
1.15
1.13
[8]
3 SRI series Stanford Res.
Inst.
HMDI PED DO [4]
4 Southern RI Southern Res.
Inst.
IPDI PTMEG BDO [4]
5 Akzo Akzo AlDI PED DO [4]
ALIPHATIC POLYETHER URETHANE UREAS
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn
(x103)
σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 SRI series Stanford Res.
Inst.
HMDI PED DA [4]
ALIPHATIC POLYCARBONATE POLYURETHANE
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Chronoflex® AL
80A
55D
65D
Cardiotech Inc.
(Polymedica)
HMDI??? PCDO EDA/DAC
80A
55D
65D
37.9
57.9
62.1
585
325
300
4.5
20.0
22.1
[3, 10]
2 Carbothane®
PC-3570A
PC-3575A
PC-3585A
PC-3595A
PC-3555D
PC-3572D
Thermedics HMDI PCDO BD
73A
84A
95A
60D
71D
96 -29 140 75
36.5
41.4
49.0
50.3
58.6
470
410
380
370
360
2.1
4.1
6.9
10.3
22.8
1.15
1.15
1.15
1.15
1.15
[7, 8]
SILOXANE URETHANE COPOLYMERS
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn (x103) σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Cardiothane® 51 Avcothane MDI PED DO PDMS 72A 43 580 [4]
2 Rimplast® Petrarch AlDI PED DO PDMS [4]
3 Elasteon® 2
85A
Aortec
(Elastomedic)c
ArDI PDMS 80A-55D
85A 28±0.7 33 580±5 10±0.3
[11]
4 Elasteon® 3
70A
H-O
H-20
H-20 opt
H-50
H-80
Aortecbio
(Elastomedic)
PDMS/PHMO
0% PDMS
20% PDMS
20% PDMS
50% PDMS
80% PDMS
100% PDMS
65A-80A
70A
89A
85A
85A
82A
82A
85A
-41
NA/-46
-116/-46
-112/-31
-112
25±1
13±1
16±1
25.5
15±2
18±1
28±2
7.0±0.6
38±4
24±1
25±2
23±3
20±1
17±1
490±11
225±35
393±50
460
361±60
473±25
472±25
5.0±0.1
[2, 11, 15]
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5 PurSil® AR
AR 10-80A
AR 20-80A
AR 30-80A
PTG MDI PTMO
10 wt% PDMS
20 wt% PDMS
30 wt% PDMS
DO
-68
-74
-86
34.5
33.7
24.8
770
770
620
5.6
6.2
7.2
1.11
1.11
1.11
[9]
6 PurSil® AL
AL-5-75A
AL-10 75A
AL-20 75AA
PTG AlDI PTMO +
5 wt% PDMS
10 wt% PDMS
20 wt% PDMS
DO
36.5
33.8
28.3
900
700
730
1.9
1.9
2.0
1.06
1.07
1.07
[9]
7 CarboSil®
10 90A
20 90A
40 90A
PTG MDI PCDO+
10 wt% PDMS
20 wt% PDMS
40 wt% PDMS
39.8
42.6
29.6
420
530
530
10.1
8.8
9.0
1.18
1.16
1.14
[9]
HYDROPHILIC POLYURETHANES
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn
(x103)
σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Hydromer® Hydromer ArDI PED/PEst H2O [4]
2 ORI Ontario Res. Inst. HMDI POADA PEG [4]
3 MIT MIT CHDI PEO DEG [4]
OTHER POLYURETHANES
# Name Producer Isocyanate Soft Segment Extender Shore γw Tg Tmh Mw (x103) Mn
(x103)
σb  (MPa) EY (MPa) εb  (%) E1 0 0 (MPa) ρ (g/cm3) Ref
1 Biostable PUR Medtronic MDI/dimer dimerDI/BDO/
dimerDO
BDO/dimer
DO
85-90A 220 120 29 21 [13]
2 Hydrothane®
80A
93A
AlDI
53.8 580
[4, 10]
3 Hydroslip® C 1.16 [4, 10]
4 Elast-Eon® 4
85D
55D-85D
85D 77 648 23 ---
[11]
5 Enka PUR®
817
923
947
981
ENKA AG
polyetherurethane
Ditto + PDMS
Polyesterurethane
Polyesterurethane
[4]
6 Thoralon® Thoratec PED DA [4]
Diisocyanates Extenders Soft segments Property
ArDI Aromatic diisocyanate DA Diamine PED Polyether diol γw Water contact angle
AlDI Aliphatic aromatic diisocyanate EDA Ethylene diamine PTMEG Polytetramethylene ether glycol Tg Glass transition temperature
MDI Methyl diphenyl Isocyanate POADA Polyoxyalkylene DA PEO Polyoxyethylene oxide Tm Melt temperature of hard segment
HMDI Hydrogenated MDI DO Diol POPG Polyoxypropylene oxide Mw Number average molecular mass
CHDI 1,4-Cyclohexane diisocyanate BDO Butane diol PO Polyol Mn Mass average molecular mass
IPDI Isopherone diisocyanate DEG Diethylene diol PesD Polyester polyol σb Stress at break
TDI Toluene diisocyanate DAC Diaminocyclohexane PBD Polybutadiene glycol EY Young’s modulus
TODI Methylene bis (toluene diisocyanate) HMOD Hydroxymethyl octadecanol PHECD Poly(1,6-hydroxyl 1,2-ethyl carbonate) diol εb Elongation at break
PHMO Polyhexamethylene oxide HDO Hexane diol PDMS Poly(dimethyl siloxane) E100 Modulus at 100% extension
PCDO Polycarbonate diol ρ Density
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Appendix B
Solubility of selected polyurethanes
Solvent δd δp δh δt
ElastEon®
2A
ElastEon®
2D
Pellethane®
2363-80AE
PurSil
35-80A
Acetic acid 14.5 8.0 13.5 21.4 3 4 2 2
Acetic anhydride 16.0 11.7 10.2 22.3 4 4 4 4
Acetone 15.5 10.4 7.0 20.0 3 3 3 2
Acetonitrile 15.3 18.0 6.1 24.4 4 4 4 4
Acrylonitrile 16.0 17.4 6.8 24.8 4 4 3 3
n-Amyl alcohol 16.0 4.5 13.9 21.7 4 4 4 3
Aniline 19.4 5.1 10.2 22.5 3 3 2 2
Benzene 18.4 1.0 2.1 18.5 3 4 3 3
Benzaldehyde 19.4 7.4 5.3 21.4 2 3 2 2
Benzyl alcohol 18.4 6.3 13.7 23.8 2 3 2 2
n-Butanol 16.0 5.7 15.8 23.1 3 4 4 3
Butyl acetate 15.8 3.7 6.3 17.4 3 4 3 3
sec Butyl alcohol 15.8 5.7 14.5 22.2 4 4 3 3
Chlorobenzene 18.6 4.3 4.1 19.5 2 3 3 3
Chloroform 17.8 3.1 5.7 18.9 2 3 2 2
m-Cresol 18.0 5.1 12.9 22.7 1 1 1 1
Cyclohexane 16.7 0.0 0.0 16.7 4 4 4 4
Cyclohexanone 17.8 6.3 5.1 19.6 1 2 1 1
Dichloroethane 19.0 7.4 4.1 20.9 3 3 3 3
Diethyl ether 14.5 2.5 5.1 15.8 3 3 4 3
Diethylene glycol 16.2 14.7 20.5 30.0 2 3 3 2
N,N dimethyl acetamide 16.8 11.5 10.2 22.7 1 1 1 1
N,N dimethyl formamide 17.4 13.7 11.3 24.8 1 1 1 1
Dimethyl sulfoxide 18.4 16.4 10.2 26.7 2 1 2 2
1,4-Dioxane 19.0 1.8 7.4 20.4 1 2 1 1
Ethanol 15.8 8.8 19.4 26.5 4 4 4 4
Ethyl acetate 15.8 5.3 7.2 18.1 3 4 3 3
Hexane 14.9 0.0 0.0 14.9 4 4 4 4
Methyl chloride 18.2 6.3 6.1 20.2 3 3 2 2
Methyl ethyl ketone 16.0 9.0 5.1 19.0 2 3 2 2
N-methyl-2-pyrrolidone 18.0 22.2 7.1 22.9 1 1 1 1
Nitrobenzene 20.0 8.6 4.1 22.2 4 4 3 2
Nitroethane 15.8 18.8 5.1 25.1 4 4 4 4
n-Propanol 16.0 6.8 17.4 24.5 4 4 4 4
Propylene glycol 16.8 9.4 23.3 30.2 4 4 4 4
Pyridine 19.0 8.8 5.9 21.8 1 1 1 1
Tetrahydrofuran 16.8 5.7 8.0 19.4 1 2 1 1
Toluene 18.0 1.4 2.0 18.2 4 4 3 3
Triethanolamine 17.2 15.6 21.3 31.5 4 4 4 4
Trimethyl phosphate 16.8 16.0 10.2 25.3 4 4 4 4
1 = Good solvent 2 = Good swelling agent 3 = Poor swelling agent 4 = Non-solvent
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Appendix C
Determination of solvent solubility parameters
C.1 Theoretical background
Focus will first be placed on cohesive energy and then solubility of polymers, in order
to provide the necessary background to the methods used to predict the solubility
parameters of the polyurethanes. The very comprehensive book by Van Krevelen [16] will
be used as reference.
C.1.1 Cohesive energy
The cohesive energy (Ecoh) of a substance in a condensed state is defined as the
increase in internal energy per mole (ΔU) of substance if all the intermolecular forces are
eliminated (Eq C.1). The solubility parameter (δ) of the polymer is defined as the square root
of the cohesive energy density in the amorphous state at room temperature (Eq. C.2) [16].
€ 
Ecoh = ΔU (C.1)
€ 
δ =
Ecoh
V
 
 
 
 
 
 
1
2
≡ ecoh
1
2 (C.2)
,where V is the specific volume and ecoh is the cohesive energy density in the amorphous
state. For liquids of low molecular mass, the cohesive energy is closely related to the molar
heat of evaporation ΔHvap (at a given temperature, T).
€ 
Ecoh = ΔUvap ≈ ΔHvap − RT (C.3)
Therefore, for low molecular mass substances Ecoh can easily be calculated from the
heat of evaporation, which is unfortunately not possible for polymers, as polymers cannot
evaporate. Indirect methods therefore have to be used, where the molar attraction constant
F (at 298K) is defined as:
€ 
F = EcohV 298( )( )
1
2 (C.4)
C.1.2 Solubility
The thermodynamic criteria of solubility are based on the free energy of mixing ∆GM.
Two substances are mutually soluble if ∆GM is negative. By definition,
∆GM = ∆HM - T∆SM (C.5)
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where ∆HM is the enthalpy of mixing; ∆SM is the entropy of mixing. As ∆SM is generally
positive, there is a limiting positive value of ∆HM below which dissolution is possible.
Hildebrand tried from as early as 1916 to correlate solubility with cohesive properties
of solvents, but it was only in 1949 that he proposed the term solubility parameter (δ).
According to Hildebrand, the enthalpy of mixing can be calculated by
∆hM = φiφj(δi - δj)2 (C.6)
where ∆hM is the enthalpy of mixing per unit volume; φi and φj are the volume fractions of
components i and j; δi and δj are the solubility parameters of components i and j.
Eq. C.6 predicts that ∆HM = 0 if δi = δj, so that two substances with equal solubility
parameters should be mutually soluble due to the negative entropy factor, as in accordance
with the general rule that chemical and structural similarity favors solubility. As the
difference between δi and δj increases, the tendency towards dissolution decreases.
It may be concluded then that as a requirement for the solubility of a polymer (1) in a
solvent (2), the value (δ1 - δ2)2 has to be as small as possible.
In the derivation of Eq. C.6 only dispersion forces between structural units have been
taken into account. For liquids and amorphous polymers, however, the cohesive energy is
also dependent on the interaction between polar groups and on hydrogen bonding.
The cohesive energy (Ecoh) may thus be divided into three parts, corresponding with
the contributions of the dispersion forces (Ed), polar forces (Ep) and hydrogen bonding (Eh),
and given by:
Ecoh = Ed + Ep + Eh (C.7)
with the corresponding equation for the solubility parameter
€ 
δ 2 = δd
2 + δp
2 + δh
2 (C.8)
The equivalent of Eq. C.6 then becomes
∆hM = φiφj[(δdi - δdj)2 + (δpi - δpj)2 + (δhi - δhj)2] (C.9)
Values of δd, δp and δh cannot be determined directly and therefore have to be determined
using indirect methods. One such a method was proposed by Hansen [16].
C.2 Indirect determination of solubility parameters
C.2.1 Method of Hansen
Hansen presumed the applicability of Eqs. C.8 and C.9 so that the solubility parameters
can be represented in three-dimensional vector space and may be depicted by the point (δp,
δd, δh) in the centre of a solubility sphere.
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€ 
δt
2 = δd
2 + δp
2 + δh
2 (C.10)
The solubility parameters of the polyurethanes (Pellethane® 2363-80AE and PurSil 35-
80A) were calculated (Eq. C.10) using the results presented in Appendix B.
€ 
δPellethane = 21.8MPa
1
2
€ 
δPurSil = 24.2MPa
1
2
C.3 Group contribution methods
It is impossible to predict solubility parameter components from the chemical structure,
since the polar and hydrogen-bonding properties are so complicated that it does not obey
simple rules. The solubility parameter can at best be described as a very rough estimate
[16]. A further complicating factor lies in the fact that the exact molecular structure of the
polymers has to be known.
The limited available information on Pellethane (Table A.2, Appendix A) was used to
deduce a very rough first approximation of its structure, based on the type, molecular mass
and stoichiometry possible of the respective raw materials and the published average
molecular mass of the polymer chains.
Two methods by which to estimate a solubility parameter have been published viz.
that of Hoftyzer and Van Krevelen (HVK) (1976) and that of Hoy (1985). In both methods
the same basic assumption is made, namely that of Hansen [16]:
Ecoh = Ed + Ep +Eh (C.7)
€ 
δ 2 = δd
2 + δp
2 + δh
2 (C.8)
C.3.1 Method of Hoftyzer and Van Krevelen
The solubility parameter components may be predicted from group contributions, using
the following equations [16]:
€ 
δd =
Fdi∑
V
(C.11)
€ 
δp =
F 2pi∑
V
(C.12)
€ 
δh =
Ehi∑
V
(C.13)
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The group contributions, Fdi and Fpi, to the dispersion and polar components of the
molar attraction coefficient can simply be added. The “F-method” is however not applicable
to the calculation of δd as the hydrogen bonding energy Ehi per structural group is
approximately constant, thus leading to the form of Eq. C.13. The group contributions Fdi, Fpi
and Ehi (Eqs. C11 - C13) for a number of structural groups can be found in the literature
[16]. The solubility parameter of Pellethane was calculated to be 19.11MPa1/2.
C.3.2 Method of Hoy
Hoy’s method is in many respects different from that of Hoftyzer and Van Krevelen. A
number of auxiliary equations are used (Eqs. C.14 - C.16)
€ 
α =
777ΔT
V
(C.14)
€ 
n = 0.5
ΔT
(C.15)
€ 
B = 277
n
(C.16)
where α is the molecular aggregation number, describing the association of the molecules;
€ 
n  is the number of repeating units per effective chain segment of the polymer; ∆T is the
Lyderson correction for non-ideality; B is the base value. Expressions for the components
of δ are given in Eqs. C.17 - C.20
€ 
δt =
Ft + B
V
(C.17)
€ 
δp = δt
1
α
Fp
Ft + B
 
 
 
 
 
 
1
2
(C.18)
€ 
δh = δt
α −1
α
 
 
 
 
 
 
1
2
(C.19)
€ 
δd = δt
2 −δp
2 −δh
2( ) (C.20)
where Ft is the molar attraction function; Fp is its polar component; V is the molar volume of
the structural unit of the polymer; δt is the molar attraction contribution to the solubility
parameter. Published values for ∆T, B, Ft Fp, and V [16] were used to calculate a solubility
parameter of 24.01 MPa1/2 for Pellethane.
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Appendix D
Crosslinking of novel modified polyurethanes
Table D.1: Molecular mass between crosslinks (Mc) for Pellx
Mc (g/mol) Pell4.5 Pell6.5 Pell8.5 Pell12.5 Pell15.0
UV Initiation
Mc (Hoy) 8443±405 6638±216 3603±16 3075±170 2309±63
Mc (Ideal) 7921±390 6120±205 3357±15 2866±157 2157±59
Heat initiation
Mc (Hoy) 11118±527 8196±510 7176±378 4789±289 2807±38
Mc (Ideal) 10523±519 7684±488 6709±359 4461±270 2618±35
Table D.2: Molecular mass between crosslinks (Mc) for Purx
Mc (g/mol) Pur11.5 Pur15.0 Pur18.5
Mc (Ideal) 16417±228 12011±618 7701±423
Mc (Hansen) 17332±241 12672±654 8107±448
Figure D.1: Wide angle X-ray scattering analysis of Pellethane (Pell) and Pell15.0
(Pell_15.0) control samples compared to Pellethane (Pell_deg) and Pell15.0
(Pell_15.0_deg) degraded in hydrogen peroxide
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Figure D.2: Wide angle X-ray scattering results of Pellethane (Pell)-Pellethane
degraded in hydrogen peroxide (Pell_deg) [Top] and Pell15.0 (Pell_15.0)-Pell15.0
degraded in hydrogen peroxide (Pell_15.0_deg) [Below]
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Appendix E
Listing of polyurethane in vitro degradation studies
Table E.1: Chronological listing of polyurethane in vitro degradation studies
Material Sample Solutions Test conditions Analysis Results Reference
Polyester urethane
Polyether urethane
Polyacrylate
Castor oil urethane
Polyester-ether urethane
Ricinoleate urethane
Films Humidity 50, 71, 85, 100 ºC
95% humidity
Shore hardness Polyester urethanes found to be
hydrolytically unstable.
[17]
Pellethane® 80A
(Dow Chemicals)
Pacemaker leads 3% H2O2 37 ºC, 60 days EDAX, FT-IR, SEM Cracks were observed after 30 days and
were severe after 60 days.
[18]
Pellethane® 80A
Pellethane® 55D
(Dow Chemicals)
ASTM (D-1708)
Microtensile
specimens
1. PtCl2, HNO3, NaClO,
AgNO3, FeCl3
2. Cu2Cl2, Cu(OAc)2,
Ni(OAc)2, Co(OAc)2
3. H2O (control)
ASTM (D-1708)
0.1 M solutions
90 0C, 35 days
FT-IR,
Tensile
Degradation rate of Pellethane® 80A higher
than 55D because of the higher ether
content of Pellethane® 80A.
[4]
Pellethane® 80A, 90A, 55D, 75D
(Dow Chemicals)
MedAdhere® 2110
(Medtronic)
Pre-stressed
tubing
(0 – 500%)
0.25-0.9 mm thick
1. PtCl2, NaClO, AgNO3,
FeCl3
Cu2Cl2, Cu(OAc)2,
Ni(OAc)2, Co(OAc)2
2. AgNO3/lactic acid, lactic
acid, Ringer’s solution
3. H2O (control)
ASTM (D-1708)
0.1 M solution
90 0C, 35 days
FT-IR,
Tensile
Ether containing urethanes (Pellethane)
degraded in oxidation media, but not in HCl
and NaOH (non-oxidizing acid and base).
[19]
Pellethane® 80A, 55D
(Dow Chemicals)
Techoflex® EG80A
(Thermedics)
Biomer®
(Ethicon)
Cardiothane®-51
(Avcothane)
MedAdhere® 2110
(Medtronic)
1. Flat films
2. Whole
pacemaker leads
3. Tubing (1.75 ×
2.0 mm)
1. AgNO3
2,3. Co salt/ H2O2
1. ASTM (D-1708)
0.1 M solution
90 0C, 35 days
2,3. 3% solution
37 0C, 6 months
FT-IR,
Tensile
Susceptibility to degradation directly
proportional to oxidation potential of metal
ions and ether content of polyurethane.
[20]
Poly(ethylene terephthalate)
Nylon 66
Poly(methyl methacrylate)
As a precipitate Trypsin, chymotrypsin,
papain and esterase
37 ºC, 15 days Thermal analyses
FT-IR
pMMA not affected by enzymes, only
hydrolytically unstable bonds.
[21]
Pellethane® 80A, 55D
(Dow Chemicals)
Flat films (0.089
mm)
Ringer’s solution
H2O (control)
ASTM (D-1708)
37, 90 0C, 6 months
Tensile Loss in tensile strength, especially at
elevated temperatures.
[22]
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Material Sample Solutions Test conditions Analysis Results Reference
MDI/PEO(1000)/BD
MDI/PTMO(1000)/BD
MDI/PBD(2000)/BD
MDI/HPBD(2100)/BD
MDI/PDMS(1350)/BD
Biomer® (Ethicon)
Biostable® PUR
(Medtronic)
Flat films (0.20
mm)
1. AgNO3
2. AgNO3/lactic acid sodium
salt
3. H2O (control)
75 0C, 10, 30 days Tensile, GPC, DSC,
XPS
High resistance could be obtained from
aliphatic polyol soft segment, high linear &
saturated hydrocarbon content.
[13]
Pellethane® 80A
(Dow Chemicals)
Pre-stressed
tubing
(400%)
(0.178 mm ID ×
0.204 mm OD)
1. PMN
2. HOCl
3. ONOO-
1. 37 0C, 3 hr
2. 25 0C, 24 hr
3. 25 0C, 24 hr
FT-IR, GPC HOCl or PMN cause degradation of
aliphatic ester and peroxynitrite of the
aliphatic ether.
[23]
PUU-PCLG
PUU-PEO/PPO
Flat films (0.30
mm)
0.25 ml CE (1 u/ml)
0.05 ml CB (2 u/ml)
0.5 ml CO (10 u/ml)
0.025 ml XO (0.025 u/ml)
37 0C, 28-30 days FT-IR, DSC, ESCA,
SEM
Biodegradation process result of multitude
of biologically mediated components acting
synergistically. Process enhanced by e.g.
material dissolution.
[24]
TDI/PTMO/ED
TDI/PCL/ED
TDI/PTMO-PEO/ED
MDI/PTMO/ED
Glass tubes coated
(0.01 mm)
Cholesterol esterase
Horseradish peroxidase
37 0C, 21 days HPLC, SEM, DSC Hydrolytic enzyme CE responsible for
degradation of urethane-urea linkages in
soft segment.
[25]
MDI/PTMO(650)/BD
MDI/PTMO(1000)/BD
MDI/PTMO(2000)/BD
Flat films Thermal 0 - 450 0C TGA Different results obtained depending on
method used.
[26]
MDI/PTMO(1000)*/BD
MDI/PTMO(2000)*/BD
MDI/PTMO(1250)*/BD
MDI/PTMO(2000)*/BD
(*fluorinated diols included)
Cardiothane® (control)
(Avcothane)
Porous
membranes
1. Activation of PKK to KK
(thrombogenicity)
2. Neutral red
Kenacid blue (Cytotoxicity)
3. HUVEC
1. 37 0C, 3 min.
2. 37 0C, 5 days
3. 37 0C, 7 days
1.
2.
3. SEM
PUs containing PCLG instead of PTMO
showed lowest thrombogenicity and best
cytocompatibility.
[27]
TDI/PTMO/ED (4.2)*
MDI/PTMO/ED (3.0)
TDI/PTMO/ED (6.8)
TDI/PCL/ED (7.5)
TDI/PCL/ED (7.5)
MDI/PTMO/ED (3.0)*
MDI/PTMO/BD (15.0)
TDI/PTMO-PEO/ED(8.5)
TDI/PTMO/ED (6.8)
TDI/PCL/ED (2.9)
*(c.p.m. mg-1 x 10-5)
Membranes Human neutrophil cell
culture
37 ºC, 5% CO2, 100%
humidity
Elastase activity Elastase as contributor to PU degradation.
Polyester urea-urethane (TDI/PCL/ED)
showed the highest cell-mediated
degradation.
[28]
Pellethane® 80A
Pellethane® 55D
(Dow Chemicals)
1. PtCl2, AgNO3, FeCl3
2. Cu2Cl2, Cu2(OAc)2,
Ni(OAc)2, Co(OAc)2
3. H2O (control)
ASTM (D-1708)
0.1 M solution
90 0C, 35 days
FT-IR,
Tensile
Degradation rate of Pellethane® 80A higher
than 55D (higher ether contents).
[29]
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Uncoated Pellethane catheter
(BN 508159, 508384)
Coated Pellethane catheter
(BN 301972, 302247)
Topecon catheter
(Ohmeda Inc.)
Catheter Various clinically used drugs 37 ºC, 24 hours UV spectroscopy Uptake of the drugs by Topecon was lower
than the Pellethane catheters, because of
higher proportion of hard segment.
[29]
MDI/PTMO(2000)/BD Flat films
(0.5 mm)
20% H2O2 / 0.1M CoCl2 37 0C, 12 days FT-IR, GPC, SEM, O2
permeability, Tensile
Surface phenomena resulting from an
autooxidation mechanism.
[30]
Pellethane® 80AE
(Dow Chemicals)
Corethane® 80A
(Corvita)
Flat films 1. 20% H2O2
2. 0.5N HNO3
3. Lipids (0.1%
cholesterol/0.25%
phosphatidylcholine)
4. Bile
ASTM (D-638)
1, 2. 50 0C, 0-21 days
3, 4. 37 0C, 0-120 days
DSC, GPC, FT-IR Degradation of Pellethane strongly
influenced by aging media. Poly(carbonate
urethane) (Corethane®) presents greater
chemical stability than does the ether-
containing Pellethane.
[5]
Pellethane® 80A
Pellethane® 55D
(Medical Profiles)
Tubing,
circumferentially
stretched (0 –
250%)
1. Cholesterol
2. Cholesteryl acetate
3. Cortisone
37 ºC, 12 days SEM, DSC Polar steroids have strong interactions with
especially Pellethane® 55D. Environmental
stress cracking observed for both
polymers at moderate strains.
[31]
PEUU/PDMS
PEUU
Biospan®
(PTG, Corvita)
Blood sacks Saline buffer solution 37 0C, 30-60 days GPC, Tensile, DMA PDMS modified PEUU showed greater
resistance to degradation.
[32]
Poly(ether)urethanes (PEU) chain
extended with:
1. 1,4-butane diol
2. 2-butene-1,4-diol
0.5 mm films 10% H2O2/0.05M CoCl2
enzyme (papain)
37 ºC, 1 week ATR-IR, XPS, AFM PEU, chain extended with 2-butene-1,4-diol
less susceptible to enzymatic (oxidative)
degradation.
[33]
Poly(carbonate) urethane
Poly(ester-urea) urethane
Polymer coated
slips
Activated human monocyte-
derived macrophages
37 ºC, 1 week
37 ºC, 1 month
SEM, Radiolabeled
release
Poly(carbonate) urethanes are less
susceptible to oxidative degradation than
poly(ether) urethanes, but are
hydrolytically unstable.
[34]
Poly(ether urethane)
(Pulse-Tech)
Poly(carbonate urethane urea)
(CPU)
Porous graft 1. Cholesterol esterase
2. 1.63M t-butyl
hydroperoxide/0.10M CoCl2
3. 0.10M glutathione/1.63M t-
butyl hydroperoxide/0.10M
CoCl2
4. Plasma
5. H2O (control)
1. 37 0C, 70 days
2, 3. 70 days
4. 37 0C, 70 days
5. 37 0C, 70 days
ESEM, GPC,
Compliance, Tensile
Poly(carbonate urethane urea) far greater
chemical stability than Poly(ether
urethane) grafts.
[35]
Pellethane® 80A, 55D
(Dow Chemicals)
Pre-strained
dumbbell (150%)
(1 mm)
Pre-strained tubing
(150-300%)
(1.8 mm O.D.)
1. Human plasma
2. 10% H2O2 / 0.1M CoCl2
1. 37 0C, 7 days
2. 50 0C, 10, 20 days
SEM Pellethane® 80A underwent considerable
stress cracking compared to Pellethane®
55D.
[36]
Tecoflex®
(Thermedics)
Flat sheet
(0.01 mm)
Sterilization 25 – 1000 kGy
(5 MGy h-1)
FT-IR, TG, SEC Small oxidized components detected
(toxicity concern).
[37]
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HMDI/PTMEG/HTPBD/HDA)
(?:0%:42.5%:57.5%)
(?:0%:32.1%:67.9%)
(?:21.3%:21.3%:21.3%)
(?:16.1%:16.1%:16.1%)
Flat sheets 1. Rabit blood
2. Mouse fibroblast cells
3. Calcium phosphate
4. Human blood
1. 37 0C, 1 min.
2. 37 0C, 1 days
3. 37 0C, 30 days
4. 22 0C, 1 h
1.Hemolysis
2.Cytocompatibility
3.Calcification
4.Blood compatibility
PUU resulted in higher calcification and
WBC consumption. PEU opposite effect.
[38]
MyoLink®
(poly(carbonate-urea) urethane)
Pulse-Tec®
(poly(ether)urethane)
Compliant
vascular grafts
(100 mm long, 5
mm ID)
1. Plasma fractions I-IV
2. A2 (PLA)
3. Cholesterol esterase
4. H2O2/CoCl2
5. t-butyl peroxide/CoCl2
6. Glutathione/ t-butyl
peroxide/CoCl2
37 ºC, 70 days 1. Thermo-mechanical
analyses
2. Dynamical
mechanical analyses
MyoLink more resistant to degradation than
Pulse-Tec and only degraded in
glutathione/ t-butyl peroxide/CoCl2.
[39]
Poly(MPC-co-EHMA) (MPC)
Tecoflex® EG-60D (SPU)
(Thermedics Inc.)
0.2 mm films Immunoglobulin 37 ºC, 60 min. Protein adsorption
(micro-BCA method)
Lower protein adsorption was found in a
blend of MPC and Tecoflex® than with just
the Tecoflex®.
[40]
HDI/PCN/BD = 3:1:2
HDI/PCN/BD = 2:1:1
HDI/PCN/BD = 3:2:1
HDI/PCN/BD = 4:3:1
HDI/PCN/BD = 3:2:1
MDI/PCN/BD = 3:2:1
HMDI/PCN/BD = 3:2:1
Small tubes (3 mm
ID)
16, 80, 160 or 400 units/ml
cholesterol esterase
pH = 7.0, 25 ºC Contact angle,
Radiolabeled
analyses,
Hydrolytic action of the enzymes used had
the most pronounced effect on the PU
manufactured from HMDI.
[41]
Corethane® 80A
(Corvita)
Pellethane® 80A
(Dow Chemicals)
ChronoFlex® AL-80A
(CardioTech Inc.)
PHMO-PU
(CSIRO)
1. Flat sheets
2. Pre-strained
(200%)
3. ASTM D-638
4. ASTM D-638
1. PBS (pH = 7.4)
2. H2O2 / CoCl2
3. 3% H2O2 + Co
4. SBF
37 ºC, 3 months Tensile (ASTM D-
638), DSC, FT-IR,
ESEM
Corethane® 80A displayed best overall
resistance to hydrolysis, ESC, MIO and
calcification. Pellethane was the least
stable.
[42]
Pellethane® 80A
Pellethane® 55D
(Dow Chemicals)
1. Flat sheets
2. ASTM D-638
0.05M CoCl2
1.63M H2O2
25 0C, 20 – 60 days Tensile, SAXS Solvent-cast Pellethane® 80A samples
failed significantly earlier than heat pressed
samples when compared to Pellethane®
55D.
[43]
Abbreviation Description Abbreviation Description Abbreviation Description
AFM Atomic force microscopy FT-IR Fourier transform infrared PDMS Poly(dimethylene siloxane)
AgNO3 Silver nitrate GPC Gel permeation chromatography PEO Poly(ethylene oxide)
ASTM American standard test method HCl Hydrochloric acid PHMO Poly(hexamethylene oxide)
BD Butane diol H2O Water PKK Prekallikrein
CB Cathepsin B H2O2 Hydrogen peroxide pMMA Poly(methyl methacrylate)
CE Cholesterol esterase HOCl Hypochlorous acid PMN Neutrophils
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Co Cobalt HPLC High pressure liquid chromatography PPO Polypropylene glycol
CO Colagnenase HTPBD Hydroxy-terminated polybutadiene PtCl2 Platinum chloride
Co(OAc)2 Cobalt acetate KK Kallikrein PTMO Poly(tetra methylene oxide)
Cu2Cl2 Copper(II) chloride MDI 4,4-methylenebis(phenylisocyanate) PUU Poly(urethane urea)
Cu(OAc)2 Copper acetate MPC 2-methacryloylethyl phosphorylcholine SAXS Small-angle X-ray scattering
DSC Differential scanning calorimetry NaOH Sodium hydroxide SEM Scanning electron microscopy
ED Ethylene diamine Ni(OAc)2 Nickel acetate SPU Segmented polyurethane
EDAX Electron dispersive analysis by X-ray ONOO- Peroxynitrite TDI 2,4-toluene diisocyanate
ESCA Electron spectroscopy for chemical analyses PBD Poly(butane) diol TGA Thermal gravimetric analysis
ESEM Environmental scanning electron microscope PCL Poly(caprolactone) WBC White blood cells
EHMA 2-ethylhexyl mechacrylate PCLG Poly(caprolactone diol) XO Xanthine oxidase
FeCl3 Ferrous(III) chloride PCN Polycarbonate XPS X-ray photoemission spectroscopy
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Appendix F
Electrospinning of cardiovascular and other medical devices
Table F.1: Summary of some recent articles on electrospinning of cardiovascular and other medical devices
Material Description Mw
(g/mol)
Conc
(wt%)
Solvent Volt
(kV)
Dist
(mm)
Flow
(ml/h)
Caplry
(mm)
Thick
(µm)
Fibre
(µm)
Results Ref
PCL Fiber collected on wire
rings. Flat sheet. Scaffolds
coated with collagen type 1.
Seeded with cells.
80 kDa 10 CHCl3
MeOH
12 6 1 10 0.25 Thin fibers obtained. Neonatal
rat cardiomyocytes attached
well to the scaffold.  Bio-
engineered patch.
[44]
PANi PANi blended with protein,
gelatin and co-electrospun.
Flat sheet. Seeded with
cells
3-8 HFIP 10 100 0.5-1 200-300 H9c2 rat cardiac myoblast
cells attached & proliferated on
scaffold. Confluent layer.
[45]
PEG-PLA Flat sheet. Influence of fiber
thickness investigated.
Seeded with cells.
10.5 kDa 8.2-25.9 HFIP 15 150 1.5 22G 0.14-2.1 MC3T3-E1 osteoprogenitor
cells adhered and proliferated.
Cell density increased with
fiber diameter.
[46]
Collagen type1/
Elastin/
PLGA
Vascular graft. Seeded with
cells. Higher PLGA conc
used than in other studies.
15 HFIP 25 150 3 18G 1000 0.72 Changing ratio of respective
materials improved physical
properties. Biocompatibility
was favorable.
[47]
Collagen type1 Flat sheet. Seeded with
cells. Wound healing.
8 HFIP 15-20 215 0.12 0.84 0.46 0.2 Human oral keratinocytes
adhered and proliferated. Wide
pore size distribution.
[48]
Silk-BMP-2/
nHAP/
hMSCs
Flat sheet. nHAP and
hMSCs included with silk
and BMP-2. Bone
regeneration
8 12 215 0.12 1.5 0.5-0.6 Incorporation of BMP-2 and
nHAP enhanced bone
formation significantly.
[49]
Fibrinogen Flat sheets for wound
healing. Mechanical
properties investigated.
HFIP 22 100 1.8 18G 0.12-0.6 Porous structures obtained
with good mechanical
properties for wound dressing.
[50]
PLA
PLGA
Flat sheet. Cardiac tissue
engineering application.
Seeded with cells.
75000 ACA 30 150 6 1 Cardiac myocytes preference
to hydrophobic surfaces. PLA
scaffolds promoted better cell
adhesion.
[51]
Chitosan/
PEO
Flat sheet. 190 kDa
900 kDa
<2 DMF
DMSO
20-25 17-20 0.5 0.04 Promoted attachment of human
osteoblasts and chondrocytes.
[52]
PEUU Flat sheet and tubes. Co-
electrospinning with SMC.
5-12 HFIP 10 230 1.5 1.2 300-500 Microintegration and alignment
of SMC possible into
degradable scaffold.
[53]
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Material Description Mw
(g/mol)
Conc
(wt%)
Solvent Volt
(kV)
Dist
(mm)
Flow
(ml/h)
Caplry
(mm)
Thick
(µm)
Fibre
(µm)
Results Ref
DegraPol Flat sheets. Scaffold for
skeletal muscle tissue
engineering.
30 CHCl3 18 100 10 Murine and rat myoblast cell
line and human satellite cells
showed adhesion and
proliferation to degradable
scaffolds.
[54]
PELA Dual porosity scaffold for
facial application.
110000 CHCl3 25 1 MMT and NaCl incorporated to
achieve nano- and
microporosity respectively
during electrospinning.
[55]
PU
(Pellethane®
2102-75A)
Flat sheet. Fiber alignment
and direction evaluated
using HLF.
20 DMF 200 18G 0.5-0.84 Aligned structure led to
increased ECM production and
was more sensitive to strain in
the longitudinal direction.
[56]
Silk fibroin Flat sheet. Wound
dressing. Seeding of cells
8 FA 15 70 1.5 Silk fibroin matrix promoted
cell adhesion and spreading of
collagen type 1.
[57]
PLCL Small diameter vascular
graft
2 CHCl3 20 200 5 0.8 50-340 0.7-0.8 Compliant small-diameter
graft spun from PLCL. Thin
wall thickness simulated
compliance of native artery
well.
[58]
PLA Flat sheets. Fibrous
scaffolds for neural tissue
engineering. Seeding of
cells
300000 2
5
DCM
DMF
12 100 1 18G 0.15-0.5
0.8-3
Neural stem cells elongated
and their neurite outgrew along
the fiber direction.
[59]
Collagen type 1
ST-gelatin
PU
PEO
Bilayered vascular graft. 1-7
2.5-10
15
HFIP
HFIP
THF
CHCl3
9.6-16
7.3-11
25
150
50
300
5
3
3
0.8
0.8
0.8
0.8
0.2-2 Multilayering and mixing
electrospinning devised to
design a mesoscopically
ordered structure.
[60]
PLGA
PLGA/Chitin
Flat sheet. Biodegradable
composite matrix for tissue
engineering.
15 HFIP 15-20 50-100 1-6 0.84 Simultaneous electrospinning
process introduced.
Attachment and spreading of
human keratinocytes
promising. 3-D structure
obtained with PLGA/Chitin
[61]
Silk fibroin Flat sheet. Cell culture of
human keratinocytes and
fibroblasts. Wound
dressing and tissue
engineering.
3-15 FA 15 70 0.495 0.03-
0.12
Wide pore size distribution.
Silk fibroin promoted cell
adhesion and spreading.
[62]
PLCL Flat sheet. Biocompatibility
of the PLCL scaffold
investigated.
3-9 Acetone 9-15 130 2 0.4-1.2 0.5-1.5 SMC and EC adhered and
proliferated well on the PLCL
scaffold.
[63]
PLGA
PLA-PEG
DNA
Flat sheet. Therapeutic
application in gene delivery
for tissue engineering.
35 DMF 25 150 1.2 20G 0.38-1.1 Electrospinning of plasmid
DNA/polymer solution
possible.
[64]
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Material Description Mw
(g/mol)
Conc
(wt%)
Solvent Volt
(kV)
Dist
(mm)
Flow
(ml/h)
Caplry
(mm)
Thick
(µm)
Fibre
(µm)
Results Ref
PLGA-Mefoxin Flat sheet. Wound healing.
Controlled release of
antibiotics.
33 DMF 23-27 150 1.2 0.7 0.17-
0.58
Mefoxin incorporated and
released from scaffold without
the loss of structural integrity.
[65]
PLA Flat sheets. Control of
biodegradability.
90000 30-50 DMF 23-27 1.2 0.7 Good hydrophilic and
mechanical properties
obtained.
[66]
PCL Flat sheets. Candidate
scaffold for bone
regeneration. Seeded with
cells
80000 10 CHCl3 13 6 1 0.2-0.6 Mesenchymal stem cells
penetrated scaffold and surface
covered after 1 week.
[67]
PLA
PCL
Bilayered tubular scaffold.
Blood vessel engineering.
76 kDa
80 kDa
12.5 CHCl3 13 200 10.6-1.2 26G 600 1-6 Multilayering electrospinning
achieved. Support attachment,
spread and growth of mouse
fibroblast and human
myofibroblasts.
[68]
Gelatin type B
Collagen type 1
Alpha-elastin
Tropoelastin
Flat sheets. Generation of
biomimetic scaffolds made
of natural polymers for
tissue engineering.
8.3
8.3
20
20
HFIP 10 150 1-10 18G 0.2-0.5
0.2-0.5
0.5-4.2
1.1-9.7
Good control over fiber
thickness. Scaffolds support
attachment and growth of
HEPM cells.
[69]
PCL Multi-filament yarn 9 CHCl3/
MeOH
15 150 0.1 16G 1.26 Fibers are 3-D suspended
between two grounded rings.
[70]
PCL Flat sheets. Scaffold for
cartilage tissue engineering
using hMSCs.
80000 FHF/DMF 12 200 0.4 18G 1000 0.7 Electrospun PCL candidate
scaffold for cell-based tissue
engineering approaches to
cartilage repair.
[71]
PCLEEP Flat sheets. Galactose
ligand surface influences
attachment etc of rat
hypocytes in culture.
70760 21.5 Acetone 17 80 0.3 27 0.3-1.5 PCLEEP promotes hepacyte
aggregates within fiber mesh
suggesting application in liver
tissue engineering.
[72]
PLGA Flat sheets. Nano-surface
structure for improved
degradation.
18000 -
23000
5 Acetone
EA
DCM
CHCl3
3-9 10-20 0.01-10 0.05-0.5 Different nano-surface
structures with change in
solvent and flow rate.
[73]
PEO
PAA
PVA
PU
PCL
Investigation into governing
parameters in
electrospinning
600000
250000
10000
80000
1-10 THF
DCM
DMF
Water
EtOH
10-100 0.02-0.6 Voltage, flow rate,
concentration, molecular
weight and nozzle-to-ground
distance key parameters.
Volume charge density follows
power law dependence on
above-mentioned parameters.
[74]
PU Flat sheets. Mechanical
properties.
7 DMF 20 0.24 1 Different mechanical response
than bulk material. Molecular
orientation within fiber and
strain-induced during spinning.
[75]
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Material Description Mw
(g/mol)
Conc
(wt%)
Solvent Volt
(kV)
Dist
(mm)
Flow
(ml/h)
Caplry
(mm)
Thick
(µm)
Fibre
(µm)
Results Ref
Estane®
PVC/
PVDF
Simultaneous spinning
side-by-side fashion.
135900 Da
250000 Da
20,25
25,20
DMAc 14
15
150
200
3
3
0.7 0.1-5
0.1-5
Bicomponent spinning in side-
by-side fashion demonstrated.
Able to control fiber thickness.
[76]
PLCL Flat sheet. Aligned fibers to
mimic medial layer in
native artery.
5 Acetone 20 150 1 0.4 0.55 Fiber aligned scaffold.
Directional growth of SMC
along fiber orientation.
[77]
Collagen type 1
PGA
PLA
PGA/PLA
Infiltration of interstitial
cells into e-spun scaffolds.
HFIP 20 125 200-250 0.5-1 Only scaffolds prepared with
collagen showed rapid, and
dense, infiltration of interstitial
and EC.
[78]
Abbreviation Description Abbreviation Description Abbreviation Description
ACA Acetic acid FA Formic acid PEG Poly(ethylene glycol)
BMP-2 Bone morphogenic protein 2 Fiber Fiber thickness PELA Poly(ethylene-b-lactide)
Caplry Capillary Flow Flow rate PEO Poly(ethylene oxide)
CHCl3 Chloroform HEPM Human embroyonic palatal mesenchymal PEUU Poly(ester urethane)urea
Conc Concentration HFIP 1,1,1,3,3,3-hexafluoro-2-propanol PGA Poly(glycolic acid)
Da Dalton HLF Human ligament fibroblast PLA Poly(lactide)
DCM Dichloromethane hMSCs Human mesenchymal stem cells PLGA Poly(D,L-lactide-co-glycolide)
Dist Distance ID Inside diameter PLCL Poly(L-lactide-co-caprolactone)
DMAc N,N-dimethyl acetamide MeOH Methanol PU Polyurethane
DMF N,N-dimethylformamide Mw Molecular weight PVA Poly(vinyl alcohol)
DMSO Dimethyl sulfoxide nHAP Hydroxyapatite PVC Poly(vinyl chloride)
DNA Deoxyribose nucleic acid PAA Poly(acrylic acid) PVDF Poly(vinylidiene fluoride)
EA Ethyl acetate PANi Polyaniline Ref Reference
EC Endothelial cells PCL Poly(caprolactone) SMC Smooth muscle cells
E-spun Electrospun PCLEEP Poly(caprolactone-co-ethyl ethylene
phosphate)
ST-gelatin Styrenated gelatin
EtOH Ethanol Volt Voltage
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Appendix G
Communication of wide-angle X-ray scattering results
-----Original Message-----
From: Fernando Ania [  mailto:emfernando@iem.cfmac.csic.es  ]
Sent: 26 July 2006 12:40 PM
To: Fourie, Aneli <  aef2@sun.ac.za  >
Cc: "Baltá Calleja, F.J."
Subject: Results
Dear Prof. Sanderson,
Please find attached the first results on the Polyurethane samples that
you sent us. Fig. 1 shows the WAXS scans of the four samples and, as you
can see, there is no clear evidence of crystalline peaks in any of the
polymers. It means that, from the point of view of X-ray scattering, the
crystallinity is negligible. This result does not exclude the possible
presence of small amounts of
crystallites, not contributing to the coherent scattering, which could be
possibly detected by other methods such as DSC.
Not having any details of the materials, just the reference names, I have
tried to compare (Fig. 2) the Pell and Pell_15.0 samples with their "deg"
(degradated?) counterparts. By subtraction, one observes a certain excess
scattering in the 2theta range 18-21° of the former polyurethanes, which
could account for the presence of such small amounts of crystallites. 
I hope that these measurements can be useful and do not hesitate to ask
in case
you need any further explanations.
Best regards,
Fernando Ania
-----------------------------------------------------
Dr. Fernando Ania
Instituto de Estructura de la Materia, C.S.I.C.
Serrano 119, 28006-Madrid , Spain
Fax: +34 915642431
Phone: +34 915619400
-----------------------------------------------------
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Appendix H
Summary of Bootstrap method
The Bootstrap method is a non-parametric test method, commonly used in statistical
comparisons between two data sets, where it is suspected that the standard assumptions
of e.g. normality and equal variance are violated [79].
The logic flow diagram of the Bootstrap method, as published by Efron and Tibshirani
[79], for the comparison of two such data sets, x1 and x2 of size n1 and n2, respectively (n1
not necessarily equal to n2) is presented in Figure H.1.
Figure H.1: Flow diagram of the Bootstrap method
STEP 1
•Create vector x (combination of x1 and x2)
•Thus x = (x1, x2)
STEP 2
•Draw random samples with replacement of
size n1 + n2 from x
•Call this sample xB
STEP 3
•Randomly divide xB into two vectors of size n1
and n2
•Call that x1B and x2B
STEP 4
•Calculate T: T = mean(x1B)-mean(x2B)
•Repeat Steps 2 - 4 for N = 1000 times
•Thus generating 1000 T values
STEP 5
•Sort the 1000 T values from low to high
STEP 6
•Now calculate Ttest: Ttest = mean(x1)-mean(x2)
STEP 7
•Determine the index, j, at which: Tj > Ttest
STEP 7
•Calculate p: p = j/N (i.e. significance level)
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